Emeritus Professor Robert (Rob) Coleman

MBBS, MD, FRCP, FRCPE, FACP

School of Medicine and Population Health

Emeritus Professor of Medical Oncology

r.e.coleman@sheffield.ac.uk
+44 114 230 5474

Broomcross Building, Floor 2, Cancer Clinical Trials Centre, Weston Park Hospital

Full contact details

Emeritus Professor Robert (Rob) Coleman
School of Medicine and Population Health
Broomcross Building, Floor 2, Cancer Clinical Trials Centre
Weston Park Hospital
Whitham Road
Sheffield
S10 2SJ

Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

Professor Robert (Rob) Coleman is Emeritus Professor of Medical Oncology at the University of Sheffield. He graduated in medicine from Kings College Hospital Medical School in 1978 and trained in London and Edinburgh before moving to Sheffield in 1991 where he was instrumental in developing clinical cancer research in the city and establishing an internationally respected bone oncology research team in Sheffield. Rob has held many leadership roles within the university and the National Institute for Health Research (NIHR) Cancer Research Network. He has published over 450 peer-reviewed manuscripts and numerous book chapters, is a past-president of the Cancer and Bone Society and the founding editor of “Journal of Bone Oncology”.

Professor Coleman was Deputy Chair and on the Board of Trustees at St Luke’s Hospice (2010-2020), on the Board of Trustees for the national charity, Breast Cancer Campaign/Breast Cancer Now (2010-2018) and a Partner Governor on behalf of the University of Sheffield for the Council of Governors at Doncaster and Bassetlaw NHS Foundation Trust (2017-2020). He remains a Board member for Weston Park Cancer Charity (since 2014) and is Chair of Governors at Clifford All Saints Primary School.

From 2014-2019 Professor Coleman was a part-time Medical Director for the global independent medical education provider, prIME Oncology™, developing and delivering both live and on-line educational activities for oncologists and other providers of cancer care. Since retiring from his formal position at the university in 2017, he remains research active, lectures on his areas of expertise around the world and provides consultancy to a range of pharma and biotech companies developing new oncology treatments.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J , Taylor C et al (2022) A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 35, 100442-100442.
Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2021) Bone metastasis : mechanisms, therapies and biomarkers. Physiological Reviews, 101(3), 797-855. View this article in WRRO
Rachner TD, Coleman R, Hadji P & Hofbauer LC (2021) Individualized Bone‐Protective Management in Long‐Term Cancer Survivors With Bone Metastases. Journal of Bone and Mineral Research, 36(10), 1906-1913.
Coleman R, Hadji P, Body J-J, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A , Van Poznak C et al (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 31(12), 1650-1663.
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I , Sohn J et al (2020) Adjuvant denosumab in early breast cancer (D-CARE) : an international, multicentre, randomised, controlled, phase 3 trial. The Lancet Oncology, 21(1), 60-72. View this article in WRRO
Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D , Bowman A et al (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of Bone Oncology, 13, 123-135. View this article in WRRO
Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero J-C , Rojo F et al (2017) Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. The Lancet Oncology, 18(11), 1543-1552.
Coleman R, Gray R, Powles T, Paterson A, Gnant M, Bergh J, Pritchard KI, Bliss J & Cameron D (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. The Lancet, 386(10001), 1353-1361.
Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R , Barrett-Lee P et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology, 15(9), 997-1006.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M , Widmark A et al (2013) Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 369(3), 213-223.
Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C , Frassoldati A et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.. Ann Oncol, 24(2), 398-405.
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ , Ritchie D et al (2011) Breast-cancer adjuvant therapy with zoledronic acid.. N Engl J Med, 365(15), 1396-1405.

Chapters

Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R & Costa L (2020) Bone metastases Springer Science and Business Media LLC

All publications

Books

(2005) Textbook of Bone Metastases. Wiley.

Journal articles

Hadji P, Aapro M, Al-Dagri N, Alokail M, Biver E, Body J-J, Brandi ML, Brown J, Confavreux C, Cortet B , Drake M et al (2025) Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology, 100694-100694.
Kong X, Liu Q, Qu Z, Wang X, Zhang W, Liu Y, Coleman R, Lin C & Wang J (2025) Mapping the Metastatic Landscape: A Population‐Based Cohort Study for Prognostic Insights Into Newly Diagnosed Stage IV Breast Cancer Cases. Cancer Innovation, 4(5).
Coleman R (2024) Out with the old (not so!) and in with the new. Journal of Bone Oncology, 100658-100658.
Brown J, Paggiosi M, Rathbone E, Dodwell D, Cameron D, Gregory W, Eastell R & Coleman R (2024) BoHFAB. The impact of adjuvant zoledronate therapy on bone health in postmenopausal patients with early breast cancer. Journal of Bone Oncology, 45, 100529-100529.
(2024) Clinical practice guidelines for full‐cycle standardized management of bone health in breast cancer patients. Cancer Innovation, 3(1).
Rugo HS, Van Poznak CH, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Vega Alonso E, Naume B, Brain E , Siegel JM et al (2024) Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. Breast Cancer Research and Treatment, 204(2), 249-259.
Coleman R (2024) Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer: editorial commentary. Annals of Translational Medicine, 12(4), 60-60.
Taylor C, Dodwell D, McGale P, Hills RK, Berry R, Bradley R, Braybrooke J, Clarke M, Gray R, Holt F , Liu Z et al (2023) Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. The Lancet, 402(10416), 1991-2003.
Velikova G, Morden JP, Haviland JS, Emery C, Barrett-Lee P, Earl H, Bloomfield D, Brunt AM, Canney P, Coleman R , Verrill M et al (2023) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 24(12), 1359-1374.
Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell’Orto P, Biasi O, Degasperi A, Brown LC, Láng I , MacGrogan G et al (2023) Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Annals of Oncology, 34(4), 397-409.
Robertson JFR, Coleman RE, Cheung K-L, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K , Rauchhaus P et al (2022) Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT). Clinical Cancer Research, 28(24), 5469-5469.
Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J , Taylor C et al (2022) A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 35, 100442-100442.
Coleman RE, Paterson AHG & Gomis RR (2022) 66P Impact of MAF selection of patients for adjuvant bisphosphonate therapy and comparison with current clinical guidance. Annals of Oncology, 33, S152-S152.
Rugo HS, Drumea K, Lee SC, Campone M, Van Poznak C, Neven P, Vega Alonso E, Naume B, Siegel JM, Li R , Uema D et al (2022) 182P Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) with bone metastases: A phase II study. Annals of Oncology, 33, S211-S212.
Cadieux B, Coleman R, Jafarinasabian P, Lipton A, Orlowski RZ, Saad F, Scagliotti GV, Shimizu K & Stopeck A (2022) Experience With Denosumab (XGEVA®) for Prevention of Skeletal-Related Events in the 10 Years After Approval. Journal of Bone Oncology, 100416-100416.
Coleman R, Chan A, Barrios C, Cameron D, Costa L, Dowsett M, Harrison D, Howell A, Lacombe D, MacKenzie M , Martin M et al (2022) Code of practice needed for samples donated by trial participants. The Lancet Oncology, 23(3), e89-e90.
Bradley R, Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, Peto R, Dodwell D, McGale P, Taylor C , Francis PA et al (2022) Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology, 23(3), 382-392.
Goyal A, Mann GB, Fallowfield L, Duley L, Reed M, Dodwell D, Coleman RE, Fakis A, Newcombe R, Jenkins V , Whitham D et al (2021) POSNOC—POsitive Sentinel NOde : adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy : a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. BMJ Open, 11(12).
Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Peto R, Davies L, Dodwell D, McGale P, Pan H , Taylor C et al (2021) Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The Lancet Oncology, 22(8), 1139-1150.
Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2021) Bone metastasis : mechanisms, therapies and biomarkers. Physiological Reviews, 101(3), 797-855. View this article in WRRO
Rachner TD, Coleman R, Hadji P & Hofbauer LC (2021) Individualized Bone‐Protective Management in Long‐Term Cancer Survivors With Bone Metastases. Journal of Bone and Mineral Research, 36(10), 1906-1913.
D'Oronzo S, Gregory W, Nicholson S, Chong YK, Brown J & Coleman R (2021) Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences. Journal of Bone Oncology, 28, 100367.
Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, Neven P, Stierer M, Holcombe C, Coleman R , Forbes J et al (2021) Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ. Cancer Research, 81(4_Supplement).
Winter M, Kendall J, Brown S, Rathbone E, Wilson C, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I , Coleman R et al (2021) Abstract PS14-02: A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. Cancer Research, 81(4_Supplement).
Sestak I, Blake G, Patel R, Cuzick J, Howell A, Coleman R & Eastell R (2021) Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years : 7-year results from the IBIS-II prevention trial. British Journal of Cancer.
Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Fearnside J, Coleman RE & Greenfield DM (2021) Correction to: Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Supportive Care in Cancer, 29(2), 1145-1145.
Coleman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, Howell S, Twelves C, Palmieri C, Anand A , MacPherson I et al (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON) : study protocol for a phase IB/IIA randomised controlled trial. Trials, 21(1). View this article in WRRO
Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C , Collinson FJ et al (2020) Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 25. View this article in WRRO
Coleman R, Hadji P, Body J-J, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A , Van Poznak C et al (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 31(12), 1650-1663.
Coleman R (2020) Bisphosphonates and breast cancer – from cautious palliation to saving lives. Bone. View this article in WRRO
D'Oronzo S, Lovero D, Palmirotta R, Cafforio P, Brown J, Wood S, Cives M, Tucci MG, Stucci LS, Coleman RE & Silvestris F (2020) 30P In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients. Annals of Oncology, 31, S26-S26.
Robertson JFR, Coleman RE, Cheung K-L, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K , Rauchhaus P et al (2020) Proliferation and AKT activity biomarker analyses after capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT). Clinical Cancer Research, 26(7), 1574-1585. View this article in WRRO
Savage P, Winter M, Parker V, Harding V, Sita‐Lumsden A, Fisher RA, Harvey R, Unsworth N, Sarwar N, Short D , Aguiar X et al (2020) Demographics, natural history and treatment outcomes of non‐molar gestational choriocarcinoma; A UK population study. BJOG: An International Journal of Obstetrics & Gynaecology. View this article in WRRO
Coleman R, Zhou Y & Chan A (2020) Adjuvant denosumab in early breast cancer – Authors' reply. The Lancet Oncology, 21(3), e125-e125.
Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M , Press MF et al (2020) Case-based review and olinical guidance on the use of genomic assays for early-stage breast cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer. View this article in WRRO
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I , Sohn J et al (2020) Adjuvant denosumab in early breast cancer (D-CARE) : an international, multicentre, randomised, controlled, phase 3 trial. The Lancet Oncology, 21(1), 60-72. View this article in WRRO
Mahtani R, Holmes F-A, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M , Press MF et al (2020) A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clinical Breast Cancer, 20(3), e251-e260.
Walsh JS, Marshall H, Smith IL, Greenfield DM, Swain J, Best E, Ashton J, Brown JM, Huddart R, Coleman RE , Snowden JA et al (2019) Testosterone replacement in young male cancer survivors : a 6-month double-blind randomised placebo-controlled trial. PLOS Medicine, 16(11). View this article in WRRO
Coleman R (2019) Clinical benefits of bone targeted agents in early breast cancer. The Breast, 48(Supplement 1), S92-S96. View this article in WRRO
Danson S, Mulvey MR, Turner L, Horsman J, Escott KJ, Coleman RE, Ahmedzai SH, Bennett MI & Andrew D (2019) An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. Journal of Bone Oncology. View this article in WRRO
Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J & Eastell R (2019) Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone, 124, 83-88. View this article in WRRO
Gray R, Bradley R, Braybrooke J, Liu Z, Peto R, Davies L, Dodwell D, McGale P, Pan H, Taylor C , Barlow W et al (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. The Lancet, 393(10179), 1440-1452. View this article in WRRO
D'Oronzo S, Coleman R, Brown J & Silvestris F (2019) Metastatic bone disease: pathogenesis and therapeutic options. Journal of Bone Oncology, 15. View this article in WRRO
Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva M , Dunning MJ et al (2019) Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. The Journal of Pathology, 247(3), 381-391. View this article in WRRO
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter-Howard F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury S et al (2019) Endogenous production of IL-1B by breast cancer cells drives metastasis and colonisation of the bone microenvironment.. Clinical Cancer Research, 25(9), 2769-2782. View this article in WRRO
Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Coleman RE & Greenfield DM (2019) Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Supportive Care in Cancer, 27(5), 1755-1763. View this article in WRRO
Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D , Bowman A et al (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of Bone Oncology, 13, 123-135. View this article in WRRO
Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider M-T, Rhee CS, Qin Y, Gregory WM , Garrido-Castro AC et al (2018) Modulating bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer. American Journal of Cancer, 78(18), 5300-5314. View this article in WRRO
Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G , Maccon K et al (2018) Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. JNCI: Journal of the National Cancer Institute, 110(8), 871-879. View this article in WRRO
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ , Bonnefoi HR et al (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 379(2), 122-137.
Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J , Schneeweiss A et al (2018) nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology, 29(8), 1763-1770.
Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M & Vogel C (2018) Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Research and Treatment, 171(1), 11-20. View this article in WRRO
Wilson C, Bell R, Hinsley S, Marshall H, Brown J, Cameron D, Dodwell D & Coleman R (2018) Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. European Journal of Cancer, 94, 70-78.
Logothetis C, Morris MJ, Den R & Coleman RE (2018) Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer and Metastasis Reviews, 37(1), 189-196. View this article in WRRO
Handforth C, D’Oronzo S, Coleman R & Brown J (2018) Cancer Treatment and Bone Health. Calcified Tissue International, 102(2), 251-264. View this article in WRRO
Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M , Rugo H et al (2018) Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment, 169(1), 1-7. View this article in WRRO
Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F, Boddington C, Bogaerts J, Bonadonna G , Bradley R et al (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer : meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology, 19(1), 27-39. View this article in WRRO
Squires H, Pandor A, Thokala P, Stevens JW, Kaltenthaler E, Clowes M, Coleman R & Wyld L (2018) Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics, 36(1), 29-38. View this article in WRRO
Rachner TD, Coleman R, Hadji P & Hofbauer LC (2018) Bone health during endocrine therapy for cancer. The Lancet Diabetes & Endocrinology, 6(11), 901-910.
Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A , Wiechno P et al (2018) Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. European Urology, 73(3), 427-435.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH , Gnant M et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 18(12), 1688-1700.
Anderson RA, Mansi J, Coleman RE, Adamson DJA & Leonard RCF (2017) The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. European Journal of Cancer, 87, 58-64.
D’Oronzo S, Brown J & Coleman R (2017) The role of biomarkers in the management of bone-homing malignancies. Journal of Bone Oncology, 9, 1-9. View this article in WRRO
Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero J-C , Rojo F et al (2017) Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. The Lancet Oncology, 18(11), 1543-1552.
Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D , Brunt AM et al (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18(7), 929-945.
D'Oronzo S, Brown J & Coleman R (2017) The value of biomarkers in bone metastasis. European Journal of Cancer Care.
Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R , O'Reilly S et al (2017) Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. The Lancet Oncology, 18(6), 755-769.
Hadji P, Aapro MS, Body J-J, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer C-C, de Villiers T, Baber R , Roodman GD et al (2017) Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology, 7, 1-12. View this article in WRRO
Dodwell D, Richmond A, Hazell S & Coleman R (2017) Doing More With Less; Are There Some ‘Easy Wins’ in the Management of Early Breast Cancer?. Clinical Oncology, 29(9), 550-552.
Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE , Ortmann O et al (2017) Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology, 35(22), 2507-2514.
Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA, Coleman RE & Anderson RA (2017) GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Annals of Oncology, 28(8), 1811-1816.
Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland Ø, Kobina S, Wilhelm S , Xu L et al (2017) An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.. Annals of Oncology, 28(5), 1090-1097. View this article in WRRO
Shore ND, Nilsson S, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, Heinrich D, Bottomley D, Hoskin P, Franzen L , Solberg A et al (2017) MP57-10 RELATIONSHIP BETWEEN QUALITY OF LIFE AND OVERALL SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN ALSYMPCA: ANALYSIS BY PRIOR DOCETAXEL SUBGROUP. Journal of Urology, 197(4S).
Nilsson S, Sartor AO, Vogelzang NJ, Coleman RE, O'Sullivan JM, Shore ND, Heinrich D, Bottomley D, Hoskin P, Franzen L , Solberg A et al (2017) Relationship between quality of life and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients in ALSYMPCA.. Journal of Clinical Oncology, 35(6_suppl), 177-177.
Coleman R, Collinson M, Bell R, Marshall H, Dodwell D, Keane M, Gil M, Gregory W & Cameron D (2017) Abstract P6-17-01: Adjuvant treatment with zoledronic acid (ZOL) in stage II/III breast cancer. The AZURE trial (BIG 01/04) 10 year follow-up. Cancer Research, 77(4_Supplement).
Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM & Coleman RE (2017) Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. European Journal of Cancer, 71, 1-6. View this article in WRRO
Baselga J, Coleman RE, Cortés J & Janni W (2017) Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology, 119, 113-122.
Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, Widmark A, Thuresson M, Xu L, Germino J & Sartori O (2017) Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clinical Genitourinary Cancer, 15(1), 42-52. View this article in WRRO
Body JJ, Terpos E, Tombal B, Hadji P, Arif A, Young A, Aapro M & Coleman R (2016) Bone health in the elderly cancer patient: A SIOG position paper. Cancer Treatment Reviews, 51, 46-53.
Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R , Seger MA et al (2016) Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. European Urology, 70(5), 875-883. View this article in WRRO
Wilson C, Hinsley S, Marshall H, Cameron D, Bell R, Dodwell D & Coleman RE (2016) Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study. Journal of Bone Oncology. View this article in WRRO
Winter MC, Tidy JA, Hills A, Ireson J, Gillett S, Singh K, Hancock BW & Coleman RE (2016) Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.. Gynecol Oncol.
Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE & Ottewell P (2016) IL-1 drives breast cancer growth and bone metastasis in vivo.. Oncotarget, 7, 75571-75584. View this article in WRRO
Coleman R (2016) Bone targeted treatments in cancer – The story so far. Journal of Bone Oncology, 5(3), 90-92. View this article in WRRO
Coleman RE (2016) Impact of Bone-Targeted Treatments on Skeletal Morbidity and Survival in Breast Cancer. Oncology, 30(8), 695-702.
Macdonald MC, Hancock BW, Winter MC, Coleman RE & Tidy JA (2016) Management and outcomes of patients with stage I and III low-risk gestational trophoblastic neoplasia treated in Sheffield, UK, from 1997–2006. Journal of Reproductive Medicine, 61(4), 341-346.
Schmidt N, Jacob L, Coleman R, Kostev K & Hadji P (2016) Erratum to: The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Research and Treatment, 157(2), 401-401.
Coleman RE, Li R, Sawhney AG, Petrenciuc O & Rugo HS (2016) A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients with bone metastases.. Journal of Clinical Oncology, 34(15_suppl), TPS622-TPS622.
Rugo HS, Li R, Petrenciuc O, Zhang A & Coleman RE (2016) A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases.. Journal of Clinical Oncology, 34(15_suppl), TPS621-TPS621.
Taylor F, Short D, Harvey R, Winter MC, Tidy J, Hancock BW, Savage PM, Sarwar N, Seckl MJ & Coleman RE (2016) Late spontaneous resolution of persistent molar pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology, 123(7), 1175-1181.
Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M & Parker C (2016) Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA. The Prostate, 76(10), 905-916. View this article in WRRO
Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, Reuning-Scherer J, Shan M, Zhan L & Parker C (2016) Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Annals of Oncology, 27(5), 868-874. View this article in WRRO
Wilson C & Coleman R (2016) Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer. JAMA Oncology, 2(4), 423-423.
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 108(4). View this article in WRRO
Wilson C, Gossiel F, Leonard R, Anderson RA, Adamson DJA, Thomas G & Coleman RE (2016) Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. Journal of Bone Oncology, 5(1), 43-49. View this article in WRRO
Coleman R (2016) Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223. Seminars in Nuclear Medicine, 46(2), 99-104.
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M , Holcombe C et al (2016) Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. The Lancet, 387(10021), 866-873. View this article in WRRO
Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz J-MA, O’Shaughnessy J, Beck RM, Ko A , Renschler MF et al (2016) Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials, 17(1). View this article in WRRO
Gregory WM, Twelves CJ, Bell R, Smye SW, Howard DR, Coleman RE & Cameron DA (2016) Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. Breast Cancer Research and Treatment, 155(2), 303-311. View this article in WRRO
Baird R, Banks I, Cameron D, Chester J, Earl H, Flannagan M, Januszewski A, Kennedy R, Payne S, Samuel E , Taylor H et al (2016) An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients. Ecancermedicalscience, 10, 608-608. View this article in WRRO
Macdonald MC, Hancock BW, Winter MC, Coleman RE & Tidy JA (2016) Management and Outcomes of Patients with Stage I and IlIl Low-Risk Gestational Trophoblastic Neoplasia Treated in Sheffield, UK, from 1997-2006.. J Reprod Med, 61(7-8), 341-346.
Schimdt N, Jacob L, Coleman R, Kostev K & Hadji P (2016) The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Research and Treatment, 155(1), 151-157.
Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology, 27(3), 379-390.
Greenfield DM, Blewitt A, Coleman RE, Walsh JS, Snowden JA, Ross RJM & Han TS (2016) Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. Clinical Endocrinology, 84(2), 296-304.
Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz J-MA, O’Shaughnessy J, Beck RM, Ko A , Renschler MF et al (2015) Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials, 16. View this article in WRRO
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H , Brain E et al (2015) Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Annals of Oncology, 26(12), 2505-2506.
Coleman R (2015) IN01 LIVING WITH METASTATIC BONE DISEASE – THE POSITIVE IMPACT OF BONE-TARGETED TREATMENTS. The Breast, 24, S21-S21.
(2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet, 386(10001), 1341-1352.
Coleman R, Gray R, Powles T, Paterson A, Gnant M, Bergh J, Pritchard KI, Bliss J & Cameron D (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. The Lancet, 386(10001), 1353-1361.
Amadori D, Rossetti C, Aglietta M, Messina C, Versari A, Vogelzang NJ, Sartor A, Coleman RE, Govi S, Fang F , Skjorestad I et al (2015) 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. Annals of Oncology, 26, vi54-vi54.
Velikova G, Morden J, Barrett-Lee P, Bloomfield D, Brunt M, Canney P, Coleman R, Russel S, Verrill M, Wardley A , Bliss J et al (2015) Quality of Life (QOL) Results of the UK TACT2 Trial: More Intensive Chemotherapy for Early Breast Cancer (EBC) Has a Measurable Impact on Patient-Reported Symptoms and Functioning (CRUK/05/019). QUALITY OF LIFE RESEARCH, 24, 91-91.
Wedel SA, Mellado B, Sartor O, Vogelzang N, Hoskin P, Nilsson S, Coleman R, Parker C, Wahba M, Haugen I & Shore N (2015) Further characterization of the effects on sequential treatment of docetaxel before or after radium-223 dichloride therapy in Castration-Resistant Prostate Cancer (CRPC) patients with symptomatic bone metastases included in the phase 3 ALSYMPCA trial. Oncology Research and Treatment, 38, 267-267.
Pavlovic M, Arnal-Estapé A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albéniz X, Morales M, Urosevic J , Gawrzak S et al (2015) Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. Journal of the National Cancer Institute, 107(12), djv256-djv256. View this article in WRRO
Price JM, Lo C, Abdi S, Winter MC, Coleman RE, Tidy J & Hancock BW (2015) The Role of Computed Tomography Scanning of the Thorax in the Initial Assessment of Gestational Trophoblastic Neoplasia. International Journal of Gynecologic Cancer, 25(9), 1731-1736.
Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O & Saad F (2015) Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. European Urology, 68(5), 850-858.
Coleman R & Hadji P (2015) Denosumab and fracture risk in women with breast cancer. The Lancet, 386(9992), 409-410.
Talari ACS, Evans CA, Holen I, Coleman RE & Rehman IU (2015) Raman spectroscopic analysis differentiates between breast cancer cell lines. Journal of Raman Spectroscopy, 46(5), 421-427. View this article in WRRO
Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S , Shepherd LE et al (2015) Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. Journal of Clinical Oncology, 33(14), 1574-1583.
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H , Brain E et al (2015) Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Annals of Oncology, 26(5), 873-879.
Wilson C, Ottewell P, Coleman RE & Holen I (2015) The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway. BMC Cancer, 15(1). View this article in WRRO
Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H , Braun A et al (2015) Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Annals of Oncology, 26(2), 368-374. View this article in WRRO
Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D’Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C , Goossen H et al (2015) A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer. Journal of Immunotherapy, 38(2), 71-76.
Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ , Martino S et al (2015) Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. New England Journal of Medicine, 372(5), 436-446.
Taylor F, Short D, Winter MC, Tidy J, Savage PM, Sarwar N, Hancock BW, Seckl MJ & Coleman RE (2015) A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom. Gynecologic Oncology, 136(2), 258-263.
Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A & Eastell R (2014) Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. The Lancet Oncology, 15(13), 1460-1468.
Mellado B, Sartor O, Vogelzang NJ, Hoskin P, Nilsson S, Coleman RE, Parker C, Wahba M, Haugen I & Shore ND (2014) P078 Further characterization of the effects on sequential treatment of docetaxel before or after radium-223 dichloride therapy in Castration-Resistant Prostate Cancer (CRPC) patients with symptomatic bone metastases included in the phase 3 ALSYMPCA trial. European Urology Supplements, 13(5), 138-138.
Kuczyk M, Parker C, Vogelzang N, Sartor O, Bottomley D, Coleman R, Skjorestad I, Whaba M & Nilsson S (2014) 1.5-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study. ONCOLOGY RESEARCH AND TREATMENT, 37, 178-178.
Wedel S, Wiechno P, Helle SI, Logue J, Nilsson S, Sartor O, Coleman RE, Kliment J, Fang F & Parker C (2014) Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group. ONCOLOGY RESEARCH AND TREATMENT, 37, 86-87.
Goyal A, Dodwell D, Reed MW & Coleman RE (2014) Axillary Treatment in Women With One or Two Sentinel Nodes With Macrometastases: More Evidence Is Needed to Inform Practice. Journal of Clinical Oncology, 32(34), 3902-3902.
Logue J, Wedel S, Chodacki A, Sartor O, Nilsson S, Coleman RE, James N, Aksnes A, Wahba M & Parker C (2014) Reasons for Patients (Pts) Discontinuing Study Treatment (Tx) in the Phase 3 Alsympca Trial of Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (Crpc) with Bone Metastases (Mets). Annals of Oncology, 25, iv264-iv264.
Conte PF, Yardley DA, Brufsky A, Coleman RE, Cortes J, Gluck S, Nabholtz J, O'shaughnessy J, Li L, Miller J , Barton D et al (2014) Tnacity: a Phase Ii/Iii Trial of Nab-Paclitaxel (Nab-P) Plus Either Gemcitabine (Gem) or Carboplatin (Carbo) Vs Gem/Carbo As First-Line Treatment for Triple-Negative Metastatic Breast Cancer (Tnmbc). Annals of Oncology, 25, iv135-iv135.
Ireson J, Singh K, Gillett S, Hills A, Everard J, Winter M, Coleman RE, Tidy J & Hancock BW (2014) Evolution of a specialist gestational trophoblastic disease service with a major nursing component: The Sheffield, United Kingdom, experience. Journal of Reproductive Medicine, 59(3), 195-198.
Coleman R, Aksnes A-K, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M & Flamen P (2014) A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Research and Treatment, 145(2), 411-418. View this article in WRRO
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J , Widmark A et al (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. The Lancet Oncology, 15(7), 738-746.
Renton T, Taylor T, Popat S, Popat R, Sivardeen Z, Fogelman I, Hawkesford A, Ruggiero S, Rogers S, Leyland S & Coleman R (2014) Oral surgery: ARONJ masterclass. British Dental Journal, 216(9), 488-489.
Coleman R, Body JJ, Aapro M, Hadji P & Herrstedt J (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 25, iii124-iii137.
Fizazi K, Coleman R, Klotz L, Pittman K, Milecki P, Costa L, Von Moos R, Ganju V, Wei R, Demonty G , Braun A et al (2014) 869 Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid. European Urology Supplements, 13(1), e869-e869a.
Shore N, Sartor O, Vogelzang N, Hoskin P, Nilsson S, Coleman R, Parker C, Wahba M & Staudacher K (2014) MP70-10 FURTHER CHARACTERIZATION OF THE EFFECTS OF PRIOR OR NO PRIOR DOCETAXEL THERAPY ON CRPC PATIENTS WITH BONE METASTASES RECEIVING RA-223 IN THE PHASE 3 ALSYMPCA TRIAL. Journal of Urology, 191(4S).
Saxton JM, Scott EJ, Daley AJ, Woodroofe MN, Mutrie N, Crank H, Powers HJ & Coleman RE (2014) Effects of an exercise and hypocaloric healthy eating intervention on indices of psychological health status, hypothalamic-pituitary-adrenal axis regulation and immune function after early-stage breast cancer: a randomised controlled trial. Breast Cancer Research, 16(2). View this article in WRRO
Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE & Ottewell PD (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line.. Endocr Relat Cancer, 21(2), 327-341.
EBCTCG (Early Breast Cancer Trialists' Collaborative Group) (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. The Lancet, 383(9935), 2127-2135.
Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R , Barrett-Lee P et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology, 15(9), 997-1006.
Ireson J, Singh K, Gillett S, Hills A, Everard J, Winter M, Coleman RE, Tidy J & Hancock BW (2014) Evolution of a specialist gestational trophoblastic disease service with a major nursing component: the Sheffield, United Kingdom, experience.. J Reprod Med, 59(5-6), 195-198.
Popescu RA, Schaefer R, Califano R, Eckert R, Coleman R, Douillard J-Y, Cervantess A, Casali PG, Sessa C, Van Cutsem E , de Vries E et al (2014) The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). ANNALS OF ONCOLOGY, 25(1), 9-15.
Agarwal R, Alifrangis C, Everard J, Savage PM, Short D, Tidy J, Fisher RA, Sebire NJ, Harvey R, Hancock BW , Coleman RE et al (2014) Management and Survival of Patients with FIGO High-risk Gestational Trophoblastic Neoplasia. JOURNAL OF REPRODUCTIVE MEDICINE, 59(1-2), 7-12.
Hofbauer LC, Rachner TD, Coleman RE & Jakob F (2014) Endocrine aspects of bone metastases. The Lancet Diabetes and Endocrinology.
Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G & Murray N (2014) Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.. Lancet Oncol, 15(1), 114-122.
Thompson J, Coleman R, Colwell B, Freeman J, Greenfield D, Holmes K, Mathers N & Reed M (2014) Preparing breast cancer patients for survivorship (PREP) - a pilot study of a patient-centred supportive group visit intervention.. Eur J Oncol Nurs, 18(1), 10-16.
Nilsson S, Schrader AJ, Kliment J, Solberg A, Franzén L, Bottomley D, Syndikus I, Parker C, Sartor O, Skjørestad I , Jensen T et al (2013) P124 Long-term safety of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study. European Urology Supplements, 12(6), 178-178.
Gregory W, Marshall H, Cameron D, Twelves C, Bell R & Coleman R (2013) Modelling residual disease volume and re-growth rates from response durations to aid in cancer trial design, interpretation and analysis, with a particular focus on breast cancer. Trials, 14(S1).
Coleman R, Hinsley S, Bell R, Cameron D, Dodwell D, Liversedge V, Burkinshaw R, Keane M, Gil M & Marshall H (2013) Adjuvant therapy in early breast cancer with zoledronic acid (AZURE - BIG 01/04): Final efficacy analysis. EUROPEAN JOURNAL OF CANCER, 49, S5-S5.
Coleman RE, Gregory W, Marshall H, Wilson C & Holen I (2013) The metastatic microenvironment of breast cancer: clinical implications.. Breast, 22 Suppl 2, S50-S56.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M , Widmark A et al (2013) Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 369(3), 213-223.
Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R , Jyothirmayi R et al (2013) Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).. J Clin Oncol, 31(21), 2685-2691.
Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N , Smith M et al (2013) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features - An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2(2), 70-76. View this article in WRRO
Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Ding B, Maniar T & Coleman RE (2013) Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.. Journal of Clinical Oncology, 31(15_suppl), TPS662-TPS662.
Savage PM, Sita-Lumsden A, Dickson S, Iyer R, Everard J, Coleman R, Fisher RA, Short D, Casalboni S, Catalano K & Seckl MJ (2013) The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 33(4), 406-411.
Young RJ & Coleman RE (2013) Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.. Future Oncol, 9(5), 633-643.
Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S , Holen I et al (2013) Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.. Clin Cancer Res, 19(10), 2755-2765.
Coleman RE, Rathbone E & Brown JE (2013) Management of cancer treatment-induced bone loss.. Nat Rev Rheumatol, 9(6), 365-374.
Patrick D, Smith MR, Cleeland C, Fallowfield L, Tombal B, Oudard S, Shore N, Saad F, Marx G, Coleman R , Gómez-Veiga F et al (2013) 99 The impact of bone metastases on pain: Results from a phase III denosumab study in men with nonmetastatic castration-resistant prostate cancer. European Urology Supplements, 12(1), e99-e100.
Vogelzang NJ, Parker C, Nilsson S, Coleman RE, O'Bryan-Tear CG, Shan M & Sartor AO (2013) Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA).. Journal of Clinical Oncology, 31(6_suppl), 11-11.
Coleman R & Hadji P (2013) JBO—Launched and flying ahead. Journal of Bone Oncology, 2(1), 1-1.
Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla J-P, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T , Hainsworth J et al (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. LANCET ONCOLOGY, 14(1), 72-80.
Aapro M, van de Velde CJH, Putter H, Markopoulos C, Bartlett JMS & Coleman RE (2013) Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?. Breast.
Awada A, Garcia AA, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ , Cocquyt V et al (2013) Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. The Lancet Oncology.
Hadji P, Coleman R & Gnant M (2013) Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Critical Reviews in Oncology/Hematology.
Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN & Galsky MD (2013) Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer. European Urology.
Taylor F, Grew T, Everard J, Ellis L, Winter MC, Tidy J, Hancock BW & Coleman RE (2013) The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. European Journal of Cancer.
Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Rebecca A, Tevaarwerk AJ, Swenson K, Lind P & Mauri D (2013) Adjuvant therapy with zoledronic acid in patients with breast cancer: A systematic review and meta-analysis. Oncologist, 18(4), 353-361.
Coleman R (2013) Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial EDITORIAL COMMENTS. JOURNAL OF UROLOGY, 189(1), S57-S58.
Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C , Frassoldati A et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.. Ann Oncol, 24(2), 398-405.
Thompson J, Coleman R, Colwell B, Freeman J, Greenfield D, Holmes K, Mathers N & Reed M (2013) Levels of distress in breast cancer survivors approaching discharge from routine hospital follow-up.. Psychooncology, 22(8), 1866-1871.
Winter MC & Coleman RE (2013) Bisphosphonates in the adjuvant treatment of breast cancer.. Clin Oncol (R Coll Radiol), 25(2), 135-145.
Scott E, Daley AJ, Doll H, Woodroofe N, Coleman RE, Mutrie N, Crank H, Powers HJ & Saxton JM (2013) Effects of an exercise and hypocaloric healthy eating program on biomarkers associated with long-term prognosis after early-stage breast cancer: a randomized controlled trial.. Cancer Causes Control, 24(1), 181-191.
Coleman RE, Rathbone EJ, Marshall HC, Wilson C, Brown JE, Gossiel F, Gregory WM, Cameron D & Bell R (2012) Abstract S6-4: Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study.. General Session Abstracts.
Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Ke C, Maniar T & Coleman RE (2012) Abstract OT2-3-03: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase 3 clinical trial. Ongoing Trials Poster Session Abstracts.
Barrett-Lee PJ, Casbard A, Abraham J, Grieve R, Wheatley D, Simmons P, Coleman R, Hood K, Griffiths G & Murray N (2012) Abstract PD07-09: Zoledronate versus ibandronate comparative evaluation (ZICE) trial - first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases.. Poster Discussion Abstracts.
Wilson C, Winter MC, Holen I, Freeman JV, Evans AC & Coleman RE (2012) Abstract P2-02-04: The interaction between menopausal status and zoledronic acid can differentially affect serum levels of the TGFβ superfamily.. Poster Session Abstracts.
Cameron D, Barrett-Lee P, Canney P, Banerji J, Bartlett J, Bloomfield D, Bowden S, Brunt M, Earl H, Ellis P , Fletcher M et al (2012) Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). General Session Abstracts.
Bliss JM, Ellis P, Kilburn L, Bartlett J, Bloomfield D, Cameron D, Canney P, Coleman RE, Dowsett M, Earl H , Verril M et al (2012) Abstract P1-13-03: Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse.. Poster Session Abstracts.
Hadji P, Coleman R, Gnant M & Green JR (2012) The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Annals of Oncology, 23(11), 2782-2790. View this article in WRRO
Brown JE, Cook RJ, Lipton A & Coleman RE (2012) Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.. Clin Cancer Res, 18(22), 6348-6355.
Wilson C, Holen I & Coleman RE (2012) Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates.. Cancer Treat Rev, 38(7), 877-889.
Sartor O, Coleman RE, Nilsson S, Vogelzang N, Cross A, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas JE, Zou J & Parker C (2012) Safety of Cytotoxic Chemotherapy Following Radium-223 Chloride (RA-223) Therapy in the Phase 3 Alsympca Study in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. Annals of Oncology, 23, ix308-ix309.
Parker C, Coleman RE, Nilsson S, Vogelzang N, Lloyd AJ, Staudacher K, van Gool R & Sartor AO (2012) Updated Survival, Quality of Life (QOL), and Safety Data of Radium-223 Chloride (RA-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases from the Phase 3 Double-Blind, Randomized, Multinational Study (ALSYMPCA). Annals of Oncology, 23, ix296-ix296.
Coleman RE, Barrios C, Bell R, Finkelstein DM, Iwata H, Martin M, Braun A, Ke C, Maniar T & Goss PE (2012) Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial. Annals of Oncology, 23, ix115-ix115.
Lester JE, Dodwell D, BrownJ.E. , Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM & Coleman RE (2012) Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial. Journal of Bone Oncology, 1(2), 57-62. View this article in WRRO
Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2012) A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. Journal of Bone Oncology, 1(2), 47-56. View this article in WRRO
Coleman RE (2012) Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.. Curr Opin Support Palliat Care, 6(3), 322-329.
Coleman R, Gnant M, Morgan G & Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality.. J Natl Cancer Inst, 104(14), 1059-1067.
Kingdon SJ, Coleman RE, Ellis L & Hancock BW (2012) Deaths from gestational trophoblastic neoplasia: any lessons to be learned?. J Reprod Med, 57(7-8), 293-296.
Coleman R & Hadji P (2012) Bone Oncology-An emerging multi-disciplinary specialty. Journal of Bone Oncology, 1(1), 1. View this article in WRRO
Coleman RE, Wright J, Houston S, Agrawal R, Purohit OP-K, Hayward L, Simmonds P, Waterhouse A & Marshall H (2012) Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer.. Journal of Clinical Oncology, 30(15_suppl), 511-511.
Marshall H, Gregory W, Bell R, Cameron DA, Dodwell DJ, Keane MM, Gil Gil MJ, Davies C & Coleman RE (2012) Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): The influence of menopausal status and age on treatment effects.. Journal of Clinical Oncology, 30(15_suppl), 502-502.
Sartor AO, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A, Johannessen DC , Nilsson S et al (2012) Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).. Journal of Clinical Oncology, 30(15_suppl), 4551-4551.
Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A , Johannessen DC et al (2012) Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).. Journal of Clinical Oncology, 30(15_suppl), LBA4512-LBA4512.
Gregory W, Marshall H, Bell R, Cameron DA & Coleman RE (2012) Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis.. Journal of Clinical Oncology, 30(15_suppl), 513-513.
Leonard RCF, Adamson D, Bertelli G, McLinden M, Haiying N, Dunlop J, Mansi J, Coleman RE, Thomas G & Anderson R (2012) The relative value of anti-Müllerian hormone to predict premature menopause in patients receiving adjuvant chemotherapy for breast cancer: Results from the OPTION trial.. Journal of Clinical Oncology, 30(15_suppl), 1094-1094.
Goss PE, Barrios CH, Bell R, Finkelstein DM, Iwata H, Martin M, Braun AH, Ke C, Maniar T & Coleman RE (2012) Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.. Journal of Clinical Oncology, 30(15_suppl), TPS670-TPS670.
Smith MR, Saad F, Coleman R, Ye Z & Goessl C (2012) Denosumab in castration-resistant prostate cancer Reply. LANCET, 379(9828), E50-E51.
Awada A, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Garcia A & Perez E (2012) 101P Significant Antitumor Activity in A Randomized Phase 2 Study Comparing 2 Schedules of Nktr-102 In Patients (Pts) with Metastatic Breast Cancer (Mbc). Annals of Oncology, 23, ii43-ii43.
Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee K-A, Coleman RE & Smith MR (2012) Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate Cancer Patients Undergoing Zoledronic Acid Administration. ONCOLOGIST, 17, 645-652.
Lewington V, Boehmer S, Franzén L, Klijer R, Mellado B, Coleman R, Cross A, Biggin C & Parker C (2012) OC-0367 RADIUM-223 CHLORIDE AND IMPROVED SURVIVAL IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH BONE METASTASES. Radiotherapy and Oncology, 103, S147-S147.
Canney P, Coleman R, Morden J, Barrett-Lee P, Banerji J, Wardley A, Murray N, Laing R, Cameron D & Bliss J (2012) 200 TACT2 Trial in Early Breast Cancer (EBC): Differential Rates of Amenorrhoea in Premenopausal Women Following Adjuvant Epirubicin (E) or Accelerated Epirubicin (aE) Followed by Capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer, 48, S102-S102.
Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R , van de Velde CJH et al (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.. J Clin Oncol, 30(7), 709-717.
Coleman RE, Marshall H, Bell R & Investigators AZURE (2012) Breast-Cancer Adjuvant Therapy with Zoledronic Acid REPLY. NEW ENGLAND JOURNAL OF MEDICINE, 366(2), 189-189.
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R , Tammela TL et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. LANCET, 379(9810), 39-46.
Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW & Lawrie TA (2012) Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. COCHRANE DATABASE OF SYSTEMATIC REVIEWS(12).
Lipton A, Cook R, Brown J, Coleman R, Body JJ & Smith M (2012) Skeletal-related Events and Clinical Outcomes in Patients with Bone Metastases and Normal Levels of Osteolysis: Exploratory Analyses. Clinical Oncology.
Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise TA, Lipton A & Aapro MS (2012) Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?. Cancer Treatment Reviews, 38(6), 798-806.
Coleman RE, Marshall H & Bell R (2012) The authors reply. New England Journal of Medicine, 366(2), 189.
Brown JE & Coleman RE (2012) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nature Reviews Clinical Oncology, 9(2), 110-118.
Coleman RE, Bertelli G, Beaumont T, Kunkler I, Miles D, Simmonds PD, Jones AL & Smith IE (2012) UK guidance document: treatment of metastatic breast cancer.. Clin Oncol (R Coll Radiol), 24(3), 169-176.
Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE & Holen I (2012) Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.. Breast Cancer Res Treat, 133(2), 523-536.
Coleman RE (2011) Bone cancer in 2011: Prevention and treatment of bone metastases.. Nat Rev Clin Oncol, 9(2), 76-78.
Pivot X, Hackmann J, Manikhas A, Moore Y, Parikh R, Kothari D, Joshi A, Aktan G & Coleman R (2011) P4-17-03: Incidence Rate of Asymptomatic Brain Metastases in Patients with HER2+ Metastatic Breast Cancer Screened for EGF111438/CEREBEL Study.. Poster Session Abstracts.
Coleman R, De BR, Eidtmann H, Neven P, von MG, Martin N, Modi A & Bundred N (2011) P2-17-01: Influence of Delayed Zoledronic Acid Initiation on Disease-Free Survival in Postmenopausal Women with Endocrine Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole: Exploratory Analyses from the ZO-FAST Trial.. Poster Session Abstracts.
Coleman R, Woodward E, Turner L, Marshall H, Collinson M, Dodwell D, Davies C, Bell R, Cameron D & Brown J (2011) P2-19-01: Impact of Zoledronic Acid on Fractures, Bone Mineral Density and Bone Remodeling in the AZURE Trial (BIG 01–04).. Poster Session Abstracts.
de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A & Coleman R (2011) Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST.. CANCER RESEARCH, 71.
Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, Braun A, Ke C, Maniar T, Braun S , Dansey R et al (2011) OT1-01-03: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE).. Ongoing Clinical Trials Poster Session Abstracts.
Coleman R, Flamen P, Naume B, Jerusalem G, Garcia C, Piccart M, OBryan-Tear CG & Aksnes A-K (2011) P4-16-04: An Open-Label, Phase IIa, Non-Randomized Study of Radium-223 in Breast Cancer Patients with Bone Dominant Disease No Longer Considered Suitable for Endocrine Therapy.. Poster Session Abstracts.
Matthews GA, Burkinshaw R, Davies C, Hiley V, Marshall HC & Coleman RE (2011) Optimising trial monitoring on the AZURE trial. Trials, 12(S1).
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ , Ritchie D et al (2011) Breast-cancer adjuvant therapy with zoledronic acid.. N Engl J Med, 365(15), 1396-1405.
Borkowski T, Smith M, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L , Damiao R et al (2011) C176 PROLONGED BONE METASTASIS-FREE SURVIVAL IN MEN WITH CASTRATE-RESISTANT PROSTATE CANCER RECEIVING DENOSUMAB: RESULTS FROM A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL. European Urology Supplements, 10(9), 656-656.
Garcia A, Awada A, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ , Cocquyt V et al (2011) Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity.. Journal of Clinical Oncology, 29(27_suppl), 269-269.
Alazzam M, Young T, Coleman R, Hancock B, Drew D, Wilson P & Tidy J (2011) Predicting gestational trophoblastic neoplasia (GTN): Is urine hCG the answer?. GYNECOL ONCOL, 122(3), 595-599.
Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO , Wardley A et al (2011) Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer. J CLIN ONCOL, 29(24), 3247-3254.
Hadji P, Gnant M, Aapro M, Lipton A & Coleman R (2011) Dosing of zoledronic acid throughout the treatment continuum in breast cancer. CRIT REV ONCOL HEMAT, 79(2), 175-188.
Din OS, Dodwell D, Winter MC, Mori S & Coleman RE (2011) Current opinion of aromatase inhibitor-induced arthralgia in breast cancer in the UK.. Clin Oncol (R Coll Radiol), 23(10), 674-680.
Wilson C & Coleman RE (2011) Adjuvant therapy with bone-targeted agents.. Curr Opin Support Palliat Care, 5(3), 241-250.
Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO , Wardley A et al (2011) Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.. J Clin Oncol, 29(24), 3247-3254.
Alazzam M, Young T, Coleman R, Hancock B, Drew D, Wilson P & Tidy J (2011) Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer?. Gynecol Oncol, 122(3), 595-599.
Walkington L, Webster J, Hancock BW, Everard J & Coleman RE (2011) Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease.. Br J Cancer, 104(11), 1665-1669. View this article in WRRO
Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, Braun AH, Dansey RD & Coleman RE (2011) A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).. J Clin Oncol, 29(15_suppl), TPS152.
Awada A, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V , Sideras K et al (2011) Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).. J Clin Oncol, 29(15_suppl), 1034.
Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, Braun AH, Dansey RD & Coleman RE (2011) A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).. Journal of Clinical Oncology, 29(15_suppl), TPS152-TPS152.
Awada A, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V , Sideras K et al (2011) Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).. Journal of Clinical Oncology, 29(15_suppl), 1034-1034.
Coleman R (2011) Prostate cancer: targeted therapy for prostate cancer metastases to bone.. Nat Rev Urol, 8(6), 296-298.
Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body J-J, Smith M , Lee K-A et al (2011) Consensus on the utility of bone markers in the malignant bone disease setting.. Crit Rev Oncol Hematol, 80(3), 411-432.
Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R , Houston SJ et al (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.. Breast Cancer Res Treat, 127(2), 429-438. View this article in WRRO
Coleman RE & McCloskey EV (2011) Bisphosphonates in oncology.. Bone, 49(1), 71-76.
Oliver RTD, Mead GM, Rustin GJS, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P & Stenning SP (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214).. J Clin Oncol, 29(8), 957-962.
Coleman RE, Bertelli G, Beaumont T, Kunkler I, Miles D, Simmonds PD, Jones AL & Smith IE (2011) UK Guidance Document: Treatment of Metastatic Breast Cancer. Clinical Oncology.
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R , Tammela TL et al (2011) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. The Lancet.
Luis IV & Coleman R (2011) Ovarian germ cell malignancy: a heterogeneous tumour requiring supra-regional management. EUR J GYNAECOL ONCOL, 32(4), 387-392.
Ring A, Reed M, Leonard R, Kunkler I, Muss H, Wildiers H, Fallowfield L, Jones A & Coleman R (2011) The treatment of early breast cancer in women over the age of 70. British Journal of Cancer, 105(2), 189-193. View this article in WRRO
Ortmann O, Pagani O, Jones A, Maass N, Noss D, Rugo H, van de Velde C, Aapro M & Coleman R (2011) Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treatment Reviews, 37, 97-104.
Aapro MS & Coleman RE (2011) Bone health management in patients with breast cancer: Current standards and emerging strategies. The Breast, 21(1), 8-19.
Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB & Thompson AM (2011) Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treatment Reviews.
Lipton A, Costa L & Coleman RE (2011) Bone turnover markers: Tools for prognosis and monitoring response to bisphosphonates?. Breast Disease, 33(2), 59-69.
Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T & Lipton A (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: Practical guidance for prevention and treatment. Annals of Oncology, 22(12), 2546-2555.
Costa L, Harper P, Coleman RE & Lipton A (2011) Anticancer evidence for zoledronic acid across the cancer continuum. Critical Reviews in Oncology/Hematology, 77(SUPPL.1).
Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E & Brown J (2011) Zoledronic acid.. Expert Opin Drug Saf, 10(1), 133-145.
Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, Beckmann MW & Coleman RE (2011) Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.. Ann Oncol, 22(4), 857-862.
Coleman R (2011) The use of bisphosphonates in cancer treatment.. Ann N Y Acad Sci, 1218, 3-14.
Arden-Close E, Absolom K, Greenfield DM, Hancock BW, Coleman RE, Eiser C & Late Effects Group Sheffield (2011) Gender differences in self-reported late effects, quality of life and satisfaction with clinic in survivors of lymphoma.. Psychooncology, 20(11), 1202-1210.
Coleman R, Cook R, Hirsh V, Major P & Lipton A (2011) Zoledronic acid use in cancer patients. Cancer, 117(1), 11-23.
Walkington L & Coleman RE (2011) Advances in management of bone disease in breast cancer.. Bone, 48(1), 80-87.
Brown HK, Ottewell PD, Coleman RE & Holen I (2011) The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.. J Cell Mol Med, 15(3), 501-513. View this article in WRRO
Holen I & Coleman RE (2010) Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.. Breast Cancer Res, 12(6), 214. View this article in WRRO
Martin M, Mackey J, Pienkowski T, Rolski J, Guastalla J-P, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T , Hainsworth J et al (2010) Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer. General Session Abstracts.
Awada A, Chan S, Jerusalem G, Huizing M, Coleman RE, Mehdi A, O'Reilly SM, Hamm JT, Patel T, Hannah AL , Masuoka LK et al (2010) Abstract P6-11-01: Significant Efficacy in a Phase 2 Study of NKTR-102, a Novel Polymer Conjugate of Irinotecan, in Patients with Pre-Treated Metastatic Breast Cancer (MBC). Poster Session Abstracts.
Lo C, Busch S, Lee AG, Searle G, Lamb R, Cramer A, Winter MC, Coleman RE, Dixon M, Bundred NJ & Landberg G (2010) Abstract P4-05-05: Stromal Response to 14-Day Preoperative Therapy in Postmenopausal Oestrogen Receptor Positive Breast Cancer. Poster Session Abstracts.
Guise TA, Brufsky A & Coleman RE (2010) Understanding and Optimizing Bone Health in Breast Cancer. Current Medical Research and Opinion, 26(sup3), 3-20.
Guise TA, Brufsky A & Coleman RE (2010) Understanding and optimizing bone health in breast cancer. CURR MED RES OPIN, 26, 6-20.
Lo C, Busch S, Lee A, Searle G, Lamb R, Cramer A, Morris J, Winter M, Coleman R, Dixon JM , Bundred N et al (2010) Stromal response to aromatase inhibition is associated with improved treatment response in breast cancer patients. European Journal of Surgical Oncology (EJSO), 36(11), 1099-1100.
Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N & Coleman R (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. ANN ONCOL, 21(11), 2188-2194.
Noon E, Singh S, Cuzick J, Spector TD, Williams FMK, Frost ML, Howell A, Harvie M, Eastell R, Coleman RE , Fogelman I et al (2010) Significant differences in UK and US female bone density reference ranges. OSTEOPOROSIS INT, 21(11), 1871-1880.
Lee A, Lamb R, Gregson H, Cramer A, Morris J, Renshaw L, Winter M, Coleman RE, Dixon JMJ, Landberg G & Bundred NJ (2010) O-46 Macrophage infiltration is associated with poor outcome in breast cancer patients and a reduced treatment response to Letrozole and Zoledronate. European Journal of Cancer Supplements, 8(6), 17-17.
Woodward EJ & Coleman RE (2010) Prevention and treatment of bone metastases.. Curr Pharm Des, 16(27), 2998-3006.
Mansi JL, Yellowlees A, Lipscombe J, Earl HM, Cameron DA, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J , Jones AL et al (2010) Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study. BREAST CANCER RES TR, 122(3), 787-794.
Price JM, Hancock BW, Tidy J, Everard J & Coleman RE (2010) Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia.. J Reprod Med, 55(7-8), 301-304.
Walsh JS, Eastell R, Coleman RE, Snowden JA, Shalet SM, Ross RJ & Greenfield DM (2010) Increased fat mass may be protective of bone mass in young male cancer survivors. Bone, 47, S189-S190.
Neville-Webbe HL, Gnant M & Coleman RE (2010) Potential anticancer properties of bisphosphonates.. Semin Oncol, 37 Suppl 1, S53-S65.
Amir E, Clemons M, Freedman OC, Miller N, Coleman RE, Purdie C, Jordan L, Quinlan P & Thompson AM (2010) Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies.. Journal of Clinical Oncology, 28(15_suppl), 1007-1007.
Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals JJ, Tres A, Coleman RE, Reise J, Cooper D & Hupperets P (2010) DEVA: Randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients.. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
Amir E, Clemons M, Freedman OC, Miller N, Coleman RE, Purdie C, Jordan L, Quinian P & Thompson AM (2010) Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospectice studies.. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
Leonard RC, Adamson D, Anderson R, Ballinger R, Bertelli G, Coleman RE, Fallowfield L, McLinden M, Mansi J & Thomas G (2010) The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P , Holen I et al (2010) Metastasis and bone loss: advancing treatment and prevention.. Cancer Treat Rev, 36(8), 615-620. View this article in WRRO
Neville-Webbe HL & Coleman RE (2010) Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease.. Eur J Cancer, 46(7), 1211-1222.
Coulson SG, Kumar VS, Manifold IM, Hatton MQ, Ramakrishnan S, Dunn KS, Purohit OP, Bridgewater C & Coleman RE (2010) Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?. Clin Oncol (R Coll Radiol), 22(4), 289-293.
Terpos E, Berenson J, Cook RJ, Lipton A & Coleman RE (2010) Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. LEUKEMIA, 24(5), 1043-1049.
Michailidou M, Brown HK, Lefley DV, Evans A, Cross SS, Coleman RE, Brown NJ & Holen I (2010) Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?. J Vasc Res, 47(6), 481-493.
Coleman R & MacCallum P (2010) Treatment and secondary prevention of venous thromboembolism in cancer.. Br J Cancer, 102 Suppl 1, S17-S23. View this article in WRRO
Din OS, Dodwell D, Wakefield RJ & Coleman RE (2010) Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?. Breast Cancer Res Treat, 120(3), 525-538.
Bhattacharya A, Watts NB, Davis K, Kotowski S, Shukla R, Dwivedi AK & Coleman R (2010) Dynamic Bone Quality: A Noninvasive Measure of Bone's Biomechanical Property in Osteoporosis. Journal of Clinical Densitometry, 13(2), 228-236.
Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D , Burkinshaw R et al (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.. Br J Cancer, 102(7), 1099-1105. View this article in WRRO
Neville-Webbe HL, Coleman RE & Holen I (2010) Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.. Br J Cancer, 102(6), 1010-1017. View this article in WRRO
Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Snowden JA, Shalet SM, DeRogatis LR & Ross RJM (2010) Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study.. Cancer, 116(6), 1592-1601.
Lester JE, Brown JE, Hannon RA, Ellis SP, Horsman JM, Purohit OP & Coleman RE (2010) The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases.. Bone, 46(3), 801-805.
Holen I & Coleman RE (2010) Bisphosphonates as treatment of bone metastases.. Curr Pharm Des, 16(11), 1262-1271.
Dranitsaris G, Coleman R & Gradishar W (2010) nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. BREAST CANCER RES TR, 119(3), 717-724.
Winter MC, Neville-Webbe HL & Coleman RE (2010) Prevention and treatment of skeletal complications, 275-297.
Brown JE & Coleman RE (2010) Biomarkers of bone turnover in oncology: Applications in diagnosis and treatment. Expert Opinion on Medical Diagnostics, 4(2), 125-138.
Brown JE, Cook RJ, Lipton A, Costa L & Coleman RE (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Research and Treatment, 123, 767-779.
Coleman RE & Walsh JS (2010) BONE Causes of low bone mass in breast cancer-time for action?. NAT REV ENDOCRINOL, 6(1), 10-12.
Murray LJ, Ramakrishnan S, O'Toole L, Manifold IH, Purohit OP & Coleman RE (2010) Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery.. Breast, 19(5), 339-344.
Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE & Holen I (2010) Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.. Int J Cancer, 126(2), 522-532.
Coleman R, Bundred N, De Boer R, Llombarto A, Campbell I, Neven P, Barrios C, Dias R, Miller J & Brufsky A (2009) Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST.. Cancer Research, 69(24_Supplement), 4082-4082.
Winter MC & Coleman RE (2009) Bisphosphonates in breast cancer: teaching an old dog new tricks.. Curr Opin Oncol, 21(6), 499-506.
Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE & Holen I (2009) Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.. Mol Cancer Ther, 8(10), 2821-2832.
Coleman R & Gnant M (2009) New results from the use of bisphosphonates in cancer patients.. Curr Opin Support Palliat Care, 3(3), 213-218.
Absolom K, Eiser C, Michel G, Walters SJ, Hancock BW, Coleman RE, Snowden JA & Greenfield DM (2009) Follow-up care for cancer survivors: views of the younger adult.. Br J Cancer, 101(4), 561-567. View this article in WRRO
Greenfield DM, Absolom K, Eiser C, Walters SJ, Michel G, Hancock BW, Snowden JA & Coleman RE (2009) Follow-up care for cancer survivors: the views of clinicians.. Br J Cancer, 101(4), 568-574. View this article in WRRO
Major PP, Cook RJ, Lipton A, Smith MR, Terpos E & Coleman RE (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer, 9(1). View this article in WRRO
Coleman R (2009) Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial COMMENT. J UROLOGY, 182(2), 515-516.
Dodwell D, Thorpe H & Coleman R (2009) Refining systemic therapy for early breast cancer: difficulties with subtraction. LANCET ONCOL, 10(8), 738-739.
Coleman RE (2009) Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?. Eur J Cancer, 45(11), 1909-1915.
Aboumarzouk OM, Coleman R, Goepel JR & Shorthouse AJ (2009) PNET/Ewing's sarcoma of the rectum: a case report and review of the literature. Case Reports, 2009(jun21 1), bcr0420091770-bcr0420091770.
Coleman RE (2009) Advanced Breast Cancer: Diagnosis and Treatment. National Institute for Health and Clinical Excellence Guideline 2009-An Opportunity Missed. CLIN ONCOL-UK, 21(5), 365-367.
El-Helw LM, Coleman RE, Everard JE, Tidy JA, Horsman JM, Elkhenini HF & Hancock BW (2009) Impact of the revised FIGO/WHO system on the management of patients with gestational trophoblastic neoplasia.. Gynecol Oncol, 113(3), 306-311.
Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE & Saad F (2009) Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC).. J Clin Oncol, 27(15_suppl), e16016.
Bundred NJ, Landberg G, Coleman RE, Morris J, Winter MC, Holen I, Cramer A, Renshaw L, Grassby S & Dixon JM (2009) Short-term biological effects of zoledronic acid combined with letrozole in postmenopausal women with estrogen receptor-positive invasive breast cancer.. J Clin Oncol, 27(15_suppl), e11625.
Dranitsaris G, Coleman R & Gradishar W (2009) Nab-paclitaxel weekly or q3w compared to docetaxel q3w as first-line therapy in patients with metastatic breast cancer: An economic analysis of a prospective randomized trial.. J Clin Oncol, 27(15_suppl), 6592.
Coleman RE, Colwell BB, Freeman JV, Holmes KR & Reed MW (2009) Preparing patients for discharge from routine hospital follow-up for breast cancer. PSYCHO-ONCOL, 18(3), 316-317.
Coleman RE (2009) Zoledronic acid ameliorates the effects of endocrine therapy on bone health in women with early-stage breast cancer.. Nat Clin Pract Endocrinol Metab, 5(2), 72-73.
Ottewell PD, Lefley DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. Poster Session Abstracts.
Noon E, Singh S, Cuzick J, Spector TD, Williams FMK, Frost ML, Howell A, Harvie M, Eastell R, Coleman RE , Fogelman I et al (2009) Significant differences in UK and US female bone density reference ranges. Osteoporosis International, 21(11), 1871-1880.
Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R , Earl H et al (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. LANCET, 373(9676), 1681-1692.
Biganzoli L, Bonnefoi H, Cardoso F, Coleman R & Thurlimann B (2009) ASCO 2009: What's New in Breast Cancer Therapy?. BREAST CARE, 4(4), 268-271.
Saad F, Cook R, Coleman R & Lipton A (2008) POD-3.05: N-telopeptide of Type I Collagen (NTX) Response to Zoledronic Acid in Patients with Bone Metastases from Prostate Cancer. Urology, 72(5), S39-S39.
Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R & Major P (2008) Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.. Cancer Treat Rev, 34(7), 629-639.
Absolom K, Eiser C, Turner L, Ledger W, Ross R, Davies H, Coleman R, Hancock B, Snowden J, Greenfield D & Late Effects Group Sheffield (2008) Ovarian failure following cancer treatment: current management and quality of life.. Hum Reprod, 23(11), 2506-2512.
Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS , Coleman RE et al (2008) Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy. CLIN CANCER RES, 14(20), 6690-6696.
Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body J-J, Boyce BF, Calvi LM, Hadji P, McCloskey EV , Saad F et al (2008) Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.. Clin Cancer Res, 14(20), 6387-6395.
Fallowfield L, Jenkins V & Coleman R (2008) Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey. BREAST, 17(5), 459-463.
Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.. Clin Cancer Res, 14(19), 6336-6342.
Zekri JM, El-Helw LM, Purohit OP, Hatton MQ & Coleman RE (2008) Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual function.. Clin Oncol (R Coll Radiol), 20(7), 513-516.
Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE & Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.. J Natl Cancer Inst, 100(16), 1167-1178.
Wardley AM, Hiller L, Howard HC, Dunn JA, Bowman A, Coleman RE, Fernando IN, Ritchie DM, Earl HM, Poole CJ & tAnGo Trial Collaborators (2008) tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. BRIT J CANCER, 99(4), 597-603. View this article in WRRO
Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A & Tubiana-Hulin M (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. ANN ONCOL, 19(8), 1407-1416.
Winter MC, Holen I & Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer.. Cancer Treat Rev, 34(5), 453-475.
Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P & Holen I (2008) Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.. Clin Cancer Res, 14(14), 4658-4666.
Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE & Coleman RE (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. CANCER, 113(1), 193-201.
Coleman RE (2008) Risks and benefits of bisphosphonates.. Br J Cancer, 98(11), 1736-1740. View this article in WRRO
Poole CJ, Hiller L, Howard HC, Dunn JA, Canney P, Wardley AM, Kennedy MJ, Coleman RE, Leonard RC & Earl HM (2008) tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). Journal of Clinical Oncology, 26(15_suppl), 506-506.
Brown JE, Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR & Coleman RE (2008) Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP.. J Clin Oncol, 26(15_suppl), 19003.
Coleman RE & ATAC Trialists’ Group (2008) Long-term effects of anastrozole on bone mineral density: Seven-year results from the ATAC trial.. J Clin Oncol, 26(15_suppl), 587.
Evans TR, Yellowlees A, Devine I, Earl HM, Cameron DA, Hutcheon AW, Coleman RE, Crown JP, Leonard RC & Mansi JL (2008) 5-year outcome for women randomised in a phase III trial comparing doxorubicin (A) and cyclophosphamide (C) with doxorubicin and docetaxel (D) as primary medical therapy of breast cancer: An Anglo-Celtic Cooperative Oncology Group Study.. J Clin Oncol, 26(15_suppl), 540.
Lester J, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study.. J Clin Oncol, 26(15_suppl), 554.
Dranitsaris G, Lidgren M, Lundkvist J & Coleman RE (2008) Nab-paclitaxel or docetaxel as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): a cost utility analysis in five European countries.. J Clin Oncol, 26(15_suppl), 6571.
Cook RJ, Hirsh V, Major PP, Saad F, Dias R, Lipton A & Coleman RE (2008) Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD): Survival in patients with high bone turnover.. J Clin Oncol, 26(15_suppl), 20562.
Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N & Hadji P (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.. Cancer Treat Rev, 34(3), 275-282.
Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J , Basaran G et al (2008) Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial. BREAST, 17(2), 180-185.
Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J , Hadji P et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. ANN ONCOL, 19(3), 420-432.
Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL & Coleman RE (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. CANCER, 112(5), 1001-1010.
Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE & Coleman RE (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J THORAC ONCOL, 3(3), 228-236.
Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW & Clack G (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.. J Clin Oncol, 26(7), 1051-1057.
Lester J, Dodwell D, Purohit O, Gutcher S, Ellis S, Thorpe R, Horsman J, Brown J, Hannon R & Coleman R (2008) OC5. Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant breast cancer therapy: Two year results from the ARIBON study. Cancer Treatment Reviews, 34, 51-52.
Coleman R (2008) PL8.3. Bone targeted therapy. Cancer Treatment Reviews, 34, 47-48.
Press MF, Finn RS, Cameron D, Leo AD, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y , Danenberg K et al (2008) HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clinical Cancer Research, 14(23), 7861-7870.
Coleman RE (2008) President's welcome. CANCER TREAT REV, 34, S1-S1.
Coleman RE, Body J-J, Gralow JR & Lipton A (2008) Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.. Cancer Treat Rev, 34 Suppl 1, S31-S42.
Coleman R (2008) Commentary: Controversies in NICE guidance on metastatic spinal cord compression.. BMJ, 337, a2555.
Eastell R, Adams JE, Clack G, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann M & Coleman R (2008) Effect of stopping anastrozole on bone mineral density: Seven-year results from the ATAC trial. CALCIFIED TISSUE INT, 82, S84-S84.
Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P & Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.. Cancer Treat Rev, 34 Suppl 1, S3-18.
Bhattacharya A, Watts NB, Gordon J, Shukla R, Waters T, Bartels S & Coleman R (2008) Bone Quantity and Quality of Youths Working on a Farm—A Pilot Study. Journal of Agromedicine, 12(4), 27-38.
Coleman R (2007) On the horizon: can bisphosphonates prevent bone metastases?. Breast, 16 Suppl 3, S21-S27.
Coleman RE (2007) Emerging strategies in bone health management for the adjuvant patient.. Semin Oncol, 34(6 Suppl 4), S11-S16.
Coleman RE (2007) Preserving skeletal wellness throughout the continuum of care in patients with cancer - Introduction. Seminars in Oncology, 34(6), S1-S3.
Daley AJ, Crank H, Mutrie N, Saxton JM & Coleman R (2007) Determinants of adherence to exercise in women treated for breast cancer. EUR J ONCOL NURS, 11(5), 392-399.
Woodward JKL, Holen I, Coleman RE & Buttle DJ (2007) The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer.. Bone, 41(6), 912-927.
Berenson J, Cook R, Lipton A, Coleman R & Terpos E (2007) Increased Levels of Urinary N-Telopeptide of Type I Collagen Correlate with Reduced Survival in Patients with Advanced Multiple Myeloma.. Blood, 110(11), 1499-1499.
Terpos E, Cook R, Coleman R, Lipton A & Berenson J (2007) Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma.. Blood, 110(11), 1482-1482.
Coleman RE (2007) The benefits and costs of bisphosphonates.. J Support Oncol, 5(10), 483-484.
Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R & Coleman RE (2007) The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.. Calcif Tissue Int, 81(5), 341-351.
Saad F, Lipton A, Cook R, Chen YM, Smith M & Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. CANCER, 110(8), 1860-1867.
Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit O-P, McCloskey E & Coleman RE (2007) Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.. Clin Cancer Res, 13(18 Pt 1), 5406-5410.
Saad F, Lipton A & Coleman R (2007) MP-08.24: Zoledronic acid-mediated normalization of NTX levels correlates with increased clinical benefits in patients with bone metastases secondary to prostate cancer. Urology, 70(3), 84-85.
Donnelly P, Hiller L, Bathers S, Bowden S & Coleman R (2007) Questioning specialists' attitudes to bireast cancer follow-up in primary care. ANN ONCOL, 18(9), 1467-1476.
Daley AJ, Crank H, Mutrie N, Saxton JM & Coleman R (2007) Patient recruitment into a randomised controlled trial of supervised exercise therapy in sedentary women treated for breast cancer. CONTEMP CLIN TRIALS, 28(5), 603-613.
Lipton A, Cook RJ, Major P, Smith MR & Coleman RE (2007) Zoledronic acid and survival in breast cancer patients with bone Metastases and elevated markers of osteoclast activity. ONCOLOGIST, 12(9), 1035-1043.
Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Eastell R, Davies HA, Snowden JA, Derogatis L, Shalet SM & Ross RJM (2007) Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study.. J Clin Endocrinol Metab, 92(9), 3476-3482.
Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ & Saad F (2007) Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. UROLOGY, 70(2), 315-319.
Coleman R (2007) Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer.. Clin Breast Cancer, 7 Suppl 1, S29-S35.
Verrill MW, Lee J, Cameron DA, Agrawal R, Coleman RE, McAdam K, Wardley A, Bowman A, Ferrigan L & Yellowlees A (2007) Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). Journal of Clinical Oncology, 25(18_suppl), LBA1005-LBA1005.
Lipton A, Cook R, Coleman RE, Major P, Terpos E, Body J, Smith MR, Brown J & Garnero P (2007) Normalization of bone markers and improved survival during zoledronic acid therapy. Journal of Clinical Oncology, 25(18_suppl), 9013-9013.
Lester JE, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Purohit OP, Dodwell D & Coleman RE (2007) Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study. Journal of Clinical Oncology, 25(18_suppl), 553-553.
Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R & Roalfe A (2007) Randomized trial of exercise therapy in women treated for breast cancer. J CLIN ONCOL, 25(13), 1713-1721.
Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Dong M, Schenk N, Lacerna L & Perez E (2007) P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). The Breast, 16, S57-S57.
Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R & Aapro M (2007) International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. EUR J CANCER, 43(5), 852-858.
Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E & Berenson JR (2007) Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. CLIN LYMPHOMA MYELOM, 7(5), 346-353.
Eiser C, Absolom K, Greenfield D, Snowden J, Coleman R, Hancock B, Davies H & Late Effects Group, Sheffield (LEGS) (2007) Follow-up care for young adult survivors of cancer: lessons from pediatrics.. J Cancer Surviv, 1(1), 75-86.
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJH, Delozier T, Alvarez I , Del Mastro L et al (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. LANCET, 369(9561), 559-570.
Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E , Bliss JM et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.. Lancet Oncol, 8(2), 119-127.
Smith I, Procter M, D Gelber R, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J , Kaufmann M et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. LANCET, 369(9555), 29-36.
Biganzoli L, Coleman R, Minisini A, Hamilton A, Aapro M, Therasse P, Mottino G, Bogaerts J & Piccart M (2007) A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx (TM)) in the treatment of elderly patients with metastatic breast cancer. CRIT REV ONCOL HEMAT, 61(1), 84-89.
Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P & Paridaens R (2007) Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. EUR J CANCER, 43(2), 331-340.
Martin J, Coleman R & Mundy G (2007) VI meeting on cancer-induced Bone Disease. Expert Review of Anticancer Therapy, 7(4), 461-464.
Hodgkinson E, Neville-Webbe HL & Coleman RE (2006) Magnesium depletion in patients receiving cisplatin-based chemotherapy.. Clin Oncol (R Coll Radiol), 18(9), 710-718.
Brown JE, Ellis SP, Silcocks P, Blumsohn A, Gutcher SA, Radstone C, Hancock BW, Hatton MQ & Coleman RE (2006) Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.. Clin Cancer Res, 12(21), 6480-6486.
Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity.. Clin Cancer Res, 12(20 Pt 2), 6243s-6249s.
El-Helw LM, Naik JD, Chester JD, Joffe JK, Selby PJ & Coleman RE (2006) High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours.. BJU Int, 98(3), 519-525.
Coleman RE & ATAC Trialists’ Group (2006) Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.. J Clin Oncol, 24(18_suppl), 511.
Shirina N, Coleman RE & Chen YM (2006) Effect of the number of bone lesions on efficacy of zoledronic acid for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.. J Clin Oncol, 24(18_suppl), 8529.
Saad F, Coleman RE, Cook R, Smith MR, Brown JE, Hei JY & Chen YM (2006) Predictors of clinical outcome in patients with bone metastases from prostate cancer. Journal of Clinical Oncology, 24(18_suppl), 4555-4555.
Steele N, Zekri J, Coleman R, Leonard R, Dunn K, Bowman A, Manifold I, Kunkler I, Purohit I & Cameron D (2006) Exemestane in metastatic breast cancer: Effective therapy after third-generation non-steroidal aromatase inhibitor failure. BREAST, 15(3), 430-436.
Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F & Smith MR (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. CLIN CANCER RES, 12(11), 3361-3367.
Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C & Piccart M (2006) A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).. Eur J Cancer, 42(7), 882-887.
Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A , Caraglia M et al (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. ONCOL REP, 15(5), 1351-1357.
Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MWR, Coleman RE & Holen I (2006) Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?. Int J Cancer, 118(8), 1901-1908.
Jiwa M, Thompson J, Coleman R & Reed M (2006) Breast cancer follow-up: could primary care be the right venue?. CURR MED RES OPIN, 22(4), 625-630.
Bundred N, Campbell , Coleman R, DeBoer R, Edidtmann H, Frassolati A, Llombart A, Monnier A, Neven P & Dias R (2006) Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). European Journal of Cancer Supplements, 4(2), 48-48.
Chong G, Bhatnagar A, Cunningham D, Cosgriff TM, Harper PG, Steward W, Bridgewater J, Moore M, Cassidy J, Coleman R , Coxon F et al (2006) Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. ANN ONCOL, 17(3), 437-442.
Ottewell PD, Coleman RE & Holen I (2006) From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies.. Breast Cancer Res Treat, 96(2), 101-113.
Greenfield DM, Wright J, Brown JE, Hancock BW, Davies HA, O'Toole L, Eiser C, Coleman RE & Ross RJ (2006) High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening.. Br J Cancer, 94(4), 469-472. View this article in WRRO
Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Coibion M, Bianco AR & ATAC Trialists' Grp (2006) The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. HUM REPROD, 21(2), 545-553.
Vasey PA, Atkinson R, Osborne R, Parkin D, Symonds R, Paul J, Lewsley L, Coleman R, Reed NS, Kaye S & Rustin GJS (2006) SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel gemcitabine as first-line chemotherapy for ovarian cancer. BRIT J CANCER, 94(1), 62-68. View this article in WRRO
Lester JE, Dodwell D, Horsman JM, Mori S & Coleman RE (2006) Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom.. Br J Cancer, 94(1), 30-35. View this article in WRRO
Coleman RE, Mccloskey EV, Guest JF, Ashford RU & Kanis JA (2006) Cost Implications of Bisphosphonates, 415-426.
Coleman RE, Ashford RU, Mccloskey EV & Kanis JA (2006) Prevention of Bone Loss, 399-414.
Reed NS, Poole CJ, Coleman R, Parkin D, Graham JD, Kaye SB, Ostrowski J, Duncan I, Paul J & Hay A (2006) A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: A study by the Scottish Gynaecological Cancer Trials Group (SGCTG). EUR J CANCER, 42(2), 179-185.
Costa L, Lipton A & Coleman RE (2006) Role of Bisphosphonates for the Management of Skeletal Complications and Bone Pain from Skeletal Metastases. Supportive Cancer Therapy, 3(3), 143-153.
Coleman RE (2006) The role of bone markers in metastatic bone disease.. Cancer Treat Rev, 32 Suppl 1, 1-2.
Burkinshaw R & Coleman R (2006) Bisphosphonates as adjuvant therapy for breast cancer.. Womens Health (Lond), 2(1), 115-126.
Coleman RE (2006) Conclusion: Bone markers in metastatic bone disease.. Cancer Treat Rev, 32 Suppl 1, 27-28.
Saxton JM, Daley A, Woodroofe N, Coleman R, Powers H, Mutrie N, Siddall V & Crank H (2006) Study protocol to investigate the effect of a lifestyle intervention on body weight, psychological health status and risk factors associated with disease recurrence in women recovering from breast cancer treatment [ISRCTN08045231].. BMC Cancer, 6, 35. View this article in WRRO
Michailidou M, Neville-Webbe HL, Woodward JK, Lefley DV, Brown NJ, Coleman RE & Holen I (2006) The effects of combined treatment using paclitaxel and zoledronic acid on tumour cells and endothelial cells in vitro. Haematologica Reports, 2(3), 48-49.
Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE & Holen I (2006) Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.. J Clin Pathol, 59(1), 56-63.
Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2006) Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro.. Tumour Biol, 27(2), 92-103.
Coleman RE (2005) Supportive care in oncology. SUPPORT CARE CANCER, 13(12), 959-960.
Thompson J, Jiwa M, Coleman R & Reed M (2005) Breast cancer aftercare; Psychosocial support in primary care (BCAPS). PSYCHO-ONCOL, 14(12), 1091-1091.
Hassadia A, Gillespie A, Tidy J, Everard R G N J, Wells M, Coleman R & Hancock B (2005) Placental site trophoblastic tumour: clinical features and management.. Gynecol Oncol, 99(3), 603-607.
El-Helw L & Coleman RE (2005) Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.. Breast, 14(5), 368-374.
Lipton A, Hei Y, Coleman R, Major P, Smith M & Cook R (2005) Breast cancer patients with persistently increased bone resorption. EJC SUPPL, 3(2), 121-121.
Lichinitser M, Coleman RE, Tjulandin SA, Bergstrom B & Body JJ (2005) Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparison of bone turnover markers. EJC SUPPL, 3(2), 113-113.
Body JJ, Lichinitser M, Tjulandin SA, Coleman RE & Bergstrom B (2005) Safety comparison of oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: Phase III data. EJC SUPPL, 3(2), 114-114.
Woodward JKL, Neville-Webbe HL, Coleman RE & Holen I (2005) Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.. Anticancer Drugs, 16(8), 845-854.
Lester J & Coleman R (2005) Bone loss and the aromatase inhibitors.. Br J Cancer, 93 Suppl 1, S16-S22. View this article in WRRO
Coleman RE, Major P, Lipton A, Brown JE, Lee K-A, Smith M, Saad F, Zheng M, Hei YJ, Seaman J & Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.. J Clin Oncol, 23(22), 4925-4935.
Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE & Eaton CL (2005) Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?. Breast Cancer Res Treat, 92(3), 207-215.
Oliver RTD, Mason MD, Mead GM, von der Maase H, Rustin GJS, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R , Kirk SJ et al (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. LANCET, 366(9482), 293-300.
Serin D, Verrill M, Jones A, Delozier T, Coleman R, Kreuser ED, Mross K, Longerey B & Brandely M (2005) Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. BRIT J CANCER, 92(11), 1989-1996. View this article in WRRO
Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E , Guevin R et al (2005) Adjuvant docetaxel for node-positive breast cancer. NEW ENGL J MED, 352(22), 2302-2313.
Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit O-P, Hancock B & Coleman R (2005) Can an annual infusion of zoledronic acid protect against cancer-treatment induced bone loss (CTIBL)?. Journal of Clinical Oncology, 23(16_suppl), 8023-8023.
Lipton A, Hei Y, Coleman R, Major P & Cook R (2005) Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome.. J Clin Oncol, 23(16_suppl), 532.
El-Helw L & Coleman RE (2005) Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours.. Cancer Treat Rev, 31(3), 197-209.
Coleman RE (2005) Bisphosphonates in breast cancer.. Ann Oncol, 16(5), 687-695.
Lester J, Dodwell D, McCloskey E & Coleman R (2005) The causes and treatment of bone loss associated with carcinoma of the breast.. Cancer Treat Rev, 31(2), 115-142.
Lester J & Coleman R (2005) The use of bisphosphonates in breast cancer.. J Br Menopause Soc, 11(1), 12-17.
Zheng M, Rosen L, Gordon D, Kaminski M, Howell A, Belch A, Apffelstaedt J, Hussein M, Hei Y & Coleman R (2005) P104 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases. The Breast, 14, S44-S44.
Reed SD, Radeva JI, Glendenning GA, Coleman RE & Schulman KA (2005) Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. AM J CLIN ONCOL-CANC, 28(1), 8-16.
Lester J & Coleman R (2005) Bisphosphonates and metastasis. Breast Cancer Online, 8(1).
Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE & Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.. Int J Cancer, 113(3), 364-371.
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee K-A, Zheng M, Hei Y-J & Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.. J Natl Cancer Inst, 97(1), 59-69.
Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Içli F, Pegram M , Piccart M et al (2005) Reducing the Global Breast Cancer Burden: The Importance of Patterns of Care Research. Clinical Breast Cancer, 6(5), 412-420.
Woodward JKL, Coleman RE & Holen I (2005) Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion.. Anticancer Drugs, 16(1), 11-19.
Coleman RE (2004) The role of bisphosphonates in breast cancer.. Breast, 13 Suppl 1, S19-S28.
Daley AJ, Mutrie N, Crank H, Coleman R & Saxton J (2004) Exercise therapy in women who have had breast cancer: design of the Sheffield women's exercise and well-being project. HEALTH EDUC RES, 19(6), 686-697.
Pezeshki M, Hancock BW, Silcocks P, Everard JE, Coleman J, Gillespie AM, Tidy J & Coleman RE (2004) The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease.. Gynecol Oncol, 95(3), 423-429.
Gennery AR, Slatter MA, Bhattacharya A, Barge D, Haigh S, O'Driscoll M, Coleman R, Abinun M, Flood TJ, Cant AJ & Jeggo PA (2004) The clinical and biological overlap between Nijmegen Breakage Syndrome and Fanconi anemia. Clinical Immunology, 113(2), 214-219.
Gilbey AM, Burnett D, Coleman RE & Holen I (2004) The detection of circulating breast cancer cells in blood. J CLIN PATHOL, 57(9), 903-911.
Hall GD, Brown JM, Coleman RE, Stead M, Metcalf KS, Peel KR, Poole C, Crawford M, Hancock B, Selby PJ & Perren TJ (2004) Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. BRIT J CANCER, 91(4), 621-626. View this article in WRRO
Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE & Holen I (2004) Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis.. Breast Cancer Res Treat, 86(3), 269-279.
Leonard RCF, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T , Verrill M et al (2004) Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial. JNCI Journal of the National Cancer Institute, 96(14), 1076-1083.
Coleman R (2004) Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial. Journal of Clinical Oncology, 22(14_suppl), 767-767.
Coleman R (2004) Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial. Journal of Clinical Oncology, 22(14_suppl), 767-767.
Poole CJ, Howard HC, Hiller L, Dunn JA, Wardley AM, Bowman A, Coleman RE, Fernando IN, Ritchie DM & Earl HM (2004) A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in ‘tAnGo’: A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide (EC)-based, adjuvant chemotherapy (CT) for early stage breast cancer. Journal of Clinical Oncology, 22(14_suppl), 821-821.
Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Crown J, Leonard RC & Mansi JL (2004) Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer. Journal of Clinical Oncology, 22(14_suppl), 521-521.
Poole CJ, Howard HC, Hiller L, Dunn JA, Wardley AM, Bowman A, Coleman RE, Fernando IN, Ritchie DM & Earl HM (2004) A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in ‘tAnGo’: A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide (EC)-based, adjuvant chemotherapy (CT) for early stage breast cancer. Journal of Clinical Oncology, 22(14_suppl), 821-821.
Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Crown J, Leonard RC & Mansi JL (2004) Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer. Journal of Clinical Oncology, 22(14_suppl), 521-521.
Brown JE, McCloskey E, Dewar JA, Body J-J, Cameron DA, Purohit OP-K, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption. Journal of Clinical Oncology, 22(14_suppl), 8056-8056.
Brown JE, McCloskey E, Dewar JA, Body J-J, Cameron DA, Purohit OP-K, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption. Journal of Clinical Oncology, 22(14_suppl), 8056-8056.
Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P & Piccart M (2004) Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, investigational drug branch for breast cancer and the new drug development group study. J CLIN ONCOL, 22(13), 2576-2586.
Brown JE & Coleman RE (2004) Metastatic Bone Disease. American Journal of Cancer, 3(4), 265-265.
Warren (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. The Women's Oncology Review, 4(2), 127-128.
Brown JE, Neville-Webbe H & Coleman RE (2004) The role of bisphosphonates in breast and prostate cancers.. Endocr Relat Cancer, 11(2), 207-224.
Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C , Fargeot P et al (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. EUR J CANCER, 40(7), 1021-1030.
Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P & Quadrament 424Sm10-11 Study Grp (2004) Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. UROLOGY, 63(5), 940-945.
Coleman RE (2004) Hormone- and chemotherapy-induced bone loss in breast cancer.. Oncology (Williston Park), 18(5 Suppl 3), 16-20.
Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP , Houghton J et al (2004) Adjuvant Use of Anastrozole in Breast Cancer. Journal of Clinical Oncology, 22(8), 1524-1526.
Gumbrell LA, Evans TRJ, Coleman RE, Smith IE, Twelves CJ, Soukop M, Rea DW, Earl HM, Howell A, Jones A , Canney P et al (2004) A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemotherapy and Pharmacology, 53(4), 341-348.
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O , Coates AS et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. NEW ENGL J MED, 350(11), 1081-1092.
Paridaens R, Dyczka J, Rutgers EJT, Coleman R, Cufer T, Jassem J, Nortier JWR, Morales L, Mattiacci MR & Therasse P (2004) Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901. European Journal of Cancer Supplements, 2(3), 70-70.
Coleman R (2004) E15. Treatment of metastatic bone disease. European Journal of Cancer Supplements, 2(3), 32-33.
Serin D, Verrill M, Jones A, Delozier T, Coleman R, Longerey B & Lafaye de Micheaux S (2004) Navelbine® (NVB) alternating oral and i.v. plus epirubicin (EPI) as first line chemotherapy of metastatic breast cancer (MBC): phase II study — final results. European Journal of Cancer Supplements, 2(3), 130-131.
Bhala N, Coleman JM, Radstone CR, Horsman JM, George J, Hancock BW, Hatton MQ & Coleman RE (2004) The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.. Clin Oncol (R Coll Radiol), 16(1), 40-47.
Coleman RE (2004) Bisphosphonates: clinical experience.. Oncologist, 9 Suppl 4, 14-27.
Clemons M, Coleman RE & Verma S (2004) Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?. Cancer Treatment Reviews, 30(4), 325-332.
Rosen LS, Gordon DH, Dugan W, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL & Coleman RE (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. CANCER, 100(1), 36-43.
Galasko CSB (2004) Metastatic Bone Disease. American Journal of Cancer, 3(4), 265-265.
Semple SE, Dick F & Cherrie JW (2004) Exposure assessment for a population-based case-control study combining a job-exposure matrix with interview data. Scandinavian Journal of Work, Environment & Health, 30(3), 241-248.
Ralston SH, Coleman R, Fraser WD, Gallagher SJ, Hosking DJ, Iqbal JS, McCloskey E & Sampson D (2003) Medical Management of Hypercalcemia. Calcified Tissue International, 74(1), 1-11.
Khan F, Everard J, Ahmed S, Coleman RE, Aitken M & Hancock BW (2003) Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects.. British Journal of Cancer, 89(12), 2197-2201. View this article in WRRO
Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP & Coleman RE (2003) Bone resorption predicts for skeletal complications in metastatic bone disease.. Br J Cancer, 89(11), 2031-2037. View this article in WRRO
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ , Chen BL et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial. CANCER, 98(8), 1735-1744.
Clamp AR, Blackhall FH, Vasey P, Soukop M, Coleman R, Halbert G, Robson L & Jayson GC (2003) A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. British Journal of Cancer, 89(7), 1152-1154.
Brown JE, Hatton MQ, Melchers R, Goldstraw P & Coleman RE (2003) Chemotherapy, erythropoietin and bloodless surgery in a Jehovah's Witness.. Clin Oncol (R Coll Radiol), 15(7), 371-377.
Brown JE & Coleman RE (2003) Metastatic Bone Disease. American Journal of Cancer, 2(4), 269-281.
Coleman R (2003) Breast Cancer: Prognosis, Treatment and Prevention. Clinical Oncology, 15(6), 369-369.
Verrill M, Serin D, Jones A, Delozier T & Coleman R (2003) 454 A phase II study of vinorebline (VRL) alterning oral and intravenous (IV) plus epirubicin (EPI) as first line chemotherapy of metastatic breast cancer (MBC). European Journal of Cancer Supplements, 1(5), S138-S139.
Neville-Webbe HL & Coleman RE (2003) The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.. Palliat Med, 17(6), 539-553.
Bukowski R, Rosen LS, Gordon D, Tchekmedyian S, Hirsh V, Yanagihara R & Coleman RE (2003) P-676 Long-term therapy with zoledronic acid is effective and safe in reducing the risk of skeletal complications in patients with bone metastases from non-small cell lung cancer. Lung Cancer, 41, S262-S263.
Eaton CL & Coleman RE (2003) Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment.. Cancer Treat Rev, 29(3), 189-198.
Chan SY, Gordon AN, Coleman RE, Hall JB, Berger MS, Sherman ML, Eten CB & Finkler NJ (2003) A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. CANCER IMMUNOL IMMUN, 52(4), 243-248.
Rosen L, Coleman R, Gordon D, Major P, Kaminski M, Apffelstaedt J, Howell A, Chen BL & Seaman J (2003) Zoledronic acid is superior to pamidronate in patients with breast cancer and bone metastases. The Breast, 12, S42-S43.
Djulbegovic B, Coleman RE, Stahel RA, Singh D & Lyman G (2003) Evidence-based oncology in cancer treatment reviews. CANCER TREAT REV, 29(1), 45-50.
Coleman RE (2003) Current and future status of adjuvant therapy for breast cancer.. Cancer, 97(3 Suppl), 880-886.
Croucher P, Jagdev S & Coleman R (2003) The anti-tumor potential of zoledronic acid. The Breast, 12, S30-S36.
Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR , Zani V et al (2003) A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology, 14(1), 29-35.
Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P & Piccart MJ (2003) Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. European Journal of Cancer, 39(17), 2439-2449.
Coleman RE (2002) Future directions in the treatment and prevention of bone metastases.. Am J Clin Oncol, 25(6 Suppl 1), S32-S38.
Coleman RE (2002) Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.. Am J Clin Oncol, 25(6 Suppl 1), S25-S31.
Coleman RE (2002) Bisphosphonates for the prevention of bone metastases.. Semin Oncol, 29(6 Suppl 21), 43-49.
Neville-Webbe HL, Holen I & Coleman RE (2002) The anti-tumour activity of bisphosphonates.. Cancer Treat Rev, 28(6), 305-319.
Brown JE & Coleman RE (2002) Assessment of the effects of breast cancer on bone and the response to therapy.. Breast, 11(5), 375-385.
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R , Lohrisch C et al (2002) Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. Journal of Clinical Oncology, 20(14), 3114-3121.
Coleman RE (2002) The clinical use of bone resorption markers in patients with malignant bone disease.. Cancer, 94(10), 2521-2533.
Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeeck I , Bruning P et al (2002) EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer. Annals of Oncology, 13(6), 910-918.
Brown JE & Coleman RE (2002) The present and future role of bisphosphonates in the management of patients with breast cancer.. Breast Cancer Res, 4(1), 24-29. View this article in WRRO
Ashford RU, McCloskey EV, Purohit OP, Ingram CE, Grimer RJ & Coleman RE (2002) Ten-Year Follow-Up of a Patient with Metastatic Ewing's Sarcoma of the Pelvis.. Sarcoma, 6(4), 131-133.
Jagdev SP, Purohit P, Heatley S, Herling C & Coleman RE (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.. Ann Oncol, 12(10), 1433-1438.
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ , Seaman JJ et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. CANCER J, 7(5), 377-387.
LIPTON A (2001) Introduction. Seminars in Oncology, 28, 1-1.
Coleman RE (2001) Should bisphosphonates be the treatment of choice for metastatic bone disease?. Semin Oncol, 28(4 Suppl 11), 35-41.
Lipton A, Coleman RE, Diel IJ & Mundy G (2001) Update on the role of bisphosphonates in metastatic breast cancer - Introduction. SEMIN ONCOL, 28(4), 1-1.
Zekri J, Ahmed N, Coleman RE & Hancock BW (2001) The skeletal metastatic complications of renal cell carcinoma.. Int J Oncol, 19(2), 379-382.
Miles DW, Smith IE, Coleman RE, Calvert AH & Lind MJ (2001) A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. EUR J CANCER, 37(11), 1366-1371.
Coleman RE (2001) Metastatic bone disease and the role of biochemical markers of bone metabolism in benign and malignant diseases. CANCER TREAT REV, 27(3), 133-135.
Jagdev SP, Coleman RE, Shipman CM, Rostami-H A & Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.. Br J Cancer, 84(8), 1126-1134. View this article in WRRO
Coleman R, Apffelstaedt J, Gordon D, Major P, Mackey J, Howell A, Theriault R, Yambros Y, Chen B & Reitsma D (2001) Zometa® is effective and well tolerated in the prevention of skeletal related events secondary to metastatic breast cancer treated with hormonal therapy. European Journal of Cancer, 37, S152-S152.
Jagdev SP, Croucher PI & Coleman RE (2001) The effects of intravenous bisphosphonate treatment on the bone microenvironment in patients with breast cancer and bone metastases. European Journal of Cancer, 37, S129-S129.
Coleman RE & Seaman JJ (2001) The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.. Semin Oncol, 28(2 Suppl 6), 11-16.
Major PP & Coleman RE (2001) Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program. SEMIN ONCOL, 28(2), 17-24.
Berenson JR, Rosen LS, Howell A, Parter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A & Seaman JJ (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases - A double-blind, randomized dose-response study. CANCER, 91(7), 1191-1200.
Gore M, ten Bokkel Huinink W, Carmichael J, Gordon A, Davidson N, Coleman R, Spaczynski M, Héron J-F, Bolis G, Malmström H , Malfetano J et al (2001) Clinical Evidence for Topotecan-Paclitaxel Non–Cross-Resistance in Ovarian Cancer. Journal of Clinical Oncology, 19(7), 1893-1900.
Cunningham D & Coleman R (2001) New options for outpatient chemotherapy – the role of oral fluoropyrimidines. Cancer Treatment Reviews, 27(4), 211-220.
Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies.. Cancer Treat Rev, 27(3), 165-176.
Lorigan PC, Sharma S, Bright N, Coleman RE & Hancock BW (2000) Characteristics of women with recurrent molar pregnancies.. Gynecol Oncol, 78(3 Pt 1), 288-292.
Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE & Hancock BW (2000) Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy.. Gynecol Oncol, 78(3 Pt 1), 309-312.
Coleman RE (2000) High dose chemotherapy: rationale and results in breast carcinoma.. Cancer, 88(12 Suppl), 3059-3064.
Gillespie AM, Broadhead TJ, Chan SY, Owen J, Farnsworth AP, Sopwith M & Coleman RE (2000) Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer.. Ann Oncol, 11(6), 735-741.
Hamilton A, Roy J-A, Beex L, Piccart M, Mauriac L, Coleman R, Paridaens R, Boes GH, van Vreckem A, Palmer P & Klijn J (2000) EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’ or ‘Potentially Hormone Sensitive’ metastatic breast cancer. Breast Cancer Research and Treatment, 60(2), 181-188.
Coleman RE, Howell A, Eggleton SP, Maling SJ & Miles DW (2000) Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group.. Ann Oncol, 11(5), 541-546.
Dobson LS, Lorigan PC, Coleman RE & Hancock BW (2000) Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.. Br J Cancer, 82(9), 1547-1552. View this article in WRRO
Coleman RE, Howell A, Eggleton SPH, Maling SJ, Miles DW & UK Study Grp (2000) Phase II study of docetaxel in patients with liver metastases from breast cancer. ANN ONCOL, 11(5), 541-546.
El Helw LM, Lorigan PC, Robinson MH, Coleman RE & Hancock BW (2000) VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.. Int J Oncol, 16(4), 777-782.
Gillespie AM, Liyim D, Goepel JR, Coleman RE & Hancock BW (2000) Placental site trophoblastic tumour: a rare but potentially curable cancer.. Br J Cancer, 82(6), 1186-1190. View this article in WRRO
Paridaens R, Biganzoli L, Bruning P, Klijn JGM, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R , Awada A et al (2000) Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over. Journal of Clinical Oncology, 18(4), 724-724.
Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE & Delmas PD (2000) Markers of bone turnover for the management of patients with bone metastases from prostate cancer. BRIT J CANCER, 82(4), 858-864. View this article in WRRO
Atkinson R, Vasey PA, Coleman R, Crawford M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul J , Reed NS et al (2000) A dose finding study of docetaxel/carboplatin as first-line. Chemotherapy for epithelial ovarian cancer - final results. International Journal of Gynecology & Obstetrics, 70, D72-D72.
Coleman RE (2000) Management of bone metastases.. Oncologist, 5(6), 463-470.
Coleman RE (2000) Uses and abuses of bisphosphonates.. Ann Oncol, 11 Suppl 3, 179-184.
Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D & Judson IR (2000) Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology, 18(10), 2081-2086.
Coleman RE (2000) Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).. Breast Cancer, 7(4), 361-369.
Sharma S, Jagdev S, Coleman RE, Hancock BW & Lorigan PC (1999) Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis.. Br J Cancer, 81(6), 1037-1041. View this article in WRRO
Gillespie AM & Coleman RE (1999) The potential of melanoma antigen expression in cancer therapy.. Cancer Treat Rev, 25(4), 219-227.
Abbey ME, Hancock BW & Coleman RE (1999) Calman-Hine and the new funding systems in the oncology setting, implementation and progress in North Trent.. BRIT J CANCER, 80, 70-70.
Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, Atkinson R, Graham J, Crawford SM, Coleman R , Thomas H et al (1999) Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer. Journal of Clinical Oncology, 17(7), 2069-2069.
Vinholes J, Coleman R, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, Wildiers J, Michel J, Leonard R, Nortier J , Mignolet F et al (1999) Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. British Journal of Cancer, 80(1-2), 221-228.
Coleman RE (1999) Bisphosphonates in the prevention and treatment of metastatic bone disease. BREAST, 8(2), 57-62.
Robertson JFR, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri E, Sainsbury JRC , Gronberg H et al (1999) The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Journal of Cancer, 35(1), 47-53.
Gillespie AM, Siddiqui N, Coleman RE & Hancock BW (1999) Gestational trophoblastic disease: does central nervous system chemoprophylaxis have a role?. Br J Cancer, 79(7-8), 1270-1272. View this article in WRRO
Dobson LS, Gillespie AM, Coleman RE & Hancock BW (1999) The presentation and management of post-partum choriocarcinoma.. Br J Cancer, 79(9-10), 1531-1533. View this article in WRRO
Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, Quinn KJ & Kanis J (1999) Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.. Ann Oncol, 10(3), 311-316.
Possinger K, Kaufmann M, Coleman R, Stuart NSA, Helsing M, Ohnmacht U & Arning M (1999) Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anti-Cancer Drugs, 10(2), 155-162.
(1999) Editorial. Cancer Treatment Reviews, 25(6), 321-321.
Coleman RE (1999) The management and clinical course of testicular seminoma: 15 years' experience at a single institution - Reply. CLIN ONCOL-UK, 11(2), 137-137.
Rubens RD & Coleman RE (1999) Twenty-five years of reviewing cancer treatment. Cancer Treatment Reviews, 25(1), 1-2.
(1999) British Association of Surgical Oncology Guidelines: The management of metastatic bone disease in the United Kingdom. European Journal of Surgical Oncology (EJSO), 25(1), 3-23.
Adams M, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD , Harper PG et al (1998) Chemotherapy for ovarian cancer - a consensus statement on standard practice. BRIT J CANCER, 78(11), 1404-1406. View this article in WRRO
Coleman RE & Rubens RD (1998) Untitled - Reply to the letter from Robertson to Blamey. BRIT J CANCER, 78(10), 1397-1397.
Awada A, Cufer T, Beex L, Coleman R, Paridaens R, Bruning P, Klijn J, Nooij M, Mauriac L, Van Vreckem A , Biganzoli L et al (1998) EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): Seven years of active European collaboration. European Journal of Cancer, 34, S21-S21.
Hamilton A, Coleman R, Mauriac L, Awada A, Piccart M, Van Vreckem A & Bruning P (1998) EORTC 10968; Phase I study of CaelyxTM at a six week interval in patients with metastatic breast cancer. European Journal of Cancer, 34, S19-S19.
Gillespie AM, Rodgers S, Wilson AP, Tidy J, Rees RC, Coleman RE & Murray AK (1998) MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue.. Br J Cancer, 78(6), 816-821. View this article in WRRO
Coleman RE (1998) How can we improve the treatment of bone metastases further?. Curr Opin Oncol, 10 Suppl 1, S7-13.
Coleman RE, Houston S, Purohit OP, Rubens RD, Kandra A & Ford J (1998) A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.. Eur J Cancer, 34(6), 820-824.
Coleman RE (1998) Monitoring of bone metastases.. Eur J Cancer, 34(2), 252-259.
Robertson JFR, Bombardieri E, Molina R, Coleman R & Jonsson P-E (1998) European Study Group for Serum Tumour Markers in Breast Cancer. Tumori Journal, 84(1), 104-105.
Robertson JFR & Blamey RW (1998) Letters to the Editor. British Journal of Cancer, 78(10), 1397-1397.
Krishnan E & Coleman RE (1998) Malignant mixed mullerian tumours of gynaecological origin: chemosensitive but aggressive tumours.. Clin Oncol (R Coll Radiol), 10(4), 246-249.
Coleman JM, Coleman RE, Turner AR, Radstone CR & Champion AE (1998) The management and clinical course of testicular seminoma: 15 years' experience at a single institution.. Clin Oncol (R Coll Radiol), 10(4), 237-241.
Coleman RE, Smith P & Rubens RD (1998) Clinical course and prognostic factors following bone recurrence from breast cancer.. Br J Cancer, 77(2), 336-340. View this article in WRRO
Coleman RE (1998) Pamidronate disodium in the treatment and management of hypercalcaemia. REV CONTEMP PHARMACO, 9(3), 147-164.
Mountney J, Maury AC, Jackson AM, Coleman RE & Johnson AG (1997) Pancreatic metastases from breast cancer: an unusual cause of biliary obstruction.. Eur J Surg Oncol, 23(6), 574-576.
Vinholes JJ, Purohit OP, Abbey ME, Eastell R & Coleman RE (1997) Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.. Ann Oncol, 8(12), 1243-1250.
Gillespie AM, Lorigan PC, Radstone CR, Waterhouse JC, Coleman RE & Hancock BW (1997) Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.. Br J Cancer, 76(10), 1382-1386. View this article in WRRO
Coleman RE, Purohit OP, Vinholes JJ & Zekri J (1997) High dose pamidronate: clinical and biochemical effects in metastatic bone disease.. Cancer, 80(8 Suppl), 1686-1690.
Coleman RE (1997) Skeletal complications of malignancy.. Cancer, 80(8 Suppl), 1588-1594.
Leonard RC, Smith IE, Coleman RE, Malpas JS, Nicolson M, Cassidy J, Jones A, McIllmurray MB, Stuart NS, Woll PJ & Whitehouse JM (1997) More money is needed to care for patients with cancer.. BMJ, 315(7111), 811-812.
El-Helw L, Lorigan PC, Coleman RE & Hancock BW (1997) The vedex regimen: An effective and well tolerated palliative treatment for non-Hodgkin's lymphoma (NHL). European Journal of Cancer, 33, S266-S266.
Robertson JFR, Kramer S, Syzmendera JJ, Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri E, Sainsbury R , Blarney RW et al (1997) 0-35. Guiding systemic therapy in metastatic breast cancer by blood tumour markers. The Breast, 6(4), 234-234.
ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M , Bolis G et al (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.. Journal of Clinical Oncology, 15(6), 2183-2193.
Coleman R (1997) Management of bone metastases. Cancer Treatment Reviews, 23, S69-S75.
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A & Van Glabbeke M (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.. Journal of Clinical Oncology, 15(9), 3149-3155.
Rustin GJ, Nelstrop AE, Crawford M, Ledermann J, Lambert HE, Coleman R, Johnson J, Evans H, Brown S & Oster W (1997) Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.. Journal of Clinical Oncology, 15(1), 172-176.
Vinholes J, Guo CY, Purohit OP, Eastell R & Coleman RE (1997) Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.. J Clin Oncol, 15(1), 131-138.
Body JJ, Coleman RE & Piccart M (1996) Use of bisphosphonates in cancer patients. CANCER TREAT REV, 22(4), 265-287.
Kent G, Wills G, Faulkner A, Parry G, Whipp M & Coleman R (1996) Patient reactions to met and unmet psychological need: A critical incident analysis. Patient Education and Counseling, 28(2), 187-190.
Vinholes J, Coleman R & Eastell R (1996) Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treatment Reviews, 22(4), 289-331.
Lorigan PC, Grierson AJ, Goepel JR, Coleman RE & Goyns MH (1996) Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA.. Cancer Lett, 104(1), 27-30.
Coleman R (1996) The management of advanced breast cancer. Current Practice in Surgery, 8(1), 7-12.
Vinholes J, Guo CY, Purohit OP, Eastell R & Coleman RE (1996) Metabolic effects of pamidronate in patients with metastatic bone disease.. Br J Cancer, 73(9), 1089-1095. View this article in WRRO
Reid RH, Hoskin P, Ell P, Coleman R & Quick D (1996) 7. Efficacy and safety of 153Sm-EDTMP in alleviating the pain of bone metastases in patients with prostate carcinoma. Nuclear Medicine Communications, 17(4), 258-258.
Lorigan PC, Crosby T & Coleman RE (1996) Current drug treatment guidelines for epithelial ovarian cancer.. Drugs, 51(4), 571-584.
Highley MS, Samandas N, Ziras N, Morgan MM, Hill ME, Stein R, Barker S, Coleman RE, Blake PR, Morris D , Slevin ML et al (1996) A phase II study of ifosfamide and bleomycin in advanced or recurrent cervical carcinoma. International Journal of Gynecological Cancer, 6(4), 323.
Coleman RE (1996) SY-8-4 New Bisphosphonates. European Journal of Cancer, 32, 44-44.
Vinholes APB & Coleman RE (1996) PP-8-16 Detection of Liver Metastases in Advanced Breast Cancer. European Journal of Cancer, 32, 51-51.
Vinholes J, Coleman R, Lacombe D, Mignolet F, Rose C, Leonard R, Nortier J & Tuibiana-Hulin M (1996) PP-8-7 Assessment of response in bone within an EORTC randomised trial of bisphosphonate treatment (10924). European Journal of Cancer, 32, 50-50.
Zekri I, Vinholes J, Purohit O & Coleman R (1996) PP-8-18 Long-term palliation of metastatic bone pain with intermittent pamidronate. European Journal of Cancer, 32, 52-52.
Coleman R, Purohit K & Vinholes J (1996) New Roles for Bisphosphonates in Cancer Therapy. Progress in Palliative Care, 4(2), 39-43.
Highley MS, Samandas N, Ziras N, Morgan MM, Hill ME, Stein R, Barker S, Coleman RE, Blake PR, Morris D , Slevin ML et al (1996) A phase II study of ifosfamide and bleomycin in advanced or recurrent cervical carcinoma. International Journal of Gynecological Cancer, 6(4), 323-327.
Coleman RE, Purohit OP & Vinholes JJ (1996) The future of bisphosphonates in cancer.. Acta Oncol, 35 Suppl 5, 23-29.
Sheridan E, Lorigan PC, Goepel J, Radstone DJ & Coleman RE (1996) Small cell carcinoma of the cervix.. Clin Oncol (R Coll Radiol), 8(2), 102-105.
Vinholes J, Vinholes APB & Coleman RE (1996) Imaging of metastatic bone disease. Imaging, 8(3), 256-273.
Coleman RE (1995) Clinically available evaluation of bone disease in breast cancer--validity and cost effectiveness.. Can J Oncol, 5 Suppl 1, 69-79.
Lorigan PC, Nevin J, Radstone C, Coleman RE & Hancock BW (1995) 1168 Etoposide and actinomycin D (EA) for methotrexate (MTX) resistant, low risk, persistent gestational trophoblastic disease (GTD) and EA with MTX (MEA) for high risk GTD. European Journal of Cancer, 31, S244-S244.
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Awada A, Selleslags J, Van Vreckem A & Van Glabbeke M (1995) 347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC). European Journal of Cancer, 31, S75-S75.
Rustin GJS, Crawford SM, Coleman RE, Lambert J, Ledermann JA, Soukop M, Karp S, Phillips RH, Habboubi N & Meely K (1995) 513 Trial of oral hexalen for relapsed ovarian carcinoma [OV/CA]: Comparison of CA125 and EORTC response definitions. European Journal of Cancer, 31, S109-S110.
Possinger K, Kaufmann M, Helsing M, Coleman R & Blatter J (1995) 369 Advanced breast cancer: A phase II trial with gemcitabine (GEM). European Journal of Cancer, 31, S80-S80.
Vinholes J, Purohit OP, Guo CY, Eastell R, Vinholes AP & Coleman R (1995) 1211 Randomised double-blind comparison of pamidronate or clodronate for hypercalcaemia of malignancy: Effects on bone metabolism markers. European Journal of Cancer, 31, S253-S253.
Adams M, Mort D, Coleman R, Williams L, Evans A & Thompson M (1995) 496 A phase II study of alternating paclitaxel and carboplatin in patients with advanced ovarian cancer. European Journal of Cancer, 31, S106-S106.
Purohit OP, Radstone CR, Anthony C, Kanis JA & Coleman RE (1995) A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.. Br J Cancer, 72(5), 1289-1293. View this article in WRRO
Coleman RE, Rubens RD, Rose C, Purohit OP, Houston S & Ford J (1995) 30. A randomized phase 11 evaluation of oral pamidronate for advanced bone metastases from breast cancer. The Breast, 4(3), 235-236.
Coleman RE, Purohit OP, Black C, Vinholes J, Kanis JA, Schlosser K, Huss H & Quinn KJ (1995) 32. Ibandronate: a well-tolerated new oral bisphosphonate for the treatment of bone metastases.. The Breast, 4(3), 236-236.
Vinholes J, Guo CY, Purohit OP, Eastell R, Vinholes APB & Coleman R (1995) 29. Evaluation of new bone resorption markers in a comparison of pamidronate or clodronate for hypercalcaemia of malignancy. The Breast, 4(3), 235-235.
Vinholes J & Coleman R (1995) The management of bone metastases. Annals of Oncology, 6(7), 713-720.
PARNIS FX, COLEMAN RE, HARPER PG, PICKERING D, TOPHAM C, WHITTINGTON JR & TEDESCHI M (1995) A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL-TRIAL ASSESSING THE TOLERABILITY AND EFFICACY OF GLUTATHIONE AS AN ADJUVANT TO ESCALATING DOSES OF CISPLATIN IN THE TREATMENT OF ADVANCED OVARIAN-CANCER. EUR J CANCER, 31A(10), 1721-1721.
LEONARD RCF, COLEMAN RE & LEWIS I (1995) STRATEGY NEEDED FOR ADOLESCENT PATIENTS WITH CANCER. BRIT MED J, 311(7001), 387-387.
Stewart A, McQuade B, Cronje JDE, Goedhals L, Gudgeon A, Corette L, Froger X, Tubiana-Hulin M, Laplaige P, Roberts JT , McRae J et al (1995) Ondansetron Compared with Granisetron in the Prophylaxis of Cyclophosphamide-lnduced Emesis in Out-Patients: A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group Study. Oncology, 52(3), 202-210.
Henderson MA, Danks JA, Powell GW, Barnes DM, Coleman RE, Rubens RD, Bennett RC & Martin TJ (1995) Immunohistochemical detection of parathyroid hormone related protein in the primary tumours of hypercalcaemic breast cancer patients. The Breast, 4(2), 112-116.
COLEMAN RE (1994) THERAPEUTIC USE OF BISPHOSPHONATES IN ONCOLOGY. BRIT MED J, 309(6963), 1233-1233.
TWELVES CJ, DOBBS NA, CURNOW A, COLEMAN RE, STEWART AL, TYRRELL CJ, CANNEY P & RUBENS RD (1994) A PHASE-II, MULTICENTER, UK STUDY OF VINORELBINE IN ADVANCED BREAST-CANCER. BRIT J CANCER, 70(5), 990-993. View this article in WRRO
Purohit OP, Anthony C, Radstone CR, Owen J & Coleman RE (1994) High-dose intravenous pamidronate for metastatic bone pain.. Br J Cancer, 70(3), 554-558. View this article in WRRO
O'Rourke NP, McCloskey EV, Rosini S, Coleman RE & Kanis JA (1994) Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).. Br J Cancer, 69(5), 914-917. View this article in WRRO
Coleman RE (1994) Evaluation of bone disease in breast cancer. The Breast, 3(2), 73-78.
Verweij J, Judson I, Steward W, Coleman R, Woll P, van Pottelsberghe C, van Glabbeke M & Mouridsen H (1994) Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine () in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. European Journal of Cancer, 30(6), 842-843.
Coleman RE & Purohit OP (1993) Osteoclast inhibition for the treatment of bone metastases.. Cancer Treat Rev, 19(1), 79-103.
COLEMAN R (1993) In: G. Humphrey, H.S. Koops and W.M. Molenaar, Editors, , Kluwer (1993) ISBN 0-7923-1905-2.. Clinical Oncology, 5(5), 333-333.
Richards MA, Coleman RE, Hamsa R, Khaled H, Gad El Mawla M, Kadry I, Hablas A, Ramadan M, Allen D, Wang DY , Rubens RD et al (1992) Advanced breast cancer in Egyptian women: Clinical features and response to endocrine therapy. The Anglo-Egyptian Health Agreement Collaborative Study. European Journal of Surgical Oncology, 18(3), 219-223.
Coleman RE, Houston S, James I, Rodger A, Rubens RD, Leonard RCF & Ford J (1992) Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. British Journal of Cancer, 65(5), 766-768. View this article in WRRO
Soukop M, McQuade B, Hunter E, Stewart A, Kaye S, Cassidy J, Kerr D, Khanna S, Smyth J, Coleman R , Cunningham D et al (1992) Ondansetron Compared with Metoclopramide in the Control of Emesis and Quality of Life during Repeated Chemotherapy for Breast Cancer. Oncology, 49(4), 295-304.
Kamthan A, Scarffe JH, Walling J, Hatty S, Peters B, Coleman R & Smyth JF (1992) A phase II study of sulofenur (LY186641) in gastric cancer. Anti-Cancer Drugs, 3(4), 331-336.
Coleman RE (1992) Glucocorticoids in cancer therapy.. Biotherapy, 4(1), 37-44.
Daley-Yates PT, Dodwell DJ, Pongchaidecha M, Coleman RE & Howell A (1991) The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcified Tissue International, 49(6), 433-435.
Coleman RE (1991) Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.. Oncology (Williston Park), 5(8), 55-60.
Coleman R, Leonard R, Cornbleet M, Gregor A, Newaishy G, Greening A, Crompton G, Stewart M & Smyth J (1991) The late results of consolidation treatment following induction chemotherapy for small cell lung cancer. Lung Cancer, 7(5), 299-307.
Coleman RE, Dirix LY, Dodwell D, Tubiana-Hulin M, Body J-J, Becher R, White GK, Rubens RD, Van Oosterom A, Howell A & Ford J (1991) Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases. European Journal of Cancer and Clinical Oncology, 27(7), 945-946.
Smyth JF, Coleman RE, Nicolson M, Gallmeier WM, Leonard RC, Cornbleet MA, Allan SG, Upadhyaya BK & Bruntsch U (1991) Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?. BMJ, 303(6815), 1423-1426.
WHILLIS D, COLEMAN RE, LESSELLS AM, HARGREAVE TB, CORNBLEET MA & HOWARD GCW (1991) Surgery Following Chemotherapy for Metastatic Testicular Teratoma. British Journal of Urology, 68(3), 292-295.
Thompson P, Wilson P, Osborne R, Slevin M, Wiltshaw F, Blake P, Harper P, Coleman R, Williams C, Sweetenham J , Young A et al (1991) The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study. British Journal of Cancer, 64(5), 973-974.
Coleman RE, Twelves CJ, O'Reilly SM, Rubens RD, Richards MA & Harper PG (1991) Influence of dexamethasone dose on the control of chemotherapy-induced nausea and vomiting. European Journal of Cancer and Clinical Oncology, 27(8), 1062-1063.
Whillis D, Coleman RE, Cornbleet MA & Howard GCW (1991) Failure of salvage treatment in metastatic testicular teratoma. Clinical Oncology, 3(3), 141-146.
COLEMAN RE, WHILLIS D, HOWARD GCW, TAYLOR RE & CORNBLEET MA (1991) Low Dose Bleomycin with Etoposide and Cisplatin for Metastatic Testicular Teratoma. British Journal of Urology, 68(3), 296-300.
Coleman RE, Fogelman I, Habibollahi F, North WRS & Rubens RD (1990) Selection of patients with breast cancer for routine follow-up bone scans. Clinical Oncology, 2(6), 328-332.
Coleman RE, Clarke JM, Slevin ML, Sweetenham J, Williams CJ, Blake P, Calman F, Wiltshaw E & Harper PG (1990) A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. Cancer Chemotherapy and Pharmacology, 27(1), 52-54.
Coleman R, Towlson K, Wiltshaw E, Slevin M, Blake P, Stein R, Coombes R & Harper P (1990) Epirubicin for pretreated advanced ovarian cancer. European Journal of Cancer and Clinical Oncology, 26(7), 850-851.
Coleman R, Clarke J, Gore M, Wiltshaw E, Slevin M & Harper P (1989) A phase II study of mitozantrone in advanced carcinoma of the ovary. Cancer Chemotherapy and Pharmacology, 24(3), 200-202.
Gallagher C, Wiltshaw E, Coleman R & Harper P (1989) A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer. Cancer Chemotherapy and Pharmacology, 24(1).
Boxer DI, Todd CEC, Coleman R & Fogelman I (1989) Bone secondaries in breast cancer: The solitary metastasis. Journal of Nuclear Medicine, 30(8), 1318-1320.
O'Reilly SM, Coleman RE & Rubens RD (1989) Phase II study of mitoxantrone for liver metastases from breast cancer. Cancer Chemotherapy and Pharmacology, 25(1), 73-74.
Twelves CJ, O'Reilly SM, Coleman RE, Richards MA & Rubens RD (1989) Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. British Journal of Cancer, 60(6), 938-941.
Coleman RE, Woll PJ, Miles M, Scrivener W & Rubens RD (1988) Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). British Journal of Cancer, 58(5), 621-625. View this article in WRRO
Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW & Rubens RD (1988) Osteocalcin: a potential marker of metastatic bone disease and response to treatment. European Journal of Cancer and Clinical Oncology, 24(7), 1211-1217.
Coleman RE, Whitaker KB, Moss DW, Mashiter G, Fogelman I & Rubens RD (1988) Biochemical prediction of response of bone metastases to treatment. British Journal of Cancer, 58(2), 205-210.
Rubens RD, Tinson CL, Coleman RE, Knight RK, Tong D, Winter PJ & North WRS (1988) Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. British Journal of Cancer, 58(5), 626-630.
Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD & Fogelman I (1988) Bone scan flare predicts successful systemic therapy for bone metastases. Journal of Nuclear Medicine, 29(8), 1354-1359.
Coleman RE, Meier CA, Rubens RD & Fogelman I (1988) Comparison of⁹⁹Tc^m-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer. Nuclear Medicine Communications, 9(7), 481-485.
Coleman RE, Fogelman I & Rubens RD (1988) Hypercalcaemia and breast cancer - An increased humoral component in patients with liver metastases. European Journal of Surgical Oncology, 14(5), 423-428.
Coleman RE, Rubens RD & Fogelman I (1988) Reappraisal of the baseline bone scan in breast cancer. Journal of Nuclear Medicine, 29(6), 1045-1049.
Coleman RE, Fogelman I & Rubens RD (1987) Are liver metastases involved in the pathogenesis of hypercalcaemia of malignancy (HM)?. Bone, 8(4), 267-267.
Coleman RE & Rubens RD (1987) The clinical course of bone metastases from breast cancer. British Journal of Cancer, 55(1), 61-66.
Coleman RE & Rubens RD (1987) 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. British Journal of Cancer, 56(4), 465-469.
Coleman RE, Harper PG, Gallagher C, Osborne R, Rankin EM, Silverstone AC, Slevin ML, Souhami RL, Tobias JS, Trask CW & Wiltshaw E (1986) A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemotherapy and Pharmacology, 18(3).
Mouridsen HT, Cornbleet M, Stuart-Harris R, Smith I, Coleman R, Rubens R, McDonald M, Rainer H, van Oosterom A & Smyth J (1985) Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. Investigational New Drugs, 3(2), 139-148.
Coleman RE & Rubens RD (1985) Bone metastases and breast cancer. Cancer Treatment Reviews, 12(4), 251-270.
Coleman RE, Maisey MN, Knight RK & Rubens RD (1984) Mitoxantrone in advanced breast cancer—a phase II study with special attention to cardiotoxicity. European Journal of Cancer and Clinical Oncology, 20(6), 771-776.
Smyth JF, Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, Rubens RD, McDonald M, Mouridsen HT, Rainer H & van Oosterom AT (1984) Mitoxantrone as first-line chemotherapy for advanced breast cancer: Results of a European collaborative study. Seminars in Oncology, 11(3 SUPPL. 1), 15-18.
Cornbleet MA, Stuart-Harris RC, Smith IE, Coleman RE, Rubens RD, McDonald M, Mouridsen HT, Rainer H, Van Oosterom AT & Smyth JF (1984) Mitoxantrone for the treatment of advanced breast cancer: Single-agent therapy in previously untreated patients. European Journal of Cancer and Clinical Oncology, 20(9), 1141-1146.
Probert J, Dodwell D, Broggio J, Coleman R, Marshall H, Darby SC & Mannu GS () Identification of recurrences in women diagnosed with early invasive breast cancer using routinely collected data in England. BJC Reports, 3(1).
O’Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell’Orto P, Lang I, Bellet M, Bonnefoi HR , Tondini C et al () Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer. JAMA Oncology.
Brown J, Paggiosi MA, Rathbone E, Gregory W, Bertelli G, Din O, McCloskey E, Dodwell D, Cameron D, Eastell R & Coleman R () Adjuvant bisphosphonate therapy and bone health. Journal of Bone and Mineral Research.
Coleman R () Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology. Journal of Bone and Mineral Metabolism.
Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B , Burstein HJ et al () Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Journal of Clinical Oncology.
Coleman R () Bone-Targeted Agents and Metastasis Prevention. Cancers, 14(15), 3640-3640.
Lovero D, D’Oronzo S, Palmirotta R, Cafforio P, Brown J, Wood S, Porta C, Lauricella E, Coleman R & Silvestris F () Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. British Journal of Cancer.
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S , Denkert C et al () Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer. JAMA Oncology.
Coleman R, Zhou Y, Jandial D, Cadieux B & Chan A () Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer. Advances in Therapy.
Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J , Jückstock J et al () Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment. JAMA Oncology.
Singh K, Gillett S, Ireson J, Hills A, Tidy JA, Coleman RE, Hancock BW & Winter MC () M‐EA (methotrexate, etoposide, dactinomycin) and EMA‐CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first line treatment of high‐risk Gestational Trophoblastic Neoplasia. International Journal of Cancer.
Wilson C, Nutter F, Brown H, Coleman R & Holen I () Effects of the female hormone inhibin-A in vivo: potential contribution to the antitumour effect of Zoledronic acid. Bone Abstracts.
Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW & Lawrie TA () Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews.
Greenfield D, Blewitt A, Coleman R, Walsh J, Snowden J, Ross R & Han T () Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. Endocrine Abstracts.
Burkinshaw R, Thorpe H & Coleman R () Bisphosphonates and prevention of metastases: the AZURE study. Breast Cancer Online, 10(11).
Papazisis KT, Habeshaw T & Miles DW () Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. International Journal of Clinical Practice, 58(6), 581-586.
Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul J , Reed NS et al () Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. British Journal of Cancer, 84(2), 170-178.

Chapters

Coleman R (2024) Bone metastases, medical treatment, Reference Module in Biomedical Sciences Elsevier
Coleman R (2022) Bone metastases—current status of bone-targeted treatments, Bone Cancer (pp. 957-966). Elsevier
Coleman RE, Brown J & Holen I (2020) Bone Metastases, Abeloff's Clinical Oncology (pp. 809-830.e3). Elsevier
Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R & Costa L (2020) Bone metastases Springer Science and Business Media LLC
Coleman R (2019) Prevention and Treatment of Skeletal Complications, Management of Breast Cancer in Older Women (pp. 193-218). Springer International Publishing
Coleman R (2019) Bone Metastases; Medical Treatment, Encyclopedia of Endocrine Diseases (pp. 320-328). Elsevier
Chow E, Finkelstein JA, Sahgal A & Coleman RE (2018) Metastatic cancer to the bone, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (pp. 1970-1982).
Wilson C, Taylor F & Coleman R (2018) Toxicity of Bone-Targeted Agents in Malignancy, Side Effects of Medical Cancer Therapy (pp. 439-460). Springer International Publishing
Coleman R (2015) Bone metastases – current status of bone-targeted treatments, Bone Cancer (pp. 677-683). Elsevier
Chow E, Finkelstein JA, Sahgal A & Coleman RE (2015) Metastatic cancer to the bone, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology: Tenth Edition
Coleman R (2015) Bone metastases - current status of bone-targeted treatments, Bone Cancer: Primary Bone Cancers and Bone Metastases: Second Edition (pp. 677-683).
Coleman RE (2014) Adjuvant systemic therapy: Bone-targeted treatments, Diseases of the Breast: Fifth Edition
Coleman RE & Holen I (2014) Bone Metastases, Abeloff's Clinical Oncology (pp. 739-763.e3). Elsevier
Coleman RE & Holen I (2013) Bone Metastases, Abeloff's Clinical Oncology: Fifth Edition (pp. 739-763).
Adler RA, Anderson DE, Arabi A, Arnett TR, Bachrach LK, Ballane G, Baran D, Barnes GL, Baron R, Bauer DC , Bauman WA et al (2013) Contributors, Osteoporosis (pp. xix-xxiii). Elsevier
Wilson C, Taylor FG & Coleman RE (2013) Toxicity of Bone-Targeted Agents in Malignancy, Side Effects of Medical Cancer Therapy (pp. 531-567). Springer London
Lipton A, Dansey R & Coleman R (2013) Cancer Treatment-Induced Bone Loss in Patients with Breast Cancer, Osteoporosis (pp. 1445-1454). Elsevier
Abbruzzese JL, Abeloff MD, Abou-Alfa GK, Abrahm JL, Abrams JS, Acs G, Aisner J, Aisner SC, Alani RM, Alberts SR , Ambinder RF et al (2008) Contributors, Abeloff's Clinical Oncology (pp. xi-xxvi). Elsevier
Coleman RE & Holen I (2008) Bone Metastases, Abeloff's Clinical Oncology (pp. 845-871). Elsevier
Coleman RE & Croucher PI (2006) Osteoblastic Metastases, Textbook of Bone Metastases (pp. 41-50).
Vinholes J & Coleman R (1997) The management of bone metastases, The Teaching Cases from Annals of Oncology (pp. 29-36). Springer Netherlands
Alazzam M, Tidy J, Osborne R, Coleman R & Hancock BW () Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia John Wiley & Sons, Ltd
Coleman RE & Neville-Webbe HL () Prevention of Bone Metastases, Textbook of Bone Metastases (pp. 387-397). John Wiley & Sons, Ltd
Coleman RE, Cook GJR & Fogelman I () Radioisotope and PET Imaging of Bone Metastases, Textbook of Bone Metastases (pp. 77-90). John Wiley & Sons, Ltd
Coleman RE () Use in Prostate Cancer, Textbook of Bone Metastases (pp. 377-385). John Wiley & Sons, Ltd
Coleman RE & Ralston SH () Management of Hypercalcaemia, Textbook of Bone Metastases (pp. 351-360). John Wiley & Sons, Ltd
Coleman RE, Plunkett TA & Rubens RD () Clinical Features and Prognosis of Bone Metastases, Textbook of Bone Metastases (pp. 63-75). John Wiley & Sons, Ltd
Coleman RE, Gwyn K & Theriault R () Treatment of Lytic Bone Metastases, Textbook of Bone Metastases (pp. 361-368). John Wiley & Sons, Ltd
Coleman RE, Guillevin R, Vallée JN, Martin-Duverneuil N, Lo D, Lafitte F, Maillard JC & Chiras J () Imaging of Spinal Bone Metastases, Textbook of Bone Metastases (pp. 91-104). John Wiley & Sons, Ltd
Coleman RE & Dunstan CR () The Role of RANK, RANK Ligand and Osteoprotegerin in the Lytic Effects and Growth of Bone Metastases, Textbook of Bone Metastases (pp. 51-62). John Wiley & Sons, Ltd
Coleman RE & Berenson JR () Use in Multiple Myeloma, Textbook of Bone Metastases (pp. 369-376). John Wiley & Sons, Ltd
Coleman RE & Rogers MJ () Mechanisms of Action of Bisphosphonates, Textbook of Bone Metastases (pp. 323-343). John Wiley & Sons, Ltd
Coleman RE & Eccles SA () General Mechanisms of Metastasis, Textbook of Bone Metastases (pp. 1-25). John Wiley & Sons, Ltd
Coleman RE, Martin TJ, Danks JA & Henderson MA () Parathyroid Hormone-Related Protein and Bone Metastases, Textbook of Bone Metastases (pp. 27-39). John Wiley & Sons, Ltd
Coleman RE, Salai M & Dudkiewicz I () Surgical Biopsy of Bone Metastases, Textbook of Bone Metastases (pp. 123-131). John Wiley & Sons, Ltd
Coleman RE & Brown JE () Monitoring Response to Treatment-the Role of Biochemical Markers, Textbook of Bone Metastases (pp. 105-121). John Wiley & Sons, Ltd
Coleman RE & Clézardin P () Antitumour Effects of Bisphosphonates, Textbook of Bone Metastases (pp. 345-350). John Wiley & Sons, Ltd

Conference proceedings papers

Coleman RE, Fried G, Kim S-B, Kuchuk I, Kiesl D, Ramos M, Sohn J, Siegel J, Li R, Uema D , Wagner V et al (2021) Abstract PS14-01: Radium-223 in women with HR-positive bone-metastatic breast cancer receiving endocrine therapy: International phase 2, randomized, double-blind, placebo-controlled trial (pp ps14-01-ps14-01)
Coleman R (2021) MANAGEMENT OF BONE DISEASE IN CANCER. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S37-S38)
Coleman R (2021) INFLUENCE OF ADJUVANT BISPHOSPHONATES AND DENOSUMAB ON BREAST CANCER OUTCOMES. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S93-S93)
Winter M, Kendall J, Brown S, Rathbone E, Wilson C, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I , Coleman R et al (2021) A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. CANCER RESEARCH, Vol. 81(4)
Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, Neven P, Stierer M, Holcombe C, Coleman R , Forbes J et al (2021) 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ. CANCER RESEARCH, Vol. 81(4)
Stavraka C, Evans TRJ, Dunlop J, Earl H, Cameron DA, Coleman RE, Perren T, Leonard RCF & Mansi JL (2020) Abstract P2-16-15: 10-year outcome for women randomized in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An anglo-celtic cooperative oncology group study. Poster Session Abstracts
Coleman R (2019) Estimating the magnitude of clinical benefit of bisphosphonates and denosumab in the adjuvant setting. The Breast, Vol. 44 (pp S12-S12)
Ottewell PD, Lefley DV, Freeman K, Gregory WM, Hanby AM, Spicer-Hadlington AR, Liu X, Bradbury SM, Hambley L, Allocca G , Cookson V et al (2019) Abstract P1-05-01: Breast cancer cell-derived IL-1B drives metastasis and colonisation of the bone microenvironment. Poster Session Abstracts
Coleman R, Gregory W, Jean-Mairet J, Tercero JC, Torres-Martin J & Gomis R (2019) Abstract P1-17-01: Long term survival benefits of adjuvant zoledronic acid associated with maf status of primary tumor. Cancer Research, Vol. 79(4_Supplement)
Gee J, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K , Rauchhaus P et al (2019) Abstract P2-12-01: Dose- and exposure-response relationship and biomarker correlation analysis in breast tumors from patients treated with capivasertib, an AKT inhibitor, in the STAKT randomized, placebo controlled pre-surgical study. Poster Session Abstracts
Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) Abstract B13: Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence. Early Clinical Opportunities
Coleman RE, Finkelstein D, Barrios CH, Martin M, Iwata H, Glaspy JA, Zhou Y, Jandial D & Chan A (2018) Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.. Journal of Clinical Oncology, Vol. 36(15_suppl) (pp 501-501)
Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Kelly S , Horgan K et al (2018) Abstract P4-04-06: AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human breast cancers. Poster Session Abstracts
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S , Denkert C et al (2018) Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial). General Session Abstracts
Janni W, Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Bauer E, Fink V , Bekes I et al (2018) Abstract GS1-06: Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study. General Session Abstracts
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S , Denkert C et al (2018) A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial). CANCER RESEARCH, Vol. 78(4)
Janni W, Friedl TWP, Fehm T, Mueller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Bauer E, Fink V , Bekes I et al (2018) Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study. CANCER RESEARCH, Vol. 78(4)
Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence.. MOLECULAR CANCER RESEARCH, Vol. 16(8) (pp 68-69)
Sestak I, Cuzick J, Blake G, Patel R, Coleman R & Eastell R (2018) Off-treatment Bone Mineral Density Changes in Postmenopausal Women after 5 Years of Anastrozole. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 46-46)
Friedl TWP, Rack B, Fehm T, Mueller V, Lichtenegger W, Blohmer J-U, Lorenz R, Forstbauer H, Bauer E, Fink V , Bekes I et al (2018) Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: results from the phase III Success A study. ONCOLOGY RESEARCH AND TREATMENT, Vol. 41 (pp 32-32)
Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Kelly S , Horgan K et al (2018) AZD5363, AN AKT INHIBITOR, SIGNIFICANTLY INHIBITS KEY BIOMARKERS OF THE AKT PATHWAY AND KI67, IN A RANDOMIZED, PLACEBO, CONTROLLED STUDY (STAKT) IN HUMAN BREAST CANCERS. BRITISH JOURNAL OF SURGERY, Vol. 105 (pp 24-24)
Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Kelly S , Horgan K et al (2018) AZD5363, an AKT inhibitor, significantly inhibits key biomarkers of the AKT pathway and Ki67, in a randomized, placebo, controlled study (STAKT) in human breast cancers. CANCER RESEARCH, Vol. 78(4)
Goyal A, Coleman RE, Dodwell D, Fallowfield L, Jenkins VA, Mann B & Reed MW (2017) Abstract OT3-03-02: Maximising recruitment and retention of patients into UK-ANZ POSNOC trial. Ongoing Clinical Trials
Rugo HS, Drumea KC, Campone M, Barnadas A, Petrenciuc O, Zhang A, Li R & Coleman RE (2017) Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases. Ongoing Clinical Trials
Coleman RE, Fried G, Petrenciuc O, Sawhney A, Li R & Rugo HS (2017) Abstract OT1-04-04: A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor–positive breast cancer patients with bone metastases. Ongoing Clinical Trials
Roberston JFR, Cheung KL, Ahmed S, Coleman RE, Evans A, Holcombe C, Rea D, Rauchhaus P, Skene A, Littleford R , Jahan A et al (2017) Abstract P3-06-03: The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT trial). Poster Session Abstracts
Coleman R, Hall A, Bell R, Cameron D, Marshall H, Jean-Mairet J, Tercero J, Rojo F, Albanell J & Gomis R (2017) Abstract P1-09-01: Impact of MAF gene amplification on disease recurrence and effects of adjuvant zoledronic acid in early breast cancer. Poster Session Abstracts
Yardley D, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J , Schneeweiss A et al (2017) Abstract P5-15-03:nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial. Poster Session Abstracts
Oke A, Knox J, Tan J, Aigret B, Schmid P, Coleman RE, Cuzick J & Thorat MA (2017) Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial. TRIALS, Vol. 18
Rugo H, Petrenciuc O, Zhang A, Li R & Coleman RE (2016) A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases. Annals of Oncology, Vol. 27 (pp vi97-vi97)
Coleman RE (2016) ADDITIVE EFFECTS OF ANTIRESORPTIVE TREATMENTS BEYOND OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S563-S563)
Cuzick J, Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P , Stierer M et al (2016) Abstract S6-03: Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS). General Session Abstracts
Coleman RE, Huang L, Petrenciuc O, Zaccarini P & Rugo HS (2016) Abstract OT2-01-05: A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy ± radium-223 dichloride in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases. Ongoing Clinical Trials
Rugo HS, Huang L, Petrenciuc O, Zaccarini P & Coleman RE (2016) Abstract OT2-01-11: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in human epidermal growth factor receptor 2–negative, hormone receptor–positive breast cancer patients with bone metastases. Ongoing Clinical Trials
Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H , Liefers GJ et al (2016) Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials. European Journal of Cancer, Vol. 54 (pp 57-63) View this article in WRRO
Amadori D, Rossetti C, Aglietta M, Messina C, Versari A, Vogelzang NJ, Sartor A, Coleman RE, Govi S, Fang F , Skjorestad I et al (2015) 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. ANNALS OF ONCOLOGY, Vol. 26 (pp 55-55)
Sartor O, Coleman RE, Morris MJ, Nilsson S, Shore N, Sweeney C, Vogelzang NJ, Petrenciuc O, Gratt J & Parker C (2015) 2530 Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA. European Journal of Cancer, Vol. 51 (pp S484-S485)
Sartor O, Coleman RE, Nilsson S, Vogelzang NJ, Staudacher K, Thuresson M & Parker C (2015) 2510 3-year follow-up of chemotherapy following radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases (Mets) from ALSYMPCA. European Journal of Cancer, Vol. 51 (pp S477-S477)
Parker C, Vogelzang NJ, Sartor AO, Coleman RE, Skjorestad I, Fang F & Nilsson S (2015) 3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.. Journal of Clinical Oncology, Vol. 33(15_suppl) (pp e16102-e16102)
Goyal A, Coleman RE, Dodwell DJ, Fallowfield L, Jenkins VA, Mann B & Reed MW (2015) POSNOC: Positive sentinel node—Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy: A randomised trial looking at axillary treatment in early breast cancer (ISRCTN54765244).. Journal of Clinical Oncology, Vol. 33(15_suppl) (pp TPS1103-TPS1103)
Coleman RE, Huang L, Petrenciuc O & Zaccarini P (2015) A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2^- hormone receptor⁺ breast cancer patients (pts) with bone metastases (mets).. Journal of Clinical Oncology, Vol. 33(15_suppl) (pp TPS1104-TPS1104)
Yardley DA, Cortes J, Coleman RE, Conte PF, Brufsky A, O'Shaughnessy J, Wright GLS, Eakle JF, Wilks S, Shtivelband M , Young RR et al (2015) Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).. Journal of Clinical Oncology, Vol. 33(15_suppl) (pp TPS1106-TPS1106)
Goldhirsch A, Gelber RD, Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos EM, Bellet M, Bonnefoi H, Climent MA , Pavesi L et al (2015) Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial. General Session Abstracts
Giobbie-Hurder A, Thürlimann B, Ejlertsen B, Neven P, Coleman RE, Smith I, Wardley AM, Láng I, Colleoni M, Debled M , Forbes JF et al (2015) Abstract P4-18-03: IBCSG BIG 1-98 study: The long-term follow-up experience. Poster Session Abstracts
Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Liefers G-J, Winter MC, Weilbaecher KN, Akazawa K, Hinsley S , Putter H et al (2015) Abstract P3-11-04: Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials. Poster Session Abstracts
Yardley DA, Coleman RE, Conte P, O'Shaughnessy J, Cortes J, Glück S, Brufsky A, Nabholtz J-MA, Li L, Miller J , Barton D et al (2015) Abstract OT2-2-01: tnAcity: A phase II/III trial ofnab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC). Ongoing Clinical Trials
Parker C, Vogelzang NJ, Sartor AO, Coleman RE, Fang F, Skjorestad I & Nilsson S (2015) 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA.. Journal of Clinical Oncology, Vol. 33(7_suppl) (pp 195-195)
Parker C, Vogelzang N, Sartor O, Bottomley D, Coleman RE, Skjorestad I, Aksnes A, Wahba M & Nilsson S (2014) 1.5-Year Posttreatment Follow-Up of Radium-223 Dichloride (Ra-223) Safety in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases from Alsympca: Characterization of Hematologic Safety Profiles. Annals of Oncology, Vol. 25 (pp iv263-iv263)
Parker C, Vogelzang NJ, Sartor AO, Bottomley D, Coleman RE, Skjorestad I, Wahba M & Nilsson S (2014) 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.. Journal of Clinical Oncology, Vol. 32(15_suppl) (pp 5070-5070)
Klotz L, Smith MR, Coleman RE, Pittman KB, Milecki P, Wei R, Balakumaran A & Fizazi K (2014) Symptomatic skeletal events (SSE) in patients with advanced prostate cancer: Results from a phase III trial of denosumab for the prevention of skeletal-related events.. Journal of Clinical Oncology, Vol. 32(15_suppl) (pp 5075-5075)
Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz J-MA, O'Shaughnessy J, Li L, Barton D , Beck RM et al (2014) tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, Vol. 32(15_suppl) (pp TPS1146-TPS1146)
Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M, Forbes JF, Singh S & Cuzick J (2014) EFFECT OF AROMATASE INHIBITION ON BONE DENSITY AND BONE TURNOVER IN HEALTHY POSTMENOPAUSAL WOMEN: RESULTS OF THE INTERNATIONAL BREAST CANCER INTERVENTION STUDY II (IBIS-II). OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S281-S281)
Velikova G, Barrett-Lee P, Bloomfield D, Brunt M, Canney P, Coleman R, Morden J, Sergenson N, Verill M, Wardley A , Bliss J et al (2014) Quality of life results of the UK TACT2 Trial: More intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). EUROPEAN JOURNAL OF CANCER, Vol. 50 (pp S109-S109)
Canney P, Barrett-Lee P, Bartlett J, Bertelli G, Coleman R, Earl H, Ellis P, Morden J, Murray N, Stein R , Cameron D et al (2014) The UK TACT2 Trial: Non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). EUROPEAN JOURNAL OF CANCER, Vol. 50 (pp S99-S100)
Pittman K, Smith M, Coleman R, Klotz L, Milecki P, Wei R, Balakumaran A & Fizazi K (2014) Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: a comparison with skeletal-related events. BJU INTERNATIONAL, Vol. 113 (pp 23-23)
Sanganalmath P, Purohit K, Winter M, Horsman J, Ramakrishnan S, Hatton M, Lee C, Dunn K, Din O & Coleman R (2014) Eribulin monotherapy in heavily pre-treated patients with advanced breast cancer: "Real world" experience. EUROPEAN JOURNAL OF CANCER, Vol. 50 (pp S181-S182)
Sestak I, Singh S, Cuzick J, Blake G, Patel R, Coleman R, Dowsett M, Forbes JF, Howell A & Eastell R (2014) Risedronate Prevents Anastrozole-Induced Bone Loss In The IBIS-II Prevention Trial.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S110-S110)
Smith MR, Coleman RE, Klotz L, Pittman KB, Milecki P, Wei R, Balakumaran A & Fizazi K (2014) Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.. Journal of Clinical Oncology, Vol. 32(4_suppl) (pp 35-35)
Nilsson S, Vogelzang NJ, Sartor AO, Bottomley D, Coleman RE, Skjorestad I, Wahba M & Parker C (2014) 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study.. Journal of Clinical Oncology, Vol. 32(4_suppl) (pp 9-9)
Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Zhou Y, Maniar T & Coleman RE (2013) Abstract OT2-6-02: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebo-controlled, randomized, double-blind, phase 3 clinical trial. Ongoing Trials Poster Session Abstracts
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Marshall H, Banks RE, Selby PJ, Coleman RE & Brown JE (2013) Abstract P2-11-07: Proteins predictive of bone metastasis development in breast cancer patients. Poster Session Abstracts
Coleman R, Gnant M, Paterson A, Powles T, von Minckwitz G, Pritchard K, Bergh J, Bliss J, Gralow J, Anderson S , Evans V et al (2013) Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. General Session Abstracts
Coleman RE (2013) THE ROLE OF BONE-MODIFYING AGENTS (BMA) IN THE TREATMENT OF BONE METASTASES. ANNALS OF ONCOLOGY, Vol. 24 (pp 26-26)
Stroelin P, Haese A, Heinzer H, Steuber T, Sartor O, Coleman RE, Nilsson S, Vogelzang N, Cross A, O'Bryan-Tear G , Staudacher K et al (2013) Safety of cytotoxic chemotherapy following Radium223-Dichlorid(Ra223)-therapy in the phase 3 ALSYMPCA study in patients with castration resistant prostate cancer (CRPC) metastatic to the bone. ONKOLOGIE, Vol. 36 (pp 20-20)
Steuber T, Heinzer H, Haese A, Stroelin P, Parker C, Coleman RE, Nilsson S, Vogelzang N, Loyd AJ, Staudacher K , van Gool R et al (2013) Updated Survival, Quality of life (QOL) and Safety-data of Radium223 Dichlorid (Ra223) in patients with castration resistant prostate cancer (CRPC) with bone metastasis from the Phase 3 double-blind randomised, multinational study (ALSYMPCA). ONKOLOGIE, Vol. 36 (pp 18-18)
Coleman R, Fossa S, Chodacki A, Wedel S, Bruland O, Staudacher K, Garcia-Vargas J & Sartor O (2013) Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S688-S688)
Coleman R (2013) Micro-environment and bone metastases. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S78-S78)
Wiechno P, Helle SI, Logue J, Nilsson S, Sartor O, Coleman RE, Kliment J, Fang F & Parker C (2013) Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S690-S691)
Sartor O, Coleman R, Nilsson S, Heinrich D, Staudacher K, Garcia-Vargas J & Vogelzang N (2013) Radium-223(Ra-223) safety and efficacy in prostate cancer with bone metastases: phase 3 ALSYMPCA study findings stratified by age. BJU INTERNATIONAL, Vol. 112 (pp 15-16)
Chan A, Goss P, Barrios C, Finkelstein DM, Iwata H, Martin M, Coleman R, Braun A, Zhou Y & Maniar T (2013) DENOSUMAB VERSUS PLACEBO AS ADJUVANT TREATMENT FOR WOMEN WITH EARLY-STAGE BREAST CANCER AT HIGH RISK OF DISEASE RECURRENCE (D-CARE). ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 9 (pp 53-53)
Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Ding B, Maniar T & Coleman RE (2013) Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
Coleman R (2013) BISPHOSPHONATES, BONE AND CANCER: MORE THAN INHIBITION OF BONE RESORPTION?. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S29-S29)
Saad F, Patrick DJ, Smith M, Cleeland C, Fallowfield L, Tombal B, Oudard S, Shore N, Marx G, Coleman R , Gomez-Veiga F et al (2013) The impact of bone metastases on pain: post-hoc analysis of a phase III study of denosumab in men with non-metastatic Castration-Resistant Prostate Cancer (CRPC). BJU INTERNATIONAL, Vol. 111 (pp 38-38)
Coleman RE (2013) THE METASTATIC MICROENVIRONMENT OF BREAST CANCER: CLINICAL IMPLICATIONS. BREAST, Vol. 22 (pp S7-S7)
Nilsson S, Sartor AO, Bruland OS, Fang F, Aksnes A-K & Parker C (2013) Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.. Journal of Clinical Oncology, Vol. 31(6_suppl) (pp 19-19)
Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M, Forbes J, Singh S & Cuzick J (2013) Effect of Aromatase Inhibition on Bone Density and Bone Turnover in Healthy Postmenopausal Women: Results of the International Breast cancer Intervention Study II (IBIS-II). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Coleman R (2012) RANKL signalling: bone metastasis and beyond. BREAST, Vol. 21 (pp S5-S5)
Parker C, Coleman RE, Nilsson S, Vogelzang N, Lloyd AJ, Staudacher K, van Gool R & Sartor AO (2012) UPDATED SURVIVAL, QUALITY OF LIFE (QOL), AND SAFETY DATA OF RADIUM-223 CHLORIDE (RA-223) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES FROM THE PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTINATIONAL STUDY (ALSYMPCA). ANNALS OF ONCOLOGY, Vol. 23 (pp 296-296)
Sartor O, Coleman RE, Nilsson S, Vogelzang N, Cross A, O'Bryan-Tear G, Staudacher K, Garcia-Vargas JE, Zou J & Parker C (2012) SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES. ANNALS OF ONCOLOGY, Vol. 23 (pp 308-309)
Coleman RE, Barrios C, Bell R, Finkelstein DM, Iwata H, Martin M, Braun A, Ke C, Maniar T & Goss PE (2012) DENOSUMAB VERSUS PLACEBO AS ADJUVANT TREATMENT FOR WOMEN WITH EARLY-STAGE BREAST CANCER AT HIGH RISK OF DISEASE RECURRENCE (D-CARE): AN IN PROGRESS, PHASE 3 CLINICAL TRIAL. ANNALS OF ONCOLOGY, Vol. 23 (pp 115-115)
Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A , Johannessen DC et al (2012) Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(18)
Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A , Johannessen DC et al (2012) Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
Gregory W, Marshall H, Bell R, Cameron DA & Coleman RE (2012) Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
Sartor AO, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A, Johannessen DC , Nilsson S et al (2012) Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
Marshall H, Gregory W, Bell R, Cameron DA, Dodwell DJ, Keane MM, Gil MJG, Davies C, Coleman RE & Investigators AZURE (2012) Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): The influence of menopausal status and age on treatment effects.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
Leonard RCF, Adamson D, Bertelli G, McLinden M, Haiying N, Dunlop J, Mansi J, Coleman RE, Thomas G & Anderson R (2012) The relative value of anti-Mullerian hormone to predict premature menopause in patients receiving adjuvant chemotherapy for breast cancer: Results from the OPTION trial. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
Goss PE, Barrios CH, Bell R, Finkelstein DM, Iwata H, Martin M, Braun AH, Ke C, Maniar T & Coleman RE (2012) Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
Coleman RE, Wright J, Houston S, Agrawal R, Purohit OP-K, Hayward L, Simmonds P, Waterhouse A, Marshall H & Investigators BISMARK (2012) Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
Awada A, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Garcia A & Perez E (2012) SIGNIFICANT ANTITUMOR ACTIVITY IN A RANDOMIZED PHASE 2 STUDY COMPARING 2 SCHEDULES OF NKTR-102 IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC). ANNALS OF ONCOLOGY, Vol. 23 (pp 43-43)
Canney P, Coleman R, Morden J, Barrett-Lee P, Banerji J, Wardley A, Murray N, Laing R, Cameron D & Bliss J (2012) TACT2 Trial in Early Breast Cancer (EBC): Differential Rates of Amenorrhoea in Premenopausal Women Following Adjuvant Epirubicin (E) or Accelerated Epirubicin (aE) Followed by Capecitabine (X) or CMF (CRUK/05/019). EUROPEAN JOURNAL OF CANCER, Vol. 48 (pp S102-S102)
de Boer R, Bundred N, Eidtmann H, Neven P, von Minckwitz G, Martin N, Modi A & Coleman R (2011) S1-3: Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST.. General Session Abstracts
Coleman RE (2011) BONE METASTASES. BREAST, Vol. 20 (pp S19-S20)
Coleman R, Marshall H, Gregory W, Bell R, Dodwell D, Keane M, Gil M, Davies C & Cameron D (2011) Discordant Treatment Effects According to Menopausal Status Following Adjuvant Zoledronic Acid in Stage II/III Breast Cancer - The AZURE Trial (BIG 01/04). EUROPEAN JOURNAL OF CANCER, Vol. 47 (pp S336-S336)
Bell R, Marshall H, Collinson M, Cameron D, Dodwell D, Keane M, Gil M, Davies C & Coleman R (2011) Reduction in Fractures Following Adjuvant Zoledronic Acid in Stage II/III Breast Cancer - the AZURE Trial (BIG 01/04). EUROPEAN JOURNAL OF CANCER, Vol. 47 (pp S376-S376)
Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) Early intervention with a single dose of doxorubicin followed by zoledronic acid induces sustained inhibition of breast cancer-induced bone disease in a mouse model. BONE, Vol. 48 (pp S255-S255)
Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22 (pp 58-58)
Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29)
Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22 (pp 58-58)
Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29)
Shankland C & Coleman R (2011) The effect of zoledronic acid on bone mineral density and bone turnover in patients with early breast cancer on the AZURE trial. BREAST, Vol. 20 (pp S71-S71)
Hadji P, Body J, Bundred N, Brufsky A, Coleman R, Gnant M, Guise T, Lipton A & Aapro M (2011) Updated guidance for the prevention of aromatase inhibitor (AI)-associated bone loss (AIBL) in early breast cancer (EBC). BREAST, Vol. 20 (pp S84-S84)
Coleman R (2011) Is caring for the bone also fighting the breast cancer?. BREAST, Vol. 20 (pp S2-S2)
Coleman RE & Giordano SH (2011) Adjuvant treatment with zoledronic acid in stage II/III breast cancer: The AZURE trial. P and T, Vol. 36(3) (pp 156)
Winter MC, Evans A, Holen I & Coleman RE (2011) The addition of zoledronic acid to combination chemotherapy decreases circulating serum levels of vascular endothelial growth factor (VEGF) in early breast cancer. BONE, Vol. 48(1) (pp S30-S31)
Westbrook JA, Peng J, Cairns DA, Ottewell PD, Holen I, Coleman RE, Selby PJ, Banks RE & Brown JE (2011) Towards biomarkers of bone-metastasis using cellular proteomics. BONE, Vol. 48(1) (pp S33-S33)
Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) Combination vs single agent treatment: The effects of zoledronic acid +/- doxorubicin on breast tumour growth in bone prior to development of osteolytic bone disease. BONE, Vol. 48(1) (pp S41-S41). Sheffield, ENGLAND, 22 September 2010 - 25 September 2010.
Ottewell PD, Brown H, Evans CA, Wind NS, Brown NJ, Coleman RE & Holen I (2011) First evidence for anti-tumour effects of doxorubicin and zoledronic acid from an immunocompetent mouse model. BONE, Vol. 48(1) (pp S42-S42)
Woodward EJ, Brown JE, Barnfield MC, Taylor J, Blake GM, Fogelman I, Turner LA, Thorpe H, Dodwell D, Joffe JK & Coleman RE (2011) Bone health in breast cancer survivors following adjuvant bisphosphonate therapy: AZURE quantitative bone scan sub-study. BONE, Vol. 48(1) (pp S29-S29)
Coleman RE, Woodward EJ, Brown JE, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R , Houston SJ et al (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE-BIG 01-04) for women with stage II/III breast cancer. BONE, Vol. 48(1) (pp S29-S29)
Body J, Cook R, Costa L, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2011) Patients with bone metastases from solid tumours and poor prognostic features may gain survival benefits from zoledronic acid. BONE, Vol. 48(1) (pp S20-S21)
Singh S, Cuzick J, Blake GM, Mesher D, Patel R, Truscott J, Coleman R, Howell A, Forbes J & Eastell R (2011) One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study. BONE, Vol. 48(1) (pp S24-S24)
Leonard R, Adamson D, Anderson R, Ballinger R, Bertelli G, Coleman R, Fallowfield L, Keerie C, McLinden M, Mansi J , Thomas G et al (2010) Abstract P5-13-07: Hormone Levels in the OPTION Trial Show No Ovarian Protection by Goserelin in Adjuvant Chemotherapy for Early Breast Cancer — An Anglo-Celtic Collaborative Group and NCRN Trial. Poster Session Abstracts
DeBoer R, Bundred N, Eidtmann H, Llombert A, Neven P, von Minckwitz G, Martin N, Modi A & Coleman R (2010) Abstract P5-11-01: The Effect of Zoledronic Acid on Aromatase Inhibitor Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The ZO-FAST Study 5-Year Final Follow-Up. Poster Session Abstracts
Holen I, Ottewell PD & Coleman RE (2010) Abstract P6-14-03: Zoledronic Acid Reduces Breast Tumour Growth When Combined with Chemotherapy — Emerging Evidence of Anti-Tumour Effects Outside Bone. Poster Session Abstracts
Winter MC, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Mori S, Holen I & Coleman RE (2010) Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer. Poster Session Abstracts
Huebner JL, Bay Jensen AC, Leeming DJ, Coleman RE, McDaniel G, Karsdal MA & Kraus VB (2010) 048 URINARYMARKERS, ALPHA CTX AND CTXII, ARE INDICATIVE OF OA SEVERITY AND BONE TURNOVER. Osteoarthritis and Cartilage, Vol. 18 (pp S29-S30)
Coleman R (2010) SHOULD BONE TARGETED TREATMENT BE USED IN THE ADJUVANT SETTING?. ANNALS OF ONCOLOGY, Vol. 21 (pp 23-23)
Coleman R (2010) A clinician's perspective. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol. 37 (pp S278-S278)
Costa L, Cook R, Body J, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2010) Zoledronic Acid Treatment Delays Disease Progression and Improves Survival in Patients With Bone Metastases From Solid Tumors and Elevated Levels of Bone Resorption. BONE, Vol. 47 (pp S302-S303)
Body J, Cook R, Costa L, Brown J, Terpos E, Saad F, Lipton A & Coleman R (2010) Possible Survival Benefits From Zoledronic Acid Treatment in Patients With Bone Metastases From Solid Tumors and Poor Prognostic Features. BONE, Vol. 47 (pp S311-S312)
Brown J, Lipton A, Cook R, Michaelson D, Coleman R & Saad F (2010) Correlations between N-telopeptide of type I collagen with survival and fractures in patients with metastatic bone disease from renal cell carcinoma. BONE, Vol. 47 (pp S312-S312)
Ottewell PD, Lefely DV, Cross SS, Coleman RE & Holen I (2010) Sustained inhibition of tumour growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid. BONE, Vol. 47 (pp S317-S317)
Brown HK, Ottewell PD, Lefely DV, Coleman RE & Holen I (2010) Effects of doxorubicin followed by zoledronic acid on early, medium and late stage breast tumour growth in bone. BONE, Vol. 47 (pp S318-S319)
Woodward EJ, Brown JE, Ellis SP, Gutcher S, Lester JE, Purohit O & Coleman RE (2010) Five year efficacy in cancer survivors of single dose zoledronic acid 4 mg in osteopaenia and annual dosing in osteoporosis. BONE, Vol. 47 (pp S310-S311)
Din OS, Brown JE, Ellis SP, Gutcher SA & Coleman RE (2010) The use of ultrasound densitometry as a screening tool for osteoporosis in early breast cancer. BONE, Vol. 47 (pp S311-S311)
Winter MC, Evans A, Holen I & Coleman RE (2010) Exploring the anti-angiogenic potential of zoledronic acid in combination with neoadjuvant chemotherapy in invasive breast cancer. BONE, Vol. 47 (pp S310-S310)
Coleman R (2010) Anti-tumor effects of bisphosphonates in man - myth or reality?. BONE, Vol. 46 (pp S18-S18)
Coleman R (2010) Partnership approach to clinical research in the UK. EJC SUPPLEMENTS, Vol. 8(3) (pp 59-59)
Coleman R (2010) Bone targeted therapy for early breast cancer. EJC SUPPLEMENTS, Vol. 8(3) (pp 123-123)
Lindman H, Lipatov O, Bondarenko I, Panasci L & Coleman R (2010) RIBBON-1: efficacy of capecitabine-bevacizumab in patients with triple-negative metastatic breast cancer (MBC). EJC SUPPLEMENTS, Vol. 8(3) (pp 204-204)
Bundred N, Cramer A, Morris J, Landberg G, Renshaw L, Winter M, Coleman RE, Grassby S, Knox WF & Dixon JM (2010) Randomised placebo controlled trial studying short term biological effects of the combination of letrozole and zoledronic acid on invasive breast cancer. EJC SUPPLEMENTS, Vol. 8(3) (pp 90-91)
Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Bliss JM, Coombes RC & Kilburn LS (2010) Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. BREAST CANCER RES TR, Vol. 124(1) (pp 153-161)
Bliss J, Kilburn L, Coleman R, Forbes J, Coates A, Jones S, Jassem J, Delozier T, Andersen J, Paridaens R & Coombes R (2009) Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES).. General Session Abstracts
Bundred N, Cramer A, Morris J, Landberg G, Renshaw L, Winter M, Coleman R, Grassby S, Knox F & Dixon M (2009) Randomised Placebo Controlled Trial Studying Short Term Biological Effects of the Combination of Letrozole and Zoledronic Acid on Invasive Breast Cancer.. Poster Session Abstracts
Coleman R, Bundred N, De Boer R, Llombarto A, Campbell I, Neven P, Barrios C, Dias R, Miller J & Brufsky A (2009) Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. CANCER RESEARCH, Vol. 69(24) (pp 733S-733S)
Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens RJ , Coombes RC et al (2009) Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES).. CANCER RESEARCH, Vol. 69(24) (pp 487S-487S)
Bundred NJ, Cramer A, Morris J, Landberg G, Renshaw L, Winter M, Coleman RE, Grassby S, Knox F & Dixon M (2009) Randomised Placebo Controlled Trial Studying Short Term Biological Effects of the Combination of Letrozole and Zoledronic Acid on Invasive Breast Cancer. CANCER RESEARCH, Vol. 69(24) (pp 595S-595S)
Banks L, Girgis S, Hodgson S, Liao J, Baffoe G, Kilburn L, Bliss J, Coombes C & Coleman R (2009) (PREMIER POSTER - AWARD CANDIDATE) INTERGROUP EXEMESTANE BREAST CANCER STUDY: REVERSAL OF SKELETAL EFFECTS FOLLOWING WITHDRAWAL OF ENDOCRINE TREATMENTS. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp S280-S280)
Dranitsaris G, Coleman R & Gradishar W (2009) Nab-paclitaxel weekly or q3w compared to docetaxel q3w as first-line therapy in patients with metastatic breast cancer: An economic analysis of a prospective randomized trial. JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15)
Bundred NJ, Landberg G, Coleman RE, Morris J, Winter MC, Holen I, Cramer A, Renshaw L, Grassby S & Dixon JM (2009) Short-term biological effects of zoledronic acid combined with letrozole in postmenopausal women with estrogen receptor-positive invasive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15)
Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE & Saad F (2009) Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15)
Hadji P, Gnant M, Aapro M, Lipton A & Coleman R (2009) DOSING OF ZOLEDRONIC ACID (ZOL) THROUGHOUT THE TREATMENT CONTINUUM IN PATIENTS (PTS) WITH BREAST CANCER (BC). ANNALS OF ONCOLOGY, Vol. 20 (pp 31-31)
Hadji P, Body J, Aapro M, Brufsky A, Coleman R, Guise T, Lipton A & Tubiana-Hulin M (2009) MANAGING AROMATASE INHIBITOR-ASSOCIATED BONE LOSS: PRACTICAL GUIDANCE. ANNALS OF ONCOLOGY, Vol. 20 (pp 32-32)
Winter MC, Cross SS, Ingram CE, Jolley IJ, Holen I, Hatton MQ, Horsman JM & Coleman R (2009) ANZAC: A NEOADJUVANT BIOMARKER STUDY EXPLORING THE ANTI-TUMOUR ACTIVITY OF THE ADDITION OF ZOLEDRONIC ACID TO CHEMOTHERAPY IN BREAST CANCER. ANNALS OF ONCOLOGY, Vol. 20 (pp 55-55)
Frassoldati A, Brufsky A, Bundred N, Lambert-Falls R, Hadji P, Schenk N, Paija O, Mena R & Coleman R (2009) The effect of zoledronic acid in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months integrated follow-up of the Z-FAST/ZO-FAST trials. BREAST, Vol. 18 (pp S51-S52)
Hadji P, Gnant M, Aapro M, Lipton A & Coleman R (2009) Dosing of zoledronic acid (ZOL) throughout the treatment continuum in patients (pts) with breast cancer (BC). BREAST, Vol. 18 (pp S60-S60)
Terpos E, Berenson JR, Lipton A, Coleman R & Cook R (2009) High Baseline NTX Predicts for Inferior Survival and Shorter Time to First SRE in Multiple Myeloma. CLIN LYMPHOMA MYELOM, Vol. 9 (pp S55-S56)
Winter MC, Thorpe HC, Burkinshaw R, Beevers SJ & Coleman RE (2009) The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response – exploratory evidence for direct anti-tumor activity in breast cancer.. Poster Session Abstracts
Eidtmann H, Bundred NJ, DeBoer R, Llombart A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N & Coleman R (2009) The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST.. General Session Abstracts
Coleman RE, Banks LM, Girgis S, Vrdoljak E, Fox J, Cawthorn S, Patel A, Coombes C, Bliss JM, Kilburn LS & on Behalf of the IES Group (2009) Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study.. Poster Session Abstracts
Coleman RE, Banks LM, Girgis S, Vrdoljak E, Fox J, Cawthorn S, Patel A, Coombes C, Bliss JM, Kilburn LS & Grp IES (2009) Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study. CANCER RESEARCH, Vol. 69(2) (pp 144S-144S)
Eidtmann H, Bundred NJ, DeBoer R, Llombart A, Davidson N, Neven P, Von MG, Miller J, Schenk A & Coleman R (2009) The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. CANCER RESEARCH, Vol. 69(2) (pp 74S-74S)
Ottewell PD, Leftey DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. CANCER RESEARCH, Vol. 69(2) (pp 200S-201S)
Winter MC, Thorpe HC, Burkinshaw R, Beevers SJ & Coleman RE (2009) The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumor activity in breast cancer.. CANCER RESEARCH, Vol. 69(2) (pp 330S-330S)
Coleman RE (2009) Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor. BREAST CANCER RESEARCH, Vol. 11 (pp S7-S7) View this article in WRRO
Frassoldati A, Brufsky A, Bundred N, Lambert-Falls R, Hadji P, Mena R, Paija O & Coleman R (2008) THE EFFECT OF ZOLEDRONIC ACID ON AROMATASE INHIBITOR (AI) ASSOCIATED BONE LOSS (AIBL) IN POSTMENOPAUSAL WOMEN (PMW) WITH EARLY BREAST CANCER (EBC) RECEIVING ADJUVANT LETROZOLE: 24 MONTHS (MOS) INTEGRATED FOLLOW-UP OF THE Z-FAST/ZO-FAST TRIALS. ANNALS OF ONCOLOGY, Vol. 19 (pp 78-78)
Coleman R, Cook R, Saad F, Hirsh V, Major P, Dias R & Lipton A (2008) EFFECTS OF ZOLEDRONIC ACID (ZOL) ON SURVIVAL IN PATIENTS WITH METASTATIC BONE DISEASE AND HIGH BONE TURNOVER: RESULTS FROM A META-ANALYSIS. ANNALS OF ONCOLOGY, Vol. 19 (pp 276-276)
Ottewell P, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell cycle arrest in sub-cutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. EJC SUPPLEMENTS, Vol. 6(9) (pp 18-18). Lyon, FRANCE, 5 July 2008 - 8 July 2008.
Cook RJ, Hirsh V, Major PP, Saad F, Dias R, Lipton A & Coleman RE (2008) Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD): Survival in patients with high bone turnover. JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
Dranitsaris G, Lidgren M, Lundkvist J & Coleman RE (2008) Nab-paclitaxel or docetaxel as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): a cost utility analysis in five European countries. JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
Coleman RE & Grp ATACT (2008) Long-term effects of anastrozole on bone mineral density: Seven-year results from the ATAC trial. JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
Poole CJ, Hiller L, Howard HC, Dunn JA, Canney P, Wardley AM, Kennedy MJ, Coleman RE, Leonard RC, Earl HM & Collaborators TT (2008) tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
Brown JE, Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR & Coleman RE (2008) Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP. JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
Evans TR, Yellowlees A, Devine I, Earl HM, Cameron DA, Hutcheon AW, Coleman RE, Crown JP, Leonard RC & Mansi JL (2008) 5-year outcome for women randomised in a phase III trial comparing doxorubicin (A) and cyclophosphamide (C) with doxorubicin and docetaxel (D) as primary medical therapy of breast cancer: An Anglo-Celtic Cooperative Oncology Group Study. JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
Lester J, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA & Coleman RE (2008) Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study. JOURNAL OF CLINICAL ONCOLOGY, Vol. 26(15)
Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA & Grp, ZF&ZFS (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. ONCOLOGIST, Vol. 13(5) (pp 503-514)
Dranitsaris G, Lidgren M, Lundkvist J & Coleman R (2008) Nab-paclitaxel or docetaxel; As alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): A cost utility analysis in five European countries. VALUE HEALTH, Vol. 11(3) (pp A71-A71)
Dranitsaris G, Lidgren M, Lundkvist J & Coleman R (2008) Nab-paclitaxel or docetaxel; as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): cost utility analysis from the perspective of the United Kingdom (UK). EJC SUPPLEMENTS, Vol. 6(7) (pp 67-67)
Coleman R (2008) Recent developments in the management of metastatic bone disease. EJC SUPPLEMENTS, Vol. 6(7) (pp 108-108)
Coleman R, Brown J & Cook R (2008) Serum lactate dehydrogenase (LDH) is a significant prognostic variable for survival in patients with metastatic breast cancer - a multivariate analysis. EJC SUPPLEMENTS, Vol. 6(7) (pp 189-189)
Burkinshaw R, Brufsky A & Coleman R (2008) Antitumor properties of bisphosphonates and possible prevention of bone metastases in breast cancer. EJC SUPPLEMENTS, Vol. 6(7) (pp 129-129)
Murray LJ, Ramakrishnan S, Purohit OP, Manifold IH & Coleman RE (2008) Adjuvant trastuzumab in routine clinical practice - the Sheffield experience and impact of cardiac monitoring guidelines on treatment delivery. EJC SUPPLEMENTS, Vol. 6(7) (pp 124-124)
Lefley DV, Holen I, Coleman RE & Ottewell PD (2008) Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid. BREAST CANCER RESEARCH, Vol. 10 (pp S40-S40) View this article in WRRO
Ottewell PD, Lefley DV, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. BREAST CANCER RESEARCH, Vol. 10 (pp S40-S41) View this article in WRRO
Coleman R, Cook R, Saad F, Hirsh V, Major P, Dias R & Lipton A (2008) Meta-analysis of effects of zoledronic acid (ZOL) on survival in patients with metastatic bone disease (MBD) and high bone turnover. CANCER TREATMENT REVIEWS, Vol. 34 (pp S86-S86)
Coleman R, Brown J & Cook R (2008) Identification of serum lactate dehydrogenase (LDH) as a significant prognostic variable for survival: Multivariate analysis in women with metastatic breast cancer (BC). CANCER TREATMENT REVIEWS, Vol. 34 (pp S78-S79)
Brown J, Cook R & Coleman R (2008) Prognostic variables for occurrence of skeletal-related events (SREs) in patients with breast cancer metastatic to bone: A multivariate analysis. CANCER TREATMENT REVIEWS, Vol. 34 (pp S79-S79)
Lester J, Dodwell D, Purohit O, Gutcher S, Ellis S, Thorpe R, Horsman J, Brown J, Hannon R & Coleman R (2008) Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant breast cancer therapy: Two year results from the AIRIBON study. CANCER TREATMENT REVIEWS, Vol. 34 (pp S51-S51)
Lipton A, Body JJ, Cookc R & Coleman R (2008) Prognosis and skeletal disease course in patients with bone metastases from breast cancer (BC) and normal baseline levels of N-telopeptide of type I collagen (NTX). CANCER TREATMENT REVIEWS, Vol. 34 (pp S53-S53)
Singh S, Cuzick J, Ferguson S, Blake G, Truscott J, Coleman R, Eastel R & Howell A (2008) Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II). CANCER TREATMENT REVIEWS, Vol. 34 (pp S53-S54)
Hirsh V, Major P, Lipton A, Cook R, Langer C, Smith M, Brown J & Coleman R (2008) N-Telopeptide of type I collagen (NTX) levels and prognosis in patients with bone metastases from non-small cell lung cancer (NSCLC) receiving zoledronic acid (ZOL) or placebo. CANCER TREATMENT REVIEWS, Vol. 34 (pp S85-S85)
Winter M, Thorpe H, Burkinshaw R, Beevers S & Coleman R (2008) Potential influence of zoledronic acid on primary tumour response during neoadjuvant chemotherapy for breast cancer. CANCER TREATMENT REVIEWS, Vol. 34 (pp S55-S56)
Ottewell P, Coleman R & Holen I (2008) Mechanisms of apoptosis and cell cycle arrest in intra-tibial breast tumours treated sequentially with doxorubicin followed by zoledronic acid. CANCER TREATMENT REVIEWS, Vol. 34 (pp S62-S62). Heriot Watt Univ, Edinburgh, SCOTLAND, 29 June 2008 - 2 July 2008.
Burkinshaw R, Winter M, Thorpe H, Pedlar J & Coleman R (2008) Osteonecrosis of the jaw and dental related adverse events during adjuvant therapy for early breast cancer: Initial dental safety findings from the AZURE study. CANCER TREATMENT REVIEWS, Vol. 34 (pp S75-S76)
Coleman RE & AZURE Investigators (2008) The AZURE trial for prevention of bone metastases. CLIN EXP METASTAS, Vol. 25 (pp 19-19)
Coleman RE (2008) New diagnostic and therapeutic approaches for cancer induced bone disease. CALCIFIED TISSUE INT, Vol. 82 (pp S24-S24)
Deboerr R, Eidtmann H, Pinotti G, Miller J, Schenk N, Dias R & Coleman R (2007) The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S36-S36)
Eastell R, Coleman R, Mansel R, Bianco A, Nagykalnai T, Cuzick J & ATAC Trialists Grp (2007) The effect of anastrozole on bone mineral density: updated results from the bone subprotocol of the ATAC trial. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S109-S109)
Lipton A, Cook R, Major P, Smith M & Coleman R (2007) Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39)
Singh S, Cuzick J, Edwards R, Blake G, Truscott J, Coleman R, Eastell R & Howell A (2007) Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S9-S9)
Woodward J, Lefley D, Cross N, Ottewell PD, Buttle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A97-A97)
Ottewell PD, Deux B, Monkkonen H, Cross SS, Coleman RE, Clezardin P & Holen I (2007) Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39)
Terpos E, Cook R, Coleman R, Lipton A & Berenson J (2007) Predictors for skeletal-related events in patients with advanced multiple myeloma. BLOOD, Vol. 110(11) (pp 443A-444A)
Berenson J, Cook R, Lipton A, Coleman R & Terpos E (2007) Increased levels of urinary N-telopeptide of type I collagen correlate with reduced survival in patients with advanced multiple myeloma. BLOOD, Vol. 110(11) (pp 449A-449A)
Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS , Coleman R et al (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone Metastases. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(28) (pp 4431-4437). San Antonio, TX, 10 December 2006 - 14 December 2006.
Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R & Aapro M (2007) Updated International Society of Geriatric Oncology (SIOG) recommendations for the use of bisphosphonates in elderly cancer patients with bone metastases. EJC SUPPLEMENTS, Vol. 5(4) (pp 174-174)
Dranitsaris G, Coleman R & Gradishar WJ (2007) Nab-Paclitaxel weekly or Q3Wks compared to Docetaxel Q3Wks as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. EJC SUPPLEMENTS, Vol. 5(4) (pp 219-219)
Lipton A, Cook RJ, Major P, Smith MR & Coleman RE (2007) Early normalization of elevated baseline bone resorption marker levels by zoledronic acid and improved survival in patients with bone metastases from solid tumors. EJC SUPPLEMENTS, Vol. 5(4) (pp 58-58)
Major P, Hirsh V, Lipton A, Cook RJ & Coleman RE (2007) Zoledronic Acid (ZOL) treatment may improve survival in patients with lung cancer and high baseline N-telopeptide levels: a multivariate Cox regression analysis. EJC SUPPLEMENTS, Vol. 5(4) (pp 94-94)
Coleman RE, Thorpe H, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Cousins J, Burkinshaw R & AZURE Investigators (2007) Tolerability of zoledronic acid - first safety data from the AZURE Trial (BIG01/04). EJC SUPPLEMENTS, Vol. 5(3) (pp 15-15)
Coleman R (2007) Role of bisphosphonates in cancer management. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1106-1106)
Ottewell PD, Deux B, Monkkonen H, Coleman RE, Clezardin P & Holen I (2007) Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1111-1111)
Woodward JKL, Lefley DV, Cross NA, Ottewell PD, Battle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1142-1143)
Lester JE, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Purohit OP, Dodwell D & Coleman RE (2007) Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
Scott E, Daley A, Woodroofe N, Coleman R, Powers H, Mutrie N, Siddall V, Crank H & Saxton JM (2007) The effect of a lifestyle intervention on body weight, psychological health status, and risk factors associated with disease recurrence in women recovering from breast cancer treatment: Study protocol and interim findings. JOURNAL OF NUTRITION, Vol. 137(1) (pp 284S-284S)
Van Pozanki C, Ottewell P, Cross S, Hudis C, Coleman RE & Holen I (2007) Osteoprotegerin (OPG) expression in breast tumors and bone metastases. INT J BIOL MARKER, Vol. 22(1) (pp 83-84)
Lipton A, Cook R, Coleman RE, Major P, Terpos E, Body J, Smith MR, Brown J & Garnero P (2007) Normalization of bone markers and improved survival during zoledronic acid therapy. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
Verrill MW, Lee J, Cameron DA, Agrawal R, Coleman RE, McAdam K, Wardley A, Bowman A, Ferrigan L & Yellowlees A (2007) Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
Coleman R (2006) The use of bisphosphonates in elderly cancer patients: SIOG guidelines. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, Vol. 60 (pp S16-S16)
Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ , Guise TA et al (2006) Advances in treating metastatic bone cancer: Summary statement for the First Cambridge Conference. CLINICAL CANCER RESEARCH, Vol. 12(20) (pp 6209S-6212S)
Lipton A, Cook R, Coleman R, Major P & Shirina N (2006) Prognostic significance of persistently elevated N-telopeptide levels in patients with bone metastases from solid tumors. ANNALS OF ONCOLOGY, Vol. 17 (pp 254-255)
Steger GG, Body JJ, Solal-Celigny P, Berardi R, Gascon P, Fan M, Kinsey A, Jun S & Coleman R (2006) Denosumab suppresses bone turnover markers in breast cancer patients (PTS) with bone metastases (METS) naive to intravenous bisphosphonates (IV BP) regardless of antineoplastic treatment. ANNALS OF ONCOLOGY, Vol. 17 (pp 288-289)
Shirina N, Coleman RE & Chen YM (2006) Effect of the number of bone lesions on efficacy of zoledronic acid for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 24(18) (pp 475S-475S)
Coleman RE & ATAC Trialists' Grp (2006) Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 24(18) (pp 5S-5S)
Coleman R (2006) Cancer and bone disease. OSTEOPOROSIS INTERNATIONAL, Vol. 17 (pp 363-364)
Burkinshaw R, Thorpe H, Pollard S, Bell R, Dodwell D, Cameron D, Coleman R & AZURE Investigators (2006) The AZURE trial - does adjuvant zoledronic acid reduce recurrence in patients with high-risk localised breast cancer?. BONE, Vol. 38(3) (pp S70-S71)
Coleman RE & Chen YM (2006) Zoledronic acid provides an enhanced reduction in skeletal-related events in patients with more than three metastatic bone lesions. CANCER TREATMENT REVIEWS, Vol. 32 (pp S51-S51)
Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of zoledronic acid and doxorubicin in breast cancer models in vivo. CANCER TREATMENT REVIEWS, Vol. 32 (pp S30-S30)
Holen I, Hannon RA, Ellis SP, Coleman RE & Brown JE (2006) Effects of clodronate on serum osteoprotogerin (OPG) in patients with metastatic bone disease. CANCER TREATMENT REVIEWS, Vol. 32 (pp S40-S40)
Lester JE, Gutcher SA, Ellis S, Thorpe R, Horsman J, Brown JE, Purohit OP, Dodwell D & Coleman RE (2006) The ARIBON study: Reversal of anastrozole (Arimidex) induced bone loss with oral monthly ibandronate (Bondronat) treatment during adjuvant therapy for breast cancer.. CANCER TREATMENT REVIEWS, Vol. 32 (pp S48-S49)
Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit O & Coleman RE (2006) Infrequent zoledronic acid produces sustained increases in bone mineral density (BMD) in patients with cancer treatment induced bone loss (CTIBL). CANCER TREATMENT REVIEWS, Vol. 32 (pp S19-S19)
Lester J, Horsman J, Purohit OP, Brown JE & Coleman RE (2006) Bone resorption marker directed therapy for metastatic bone disease. BONE, Vol. 38(3) (pp S79-S79)
Lester JE, Penty L, Brown JE, Radstone C, Purohit OP & Coleman RE (2006) Characteristics and toxicity profile of patients receiving more than 2 years treatment with bisphosphonates for bone metastases from breast cancer. BONE, Vol. 38(3) (pp S79-S80)
Neville-Webbe HL, Lefley D, Coleman RE & Holen I (2006) Zoledronic acid (ZOL) and letrozole (LET) induce synergistic levels of apoptosis in breast cancer cells. BONE, Vol. 38(3) (pp S58-S59)
Body JJ, Lichinitser M, Coleman RE & Bergstrom B (2006) Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: Comparative bone turnover marker and safety data. BONE, Vol. 38(3) (pp S69-S69)
Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit O & Coleman RE (2006) For how long can a single infusion of zoledronic acid suppress bone resorption in patients with cancer treatment induced bone loss (CTIBL)?. BONE, Vol. 38(3) (pp S70-S70)
Van Poznak C, Ottewell P, Cross S, Hudis C, Coleman RE & Holen I (2006) Osteoprotegerin (OPG) expression in breast tumours and bone metastases. BONE, Vol. 38(3) (pp S31-S32)
Holen I, Patel R, Lefley DV, Webbe HLN, Coleman RE & Woodward JKL (2006) Effects of zoledronic acid on apoptosis in tumour cell lines; repeated low dosing compared to continuous treatment. BONE, Vol. 38(3) (pp S51-S52)
Michailidou M, Neville-Webbe HL, Evans CA, Brown NJ, Coleman RE & Holen I (2006) Effects of Zoledronic acid and Paclitaxel on endothelial cells in vitro. BONE, Vol. 38(3) (pp S57-S58)
Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC & Bekker P (2006) A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. CLINICAL CANCER RESEARCH, Vol. 12(4) (pp 1221-1228)
Michailidou M, Brown N, Coleman RE & Holen I (2006) Effects of combined treatment with Zometa and Taxol on endothelial cells in vitro. BREAST CANCER RESEARCH, Vol. 8 (pp S18-S18) View this article in WRRO
Holen I, Neville-Webbe H & Coleman RE (2006) Benefits of combined treatments using antiresorptive agents and cytotoxic drugs. BREAST CANCER RESEARCH, Vol. 8 (pp S4-S4) View this article in WRRO
Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo. BREAST CANCER RESEARCH, Vol. 8 (pp S17-S17) View this article in WRRO
Bhalla S, Hibbert C, Chetty M, Poole C, Miles D, Coleman R, Bruce G, Beard S & Watkins J (2006) An evaluation of the clinical and cost-effectiveness of combination chemotherapy with gemcitabine plus paclitaxel for the treatment of metastatic breast cancer (MBC) in the UK from an NHS perspective.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S232-S232)
Coleman R, Thorpe H, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Cousins J & Burkinshaw R (2006) Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy - first safety data from the AZURE trial (BIG01/04).. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S107-S107)
Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and anti-resorptive agents in vitro and in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S290-S290)
Poole CJ, Hiller L, Howard HC, Loi S, Dunn JA, Canney P, Wardley AM, Crown JP, Coleman RE, Verrill MW , Ellis PA et al (2006) Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S114-S114)
Cook RJ, Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Chen YM & Hei YJ (2005) Prognostic significance of biochemical markers of bone metabolism in patients with bone lesions from multiple myeloma (MM).. BLOOD, Vol. 106(11) (pp 335B-335B)
Lipton A, Coleman RE, Major P, Brown JE, Lee KA, Smith M, Saad F, Chen YM, Hei YJ & Cook R (2005) Baseline N-telopeptide levels correlate with risk of skeletal morbidity in patients with multiple myeloma during zoledronic acid therapy.. BLOOD, Vol. 106(11) (pp 964A-965A)
Banks L, Girgis S, Coleman R, Porter L, Baffoe G, Price D, Hall E, Bliss J & Coombes C (2005) Skeletal effect of exemestane in patients with breast cancer.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S327-S327)
Woodward JKL, Neville-Webbe H, Coleman RE & Holen I (2005) The effects of zoledronic acid and doxorubicin in combination on breast cancer cell invasion in vitro. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(7) (pp 1299-1299)
Lipton A, Hei Y, Coleman R, Major P & Cook R (2005) Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(16) (pp 11S-11S)
Brown JE, Lester J, Ellis S, Gutcher S, Turner L, Purohit OP, Hancock B & Coleman R (2005) Can an annual infusion of zoledronic acid protect against cancer-treatment induced bone loss (CTIBL)?. JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(16) (pp 734S-734S)
Coleman RE (2005) Breast cancer and bone. BONE, Vol. 36 (pp S114-S115)
Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M , Crown J et al (2005) Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study. JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(13) (pp 2988-2995)
Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S , Trudeau M et al (2005) Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the National Cancer Institute of Canada Clinical Trials Group. JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(9) (pp 1859-1866)
Aapro M, Schulman C, Zheng M & Coleman R (2005) Onset of time to first skeletal-related event in patients with advanced cancer metastatic to bone and the clinical benefit of bisphosphonates. CANCER TREATMENT REVIEWS, Vol. 31 (pp S24-S24)
Lipton A, Rosen L, Kohno N, Coleman R, Zheng M & Milton S (2005) Zoledronic acid provides long-term reduction of bone pain in patients with bone metastases secondary to breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S29-S30)
Coleman R (2005) Developing more rational use of bisphosphonates in malignancy. CANCER TREATMENT REVIEWS, Vol. 31 (pp S19-S19)
Burkinshaw R, Bell R, Dodwell D, Cameron D, Coleman R & AZURE Investigators (2005) The AZURE trial - Does adjuvant zoledronic acid reduce recurrence in patients with high-risk localised breast cancer?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S46-S47)
Woodward J, Coleman R, Neville-Webbe H & Holen I (2005) The combined effects of zoledronic acid (ZOL) and doxorubicin (DOX) on breast cancer cell invasion in vitro. CANCER TREATMENT REVIEWS, Vol. 31 (pp S43-S43)
Lichinitser MR, Coleman RE, Tjulandin SA, Bergstrom B & Body JJ (2005) Non-inferiority of oral ibandronate to intravenous zoledronic acid for reducing markers of bone turnover in metastatic breast cancer patients. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S259-S259)
Body JJ, Lichinitser MR, Tjulandin SA, Coleman RE & Bergstrom B (2005) Safety of oral ibandronate and intravenous zoledronic acid in breast cancer patients with metastatic bone disease. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S260-S260)
Hei YJ, Saad F, Coleman RE & Chen YM (2005) Fractures negatively affect survival in patients with bone metastases from breast cancer. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S260-S260)
Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Porter LS, Snowdon CF, Hall E, Bliss JM, Coombes RC & IES (2005) Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone biomarker data. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S233-S233)
Lipton A, Hei YJ, Coleman RE, Major P, Smith M, Cook RJ & Milton S (2005) Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S129-S129)
Lester JE, Brown JE, Ellis SP, Gutcher S, Horsman JM & Coleman RE (2005) The use of point of care devices for the monitoring of urinary NTX levels in metastatic breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S52-S53)
Brown JE, Ellis SP, Silcock P, Gutcher SA, Radstone C, Blumsohn A, Hancock BW, Hatton MQ & Coleman RE (2005) Do long-term cancer survivors, treated for testicular cancer or lymphoma, suffer chemotherapy-induced bone loss?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S46-S46)
Ellis SP, Brown JE, Everard JE, Neville-Webbe HL, Hancock BW & Coleman RE (2005) A study to determine whether the bisphosphonate zoledronic acid can be shown to exert a direct anti tumour effect in vivo. CANCER TREATMENT REVIEWS, Vol. 31 (pp S48-S49)
Lester JE, Horsman JM, Mori S, Dodwell D & Coleman RE (2005) Breast cancer and treatment induced bone loss questionnaire. CANCER TREATMENT REVIEWS, Vol. 31 (pp S52-S52)
Evans CA, Neville-Webbe HL, Coleman RE & Holen I (2005) Differential induction of apoptosis following sequential treatments using cytotoxic drugs and zoledronic acid. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S36)
Cross SS, Yang Z, Woodward JKL, Balasubramanian SP, Reed MWR, Coleman RE, Brown NJ & Holen I (2005) Tumour endothelial cells express osteoprotegerin (OPG) - A potential role in tumour angiogenesis?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S37-S38)
Neville-Webbe HL, Coleman RE & Holen I (2005) Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S41-S41)
Neville-Webbe HL, Coleman RE & Holen I (2005) Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S28-S28)
Brown JE, Ellis SP, Gutcher SA, Purohit OP, Turner L, Neville-Webbe HL & Coleman RE (2005) Using bone turnover markers to direct bisphosphonate therapy: Is this a feasible approach?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S30-S30)
Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A & Kaye SB (2004) Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma. JNCI Journal of the National Cancer Institute, Vol. 96(22) (pp 1682-1691)
Conte P & Coleman R (2004) Bisphosphonates in the treatment of skeletal metastases. Seminars in Oncology, Vol. 31 (pp 59-63)
Coleman R, Heidenreich A & Bell R (2004) Managing metastatic bone disease: Three case studies. Seminars in Oncology, Vol. 31 (pp 83-86)
Coleman R (2004) Expanding indications for bone-specific treatments in oncology. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1568-1569)
Peterson MC, Martin SW, Stouch BJ, Chen D, Bauhman S, Holloway DL, Rasmussen AS, Lipton A, Coleman R, Body JJ , Bekker PJ et al (2004) Serum concentrations of AMG 162 were maintained and bone resorption was suppressed for 3 months following a single subcutaneous dose in patients with breast cancer-related bone metastases. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1595-1595)
Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2004) Zoledronic acid (ZOL) in combination with doxorubicin (DOX) has synergistic effects on apoptosis of breast cancer cells (BCCs) in vitro. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1598-1598)
Brown JE, Ellis S, Gutcher S, Lester JE, Turner L, Purohit OP, Hancock BW & Coleman RE (2004) Effect of an annual infusion of zoledronic acid on bone mineral density in cancer survivors following antineoplastic therapy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
Cook RJ, Coleman RE, Saad F, Smith M, Lipton A, Lee KA, Brown JE, Zheng M, Hei YJ & Major P (2004) The predictive value of bone resorption and formation markers in patients with prostate cancer metastatic to bone. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
Brown JE, Cook RJ, Major P, Lipton A, Lee KA, Zheng M, Hei YJ & Coleman RE (2004) The prognostic significance of biochemical markers of bone metabolism in patients with bone metastases from solid tumors other than breast and prostate cancer. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1596-1596)
Ellis SP, Brown JE, Gutcher SA, Hancock BW, Hatton MQ, Rigby AS & Coleman RE (2004) An investigation of the long-term effects of chemotherapy on bone in male long-term cancer survivors. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1587-1587)
Body JJ, Coleman RE, Lipton A, Murphy R, Holloway DL, Bekker PJ & DePaoli AM (2004) Rapid, profound, and prolonged suppression of bone turnover with a single SC dose of AMG 162 in women with breast cancer metastatic to bone. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1593-1593)
Coleman R & ATAC Trialists Grp (2004) Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 68S-68S)
Peterson MC, Martin SW, Stouch B, Chen D, Holloway DL, Body JJ, Lipton A, Coleman R & Bekker PJ (2004) Pharmacolkinetics (PK) and pharmacodynamics (PD) of AMG 162, a fully human monoclonal antibody to receptor activator of NF kappa B ligand (RANKL), following a single subcutaneous dose to patients with cancer-related bone. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 755S-755S)
Brown JE, McCloskey E, Dewar JA, Body JJ, Cameron DA, Purohit OPK, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 743S-743S)
Evans TRJ, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Crown J, Leonard RC & Mansi JL (2004) Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 8S-8S)
Poole CJ, Howard HC, Hiller L, Dunn JA, Wardley AM, Bowman A, Coleman RE, Fernando IN, Ritchie DM & Earl HM (2004) A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in 'tAnGo': A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide (EC)-based, adjuvant chemotherapy (CT) for early stage breast cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 81S-81S)
Herbertson RA, Hatton MQ, Coleman J & Coleman RE (2004) A retrospective study of the management and outcome of patients with stage 1 (marker negative) teratoma. BRITISH JOURNAL OF CANCER, Vol. 91 (pp S39-S39)
Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2004) Combined treatments of breast cancer cells using bisphosphonates and doxorubicin. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(6) (pp 1035-1035)
Neville-Webbe H, Coleman RE & Holen I (2004) Zoledronic acid and paclitaxel have synergistic antitumor activity and induce apoptotic tumor cell death at clinically relevant concentrations. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S132-S132)
Neville-Webbe HL, Evans A, Coleman RE & Holen I (2004) Sequential exposure of breast cancer cells to cytotoxic agents and zoledronic acid induces synergistic increase in apoptotic cell death.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S72-S72)
Neville-Webbe HL, Evans A, Coleman RE & Holen I (2004) Presence of BRCA1 gene enhances levels of apoptosis induced by combination treatment with doxorubicin (DOX) and zoledronic acid (ZOL).. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S73-S73)
Coleman RE, Banks LM, Hall E, Price D, Girgis S, Bliss JM & Coombes RC (2004) Intergroup Exemestane Study: 1 year results of the bone sub-protocol. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S35-S35)
Van Poznac C, Cross SS, Saggese M, Lippitt JM, Hudis C, Coleman RE & Holen I (2004) Human breast cancers express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and receptor activator of nFkB ligand (RANKL). BONE, Vol. 34 (pp S29-S29)
Evans A, Neville-Webbe H, Coleman RE & Holen I (2004) Zoledronic acid and TRAIL induce synergistic increase in apoptotic tumor cell death. BONE, Vol. 34 (pp S56-S56)
Neville-Webbe H, Coleman RE & Holen I (2004) Paclitaxel and zoledronic acid induce synergistic increase in apoptotic tumour cell death at clinically relevant concentrations. BONE, Vol. 34 (pp S67-S68)
Van Poznak CH, Cross SS, Hudis C, Panageas KS, Coleman RE & Holen I (2003) Osteoprotegerin expression correlates with ER/PR status in human breast tumors.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S310-S310)
Goodhart LM, Brown JE, Ellis S, Gutcher S, Purohit OP & Coleman RE (2003) Development of a touch screen questionnaire approach for measurement of pain assessment scales in cancer patients with bone metastasis. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S67-S67)
Khan FK, Everard J, Ahmed S, Coleman RE, Aitken M & Hancock BW (2003) Low risk persistent gestational trophoblastic disease treated with low dose methotrexate. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S18-S18)
Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD , Nakanishi A et al (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. CANCER, Vol. 97(3) (pp 887-892)
Coleman R (2003) Guidelines for the use of bisphosphonates in bone metastases. European Journal of Cancer Supplements, Vol. 1(6) (pp 299-306)
Coleman RE (2003) Treatment of Skeletal Complications of Cancer with Zoledronic Acid (Zometa): Editorial. Seminars in Oncology, Vol. 29(6 SUPPL. 21) (pp 1-2)
Biganzoli L, Cufer T, Bruning P, Coleman RE, Duchateau L, Rapoport B, Nooij M, Delhaye F, Miles D, Sulkes A , Hamilton A et al (2003) Doxorubicin-paclitaxel - A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial. CANCER, Vol. 97(1) (pp 40-45)
Van Poznak CH, Cross SS, Hudis C, Norton L, Panageas KS, Coleman RE & Holen I (2003) Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) are expressed in human breast tumors.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 82 (pp S162-S162)
Fernie NL, Zekri J, Leonard RCF, Coleman RE & Cameron DA (2003) Exemestane in metastatic breast cancer: effective therapy after 3(rd) generation aromatase inhibitor failure.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 82 (pp S104-S104)
Coleman RE (2002) Introduction: Setting New Standards in Bisphosphonate Therapy. American Journal of Clinical Oncology, Vol. 25 (pp S1-S2)
Coleman RE, Rosen LS, Gordon D, Major P, Kaminski M, Apffelstaedt J, Howell A, Chen BL & Seaman JJ (2002) Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 76 (pp S95-S95)
Holen I, Wells JM, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Jagdev SP, Hamdy FC & Eaton CL (2002) The role of osteoprotegerin in breast and prostate cancer. J BONE MINER RES, Vol. 17(7) (pp 1339-1339)
Brown JE, Ellis S, Gutcher S, Turner L, Purohit OP & Coleman RE (2002) Bone marker directed bisphosphonate therapy in metastatic bone disease. BRIT J CANCER, Vol. 86 (pp S19-S19)
Abdallah SY, Everard J, Ingram CE, Nakielny R, Coleman RE & Hancock BW (2002) An evaluation of patients with persistent gestational trophoblastic disease (PGTD) with lung metastases only on chest X-ray or CT scan of the chest, is there extra benefit from CT scan?. BRIT J CANCER, Vol. 86 (pp S45-S45)
Bhala N, George J, Coleman JM, Radstone CR, Horsman JM, Hancock BW, Hatton MQ & Coleman RE (2002) Management of patients with advanced germ cell tumours (GCT): Is there a role for POMB-ACE?. BRIT J CANCER, Vol. 86 (pp S65-S65)
Brown JE, Ellis S, Gutcher S, Thompson C, Purohit OP & Coleman RE (2002) Relationship between bone resorption and skeletal events in metastatic bone disease. BONE, Vol. 30(3) (pp 47S-47S)
Brown JE, Ellis S, Gutcher S, Turner L, Purohit OP & Coleman RE (2002) Bone marker directed bisphosphonate treatment. A pilot study to determine feasibility. BONE, Vol. 30(3) (pp 47S-47S)
Holen I, Croucher PI, Evans AC, Lippitt JM, Hamdy FC, Coleman RE & Eaton CL (2002) OPG is a survival factor for breast- and prostate cancer cells in vitro. BONE, Vol. 30(3) (pp 28S-28S)
Lipton A, Coleman RE, Diel IJ & Mundy G (2001) Introduction. Seminars in Oncology, Vol. 28(4I) (pp 1-1)
Nevin J, Silcocks P, Hancock B, Coleman R, Nakielny R & Lorigan P (2000) Guidelines for the Stratification of Patients Recruited to Trials of Therapy for Low-Risk Gestational Trophoblastic Tumor. Gynecologic Oncology, Vol. 78(2) (pp 92-96)
Ahmed SI, George J, Coleman JM, Radstone CR, Horsman JM, Hatton MQ & Coleman RE (2000) Ten year review of survival of patients with advanced non-seminomatous germ cell tumours (NSGCT): The Weston Park experience. BRIT J CANCER, Vol. 83 (pp 78-78)
Ahmed SI, Higgins J, Briggs T, Pledge SD & Coleman RE (2000) Preliminary results of a phase II study of weekly paclitaxel and etopophos chemotherapy in patients with relapsed ovarian carcinoma. BRIT J CANCER, Vol. 83 (pp 79-79)
Coleman RE (1998) Adjuvant therapy of breast cancer - A review. Imaging, Vol. 10(1) (pp 28)
Coleman RE (1998) Developments in the palliation of metastatic bone disease. EUR J CANCER, Vol. 34 (pp S90-S90)
Coleman RE, Howell A, Eggleton SPH, Maling SJ & Miles DW (1998) An open phase II study of Taxotere in 42 patients with liver metastases from breast cancer. ANN ONCOL, Vol. 9 (pp 15-15)
Dobson LS, Lorigan PC, Coleman RE & Hancock BW (1998) Toxicity associated with etoposide and Dactinomycin (EA) for methotrexate (MTX) resistant, low risk persistent trophoblastic disease (PTD) and EA with MTX (MEA) for high risk PTD. ANN ONCOL, Vol. 9 (pp 66-67)
Broadhead TJ, Gillespie AM, Coleman RE, Owen J, Skelton L, Stephens S, Farnsworth A, Sopwith M & Chan SY (1998) CMB-401: A cytotoxic immunoconjugate for targeted therapy of epithelial ovarian cancer. ANN ONCOL, Vol. 9 (pp 85-85)
Gillespie AM, Coleman RE & Hancock BW (1998) Is computed tomography necessary to evaluate pulmonary metastases in patients with persistent trophoblastic disease?. BRIT J CANCER, Vol. 78 (pp 42-42)
Dobson LS, Clive S, Dawson L, Anderson A, Leonard RCF, Kunkler I & Coleman RE (1998) Treosulphan monotherapy for metastatic breast cancer - A phase II study.. BRIT J CANCER, Vol. 78 (pp 42-42)
Broadhead TJ, Gillespie AM, Coleman RE, Owen J, Skelton L, Stephens S, Farnsworth A, Sopwith M & Chan SY (1998) CMB-401 - A new agent for immunotherapy of epithelial ovarian cancer: Immune response and pharmacokinetics. BRIT J CANCER, Vol. 78 (pp 44-44)
Gillespie AM, Siddiqui N, Coleman RE & Hancock BW (1998) Does central nervous system chemoprophylaxis have a role in the management of gestational trophoblastic disease?. BRIT J CANCER, Vol. 78 (pp 13-13)
Gillespie AM, Broadhead TJ, Chan SY, Owen J, Farnsworth AP, Sopwith M & Coleman RE (1998) Phase I study of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer.. BRIT J CANCER, Vol. 78 (pp 20-20)
Hough RE, Browne S, El-Helw LM, Coleman RE, Robinson MH & Lorigan PC (1998) High dose chemotherapy for soft tissue Ewing's sarcomas.. BRIT J CANCER, Vol. 78 (pp 42-42)
Zekri J & Coleman RE (1998) Possible adverse effects of curative chemotherapy on bone mass in men: Use of bone ultrasound to evaluate bone architecture. BRIT J CANCER, Vol. 78 (pp 12-12)
ElHelw L, Lorigan PC, Coleman RE & Hancock BW (1997) The vedex regimen: An effective and well tolerated palliative treatment for non-Hodgkin's lymphoma (NHL). EUR J CANCER, Vol. 33 (pp 1201-1201)
Coleman RE (1996) Recent developments in the medical management of bone metastases. XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2 (pp 105-113)
Rustin GJS, Crawford SM, Coleman RE, Lambert J, Ledermann JA, Soukop M, Karp S, Phillips RH, Habboubi N & Meely K (1995) Trial of oral Hexalen for relapsed ovarian carcinoma [OV/CA]: Comparison of CA125 and eortc response definitions. EUR J CANCER, Vol. 31A (pp 513-513)
Lorigan PC, Nevin J, Radstone C, Coleman RE & Hancock BW (1995) Etoposide and actinomycin D (EA) for methotrexate (MTX) resistant, low risk, persistent gestational trophoblastic disease (GTD) and EA with MTX (MEA) for high risk GTD. EUR J CANCER, Vol. 31A (pp 1168-1168)
Coleman RE, Paterson AHG, Conte PF, Tyrrell CJ, Walls J, Henderson MA, Bundred NJ, Murray R, Fife K, Blamey RW & Rubens RD (1994) Advances in the management of metastatic bone disease. The Breast, Vol. 3(3) (pp 181-185)

Preprints

Rugo HS, Poznak CHV, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Alonso EV, Naume B, Brain E , Siegel JM et al (2022) Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials, Research Square Platform LLC.

Research group

PhD Students

Dr Matt Winter
Dr Omar Din
Dr Emma Woodward

School of Medicine and Population Health

School of Medicine and Population Health

Emeritus Professor Robert (Rob) Coleman

Featured publications

Journal articles

Chapters

All publications

Books

Journal articles

Chapters

Conference proceedings papers

Preprints

PhD Students

Links